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SUMMARY
The aim of this study was to assess to the applicability of the CGH technique to 
analysis of various kinds of malignancies in particular hematological 
malignancies and solid tumours, and to optimise a CGH technique for use on 
very small amounts of DNA from paraffin embedded tissue.
During the initial part of the study several FISH experiments were also performed. 
First, interphase FISH with selected chromosome specific alpha satellite probes 
was applied to 22 cases with acute lymphoblastic leukemia, to investigate 
whether this could contribute to the detection of hidden hyperdiploidy or detect 
aneuploidy in cases where cytogenetic analysis had failed. Then CGH 
and interphase FISH were both performed in 19 cases with acute lymphoblastic 
leukemia to compare the efficiency of the two approaches. CGH showed 
potential as a comprehensive screening method for detection of hyperdiploid 
cases and additionally unbalanced DNA copy number changes including one 
amplification on 6p23-pter were detected. Interphase FISH also might be a 
complementary method to confirm CGH results, especially in hyperdiploid or 
hypotriploid cases which failed by conventional karyotyping.
CGH analysis in twenty-two cases of AML, MDS or MDS in transformation, 
revealed that net gains and losses of chromosomal material could be detected 
more simply and accurately by CGH than by conventional karyotyping in cases 
with a complex karyotype. CGH followed by FISH using specific probes which 
were chosen according to discordance between CGH and conventional 
karyotyping could identify the origin of marker chromosomes, and CGH also 
could detect amplification sites where candidate genes related to pathogenesis of 
cancer might be harbored.
A further fourteen cases of other hematological malignancies were analysed 
by CGH and another hidden abnormality which was missed by conventional 
karyotyping was detected in 1 case.
Next, CGH experiments moved to fresh frozen solid tumours. Five cases of well 
differentiated liposarcoma and seventeen cases of malignant melanoma were 
analysed. In well differentiated liposarcoma CGH could detect additional 
amplifications including one amplification (3ql2-ql3.3) which was 
hitherto unreported and helped to evaluate the composition of marker 
chromosomes. In cases with malignant melanoma, CGH could identify
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frequently involved regions of gains and losses, the inter-relationship between 
abnormalities, and found three new sites of amplification ( lp ll .l-p l2 , 3p24, and 
22) and amplification on 17q24-qter in malignant melanoma.
The CGH technique was next applied to very small amounts of DNA from 
paraffin-embedded tissue of solid tumours. For success of this experiment, 
several steps from the extraction of DNA to CGH itself had to be optimised. 
Although it would have been ideal to move to the next step after completing 
the optimisation of one step, most experiments involving the extraction of 
DNA went on to attempt CGH because these test samples were precious material 
and the final goal of this experiment was to obtain successful CGH result.
For obtaining an adequate quantity of high quality of DNA, fifteen different 
parameters were investigated to discover the optimal method for extraction of 
DNA from paraffin-embedded tissue. According to this optimisation process, in a 
very small sample (1 x 7pm) a single step cell lysis method (without 
phenol/chloroform extraction) and higher dosage of proteinase K (1-2 mg/ml) 
with shorter duration (< 24 hrs) showed better results.
For whole genome amplification, two methods -  primer extension 
preamplification (PEP) and degenerate oligonucleotide primed-PCR (DOP-PCR) 
were used. DOP-PCR was performed with 8 different minor modifications. The 
DOP-PCR method without disruption from start to finish was the better method 
for avoidance of contamination and cases using thermosequenase showed better 
results than those using combination of topoisomerase and T7 sequenase. PEP 
was performed with several modifications to assess if whole genome 
amplification (WGA) using PEP could produce analysable CGH images and if so 
what volume of starting template DNA could produce CGH images by this 
method. Another aim was to evaluate the difference of results in comparison with 
DOP-PCR. Although PEP produced some successful CGH images, it showed 
some limitation to amplify a sufficient amount of DNA to produce reliable CGH 
from very small samples. By comparing results between both methods, there are 
some discrepancies of amplification pattern.
After the optimisation process was almost completed, this technique was applied 
to three kinds of serially diluted samples (DNA from normal female blood, 
abnormal bone marrow with AML/MDS, and thick-sectioned paraffin- 
embedded ovarian cancer tissue).
These experiments showed that the smallest amount of template DNA which 
could produce reliable CGH images was above 10 pg of DNA from normal
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female blood, above 50 pg of DNA from abnormal bone marrow with complex 
chromosome aberrations, and above 100 pg of DNA from thick sectioned 
paraffin-embedded ovarian cancer tissue. This study also revealed that the 
application of the same amplification and labelling method to both test and 
control DNA was the ideal method for decreasing bias developed during the 
amplification and labelling process. The experiments with proofreading enzyme 
showed an increase of sensitivity and reliability.
Finally, this optimised technique was employed to unknown malignant melanoma 
samples. Five cases were studied. In the first experiment one whole section of 7 
pm thickness was analysed from each, and in the second experiment 
microdissected samples from the sections of different thickness (3 pm and 7 pm) 
from each case were studied. In four of the five cases, constant abnormal findings 
were observed. The fifth case failed to obtain proper result because of insufficient 
amount of sample.
For validation of these results, inverse labelling of CGH, tissue in 
situ hybridisation, and single round PCR with specific sequence of primers were 
performed.
CGH could not detect 100% of abnormal copy numbers, especially loss of 
DNA copy number, in experiments using very small amounts of DNA. It is 
thought that this is caused by limits of resolution of CGH for detecting deletion, 
problems in the samples themselves (e.g. contamination of normal cells), and 
some bias developed during the amplification process. However, in spite of these 
limitations and the difficulties encountered during the whole optimisation 
process, it can be concluded from the work described here that reliable CGH 
studies can indeed be undertaken on amplified DNA obtained from a very small 
amount of paraffin-embedded tissue.
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1. INTRODUCTION
1.1 General Introduction
Although diseases of the heart and blood vessels are still the main cause of death 
especially in an aging population, cancer has become one of the most common 
causes of death in humans today due to increased environmental hazards such as 
cigarette smoking, exposure to chemicals and radiation, and prolonged life 
expectancy. Accumulation of genetic alterations are at the very centre of 
tumorigenesis so that at a cellular level cancer can be designated a genetic 
disorder. To identify the cancer-associated gene mutations is very important to 
understanding the genetic pathology of cancer. Although other molecular 
techniques are important in the discovery of the numerous genes that contribute 
to tumorigenesis, cytogenetic study is also essential to obtain a comprehensive 
view of cancer genetics. Identification of chromosomal aberrations is having an 
increasingly important role in clinical management of cancer patients because 
they can provide critical information for diagnosis and prognosis. The discovery 
of the Philadelphia chromosome in chronic myeloid leukemia by Nowell and 
Hungerford in 1960 gave the first direct evidence of a constant chromosomal 
aberration in a tumour.
Although classical cytogenetics still represents the major tool for evaluation of 
the chromosomal abnormalities, it has some limitations in the resolution of 
complex karyotypes with multiple chromosomal rearrangements. To facilitate 
more accurate definition of rearrangements as well as the identification of 
previously undetected chromosomal aberrations, various molecular cytogenetic 
techniques such as FISH, multi-colour FISH, and CGH are developing as a 
complementary method to aid more accurate comprehensive genetic analysis, 
especially in cancer genetics.
The role of cytogenetics within modern biology is continually changing and 
developing by adding molecular technology, and modern computer science, and
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thus the value of cytogenetics is becoming more important in the field of cancer 
genetics.
1.2 DNA
1.2.1 The double helix
DNA is a heteropolymer composed of a chain of nucleotides. Each nucleotide 
consists of a sugar molecule (deoxyribose), a phosphate group and one of four 
bases: a purine (adenine or guanine) or a pyrimidine (cytosine or thymine). The 
sugar/phosphate components of the nucleotide are important in determining the 
structural characteristics of polynucleotides, with the nitrogenous bases 
determining their information storage and transmission characteristics.
A single stranded DNA is composed of the sugar-phosphate backbone structure 
of the DNA molecule lying on the outside of the DNA fibre with the bases 
projected inward from the backbone. The free 3' and 5' ends as a result of the 
phosphodiester linkage between their sugars give the molecule a polarity.
To form the double helix, two complementary strands of DNA with opposite 
polarities pair with each other. The pairing attraction holds by the formation of 
hydrogen bonds between the purines and pyrimidines (A-T, G-C).
Among the conformations constructed by the double-stranded DNA molecule, 
the most common form is a right-handed double helix (B-form). There are 10 
base pairs in each turn of the helix and both strands are coiled in the same 
direction.
The stability of the double helical structure of DNA is maintained by stacking 
forces and by hydrogen bonds between two bases. G-C pairs are more stable 
than A-T pairs because G-C pairs have three hydrogen bonds whereas A-T pairs 
have only two hydrogen bonds.
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Fig 1.1 DNA double helical structure (adopted from Bradley et al; Lecture notes 
on molecular medicine, 1995)
1.2,2 The stream of gene expression of genetic information
The human haploid genome contains approximately 3x 109 bp o f  D N A  
containing approximately 50000 to 100000 different genes. A linear arrangement 
o f  codons that carries the information needed to encode a specific polypeptide is 
known as a gene. The stream o f  genetic information is unidirectional, from D N A  
to protein, with messenger RNA as an intermediate. During the expression o f  a 
gene, the segment o f  DNA is first transcribed into a single stranded mRNA, and
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then translated from RNA into protein. Proteins, particularly enzymes that 
catalyze the reaction of metabolism, manifest the final expression of genetic 
information (Bradley et al., 1995; Nicholl, 1996).
1.2.3 DNA constitution
DNA in both the form of base composition and the type of DNA varies from 
organism to organism. DNA can be divided into three categories, depending on 
their abundance in the genome.
1) Single or low-copy DNA.
Single copy genes and their related regulatory sequences occupy approximately 
65-70% of total DNA. It contains most of the transcribed genes, but also 
untranscribable material.
2) Repetitive DNA
a) Highly repetitive DNA is composed of satellite DNA and interspersed DNA. 
Satellite DNA consists of simple sequences repeated many thousand times 
and is frequently non-coding. This satellite DNA consists of three types of 
repetitive sequences- satellite, minisatellite (telomeric family and 
hypervariable family) and microsatellite. Interspersed repetitive DNAs are 
found scattered throughout the genome such as short and long repetitive 
sequences (SINES and LINES). Some of this is transcribed and some of it 
consists of elements that are present in many genes. One of the most 
common SINES is the Alu family.
b) Middle (moderately) repetitive DNA are sequences which code for most of 
the structural components of a cell such as histones, ribosomal RNA and 
transfer RNAs (Lichter and Cremer, 1992; Rasko and Downes, 1995; Clark 
and Wall, 1996).
1.2.4 Cot curve
The curve of the rate at which denatured DNA becomes a double helical 
structure is called the Cot curve.
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The Cot analysis of DNA by hybridisation is based on the fact that DNA 
denatured by extremes of temperature and pH will reanneal with their 
complementary sequences to form stable double helices under optimal 
conditions.
The rate of hybridisation depends on the Cot factor, the production of the Co x t. 
where
Co= initial concentration of DNA in moles of nucleotide per litre.
T= renaturation time in seconds.
If the DNA is fragmented into small,i.e. 400-600bp pieces, and denatured, the 
highly repetitive sequences will reanneal first because there is a greater 
probability of complementary sequences encountering each other. The low-copy 
or single copy sequences will reanneal finally because they take longer to find 
their complementary strand. The more complex the genome, the longer the time 
will be needed to find their complementary strands (Fig 1.2) (Rasko and Downes, 
1995; Clark and Wall, 1996).
Nucleotide pairs
1
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Fig 1.2 A Cot curve (adopted from Clark and Wall; Chromosome, 1996)
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1.3 Chromosome
In humans the normal cell nucleus contains 46 chromosomes (23 pairs). One 
chromosome of each pair is of paternal origin and the other is of maternal origin, 
and there are 22 pairs of autosomes and 1 pair of sex chromosomes (XX or XY). 
During each cell cycle the DNA within the chromosomes duplicates itself and 
the cell then divides into two daughter cells each identical to the parental cell.
By light microscopy, the nucleus appears as an amorphous network of variably 
condensed fibers not distinguishable as individual entities. This material is called 
chromatin, which is a nucleoprotein complex. In cell division, the chromatin 
condenses into deeply staining threadlike or rod-like structures called 
chromosomes, which are present in specific numbers in each cell of a given 
species. A metaphase chromosome consists of two symmetrical chromatids 
which contain a single, uninterrupted and highly folded molecule of DNA. The 
metaphase chromosome is the most compact form of DNA which can be seen 
under the light microscope during mitotic cell division.
1.3.1 Chromosome architecture
The total length of DNA in a diploid mammalian cell if extended would be two 
metre. Therefore each human chromosome is composed of between 1.4 and 7.3 
cm of DNA (average 5 cm of DNA), packaged into a few micrometers of 
chromatid (average 5 um). This constitutes a packing ratio of 1: 10000, most of 
which results from the interaction of the DNA-chromatin proteins.
At the first level of packing, the DNA is wound around hi stone disks, so-called 
nucleosomes, which are the fundamental unit of chromatin. Each disk or bead is 
an octamer of four core histone proteins (two each of H2A, H2B, H3, and H4) 
around which a strand of DNA containing 146 bp is wound one and three-quarter 
times. DNA linkers of 20-100 nucleotide pairs exist between the successive 
nucleosome cores, interacted rather less strongly with HI. The linker length 
varies depending on the kind of tissue from which the chromatin is extracted
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(Clark and Wall, 1996; Jackson, 1996).
At the second level of folding, interactions between HI histones and 
nucleosomes induce the formation of higher-order structures. One of these is the 
solenoid structure, a fiber 30 nm in diameter consisting of helical arrangement 
with 6-7 nucleosomes per turn. The exact structure of the 30-nm strand has not 
yet been established (Therman and Susman, 1993).
The next order of packing is a loop structure. The solenoid fibers form a series of 
loops, averaging typically 60-100 kb in length. They are held together at the 
bases of each loop by nuclear matrix which consists of nonhistone protein.
At last, these loops are arranged into rosettes, consisting of a total of 300kb of 
DNA, producing a 200-300 nm fiber which is the form of the decondensed 
interphase chromosome. Then these loops are further packed into coils, with 
each coil corresponding to an average human G-band (approximately 9 Mb of 
DNA). These coils are then further coiled or stacked to achieve the final 
metaphase chromosome structure. The number of coils varies according to the 
amount of DNA in each chromosome (Fig 1.3) (Rasko and Downes, 1995; Clark 
and Wall, 1996; Jackson, 1996).
1.3.2 Basic structures in a chromosome
These include euchromatin, heterochromatin, centromeres, kinetochores, and 
telomeres. Chromosomes are composed of two major classes of DNA- 
euchromatin and heterochromatin.
Euchromatin
Euchromatin is defined as that part of the chromosome which is not 
heterochromatin, it contains the majority of the active genes and makes up the 
great majority of the chromosome material in humans. It is believed to be less 
contracted than the heterochromatin which is enriched with repetitive sequences 
and highly contracted.
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Heterochromatin
Heterochromatin can be divided into constitutive and facultative. Facultative 
heterochromatin is basically composed of inactivated and condensed 
euchromatic DNA. One of the well-known examples of facultative 
heterochromatin is the inactive X in the mammalian female which is condensed 
in interphase, shows no transcription and is replicated late during the S period. 
The mechanism bringing about the characteristics of facultative heterochromatin 
is still unknown (Therman and Susman, 1993).
Constitutive heterochromatin does not contain any unique sequences and has no 
apparent coding potential. There is considerable variation between individuals in 
both the amount and distribution of heterochromatin which tends to be 
concentrated near the centromeres of all the chromosomes, the satellite and 
short-arm regions of the acrocentric chromosomes, and at the distal end of the Y 
chromosome (Therman and Susman, 1993; Bradley et al., 1995; Clark and Wall, 
1996). It consists of simple repeated sequence DNA. The variation which is 
found in all the centromeric regions can most easily be visualized in the large 
blocks of heterochromatin present in chromosomes 1, 9, and 16 by the C- 
banding technique. Constitutive heterochromatin is not tissue-specific but is 
individual-specific.
Centromeres
The centromere is the point at which the two chromatids of the metaphase 
chromosome are held together. It is also the site of the kinetochore, the point of 
attachment to the spindle fibre during nuclear division.
Centromeric DNA in human chromosomes is largely made up of long tandem 
repeats of a basic monomeric sequence that is approximately 170 bp (Choo et al., 
1991). These are alphoid satellite repeats which represent approximately 0.75% 
of the human genome or 3-5% of each chromosome (Choo et al., 1991; Bartch 
and Schwinger, 1991). The repeat sequences in centromeres are often highly
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conserved between the chromosomes (Bartch and Schwinger, 1991). Among at 
least 33 different alphoid subfamilies which have been already identified, some 
of these families are specific for a single chromosome, while others are common 
to a small group of chromosomes. In other words, some chromosomes appear to 
have only a single subfamily within their centromeres, whereas other 
chromosomes may consist of several different subfamilies (Choo et al., 1991).
A GGAAT repeat has been found to be extremely common and an AT repeat also 
has been found frequently at centromeres. Although the total length of the 
centromeric DNA is different from chromosome to chromosome, all centromeres 
are very large, ranging from about 300 to 5000 kbp. The size of the centromeric 
heterochromatin is polymorphic and is important to maintain chromosome 
integrity (Clark and Wall, 1996).
Telomeres
Normal chromosome ends are capped by so-called telomeres which consist of 
both protein and DNA. These DNA sequences are an essential component in the 
control of chromosome integrity. Telomeres prevent normal chromosome ends 
from joining each other, whereas broken ends losing telomeres often tend to fuse 
end to end, leading to dicentric, ring or other unstable chromosome forms.
It seems that normal chromosome duplication brings on progressive shortening 
of telomeres after a number of cell divisions, eventually the chromosomes start 
to lose genetic material and the cell dies. The function of the telomeres to 
prevent shortening of the chromosomes after each round of cell division is 
brought about as a result of the action of the enzyme telomerase.
In human chromosomes, the sequence motif of telomere is TTAGGG (Moyzis et 
al., 1988) repeated over and over to make a strand of DNA around 10 kilobase 
(kb) pairs long in sperm and 15kb long in somatic cells at the end of each 
chromosome. This repeated sequence has a highly conserved nature (Clark and 
Wall, 1996).
DNA at the extreme ends of telomeres is in the form not of a double helix but a 
single G-rich strand which protrudes beyond the complementary C-rich strand
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by formation of the hairpin structure necessary for telomere integrity.
Telomerase is an enzyme for replicaton of telomeres which acts by adding new 
repeat units to the 3'-end of the G-rich strand. This enzyme is a reverse 
transcriptase, synthesizing DNA from an RNA template, which may have a 
tissue-specific activity level (Blackburn, 1991). Defective telomerase activity in 
cells results in progressive shortening of their chromosomes, senescence, and 
death.
In tumor cells, chromosome breaks and cryptic translocations may be able to 
stabilize by the capture of telomere repeats from another chromosome. Although 
it is not yet discovered how much is causal and how much is secondary, this 
could be a major explanation of the etiology of the chromosome 6 involvement 
in melanoma (Meltzer et al., 1993; Clark and Wall, 1996). The activation of 
telomerase might be associated with preventing cell senescence and death by 
chromosome loss in tumour cells, for example ovarian cancer (Clark and Wall, 
1996).
1.4 Nuclear division and Cell cycles
1.4.1 Nuclear division
In order to be transmitted to the next generation, parental genes have to duplicate 
their genetic material and transfer the copies to the offspring. The genetic 
information existing in each cell is transferred during cell division, both in 
mitosis and meiosis. Mitosis, which occurs in the division of somatic (non- 
reproductive) cells, results in accurate reproduction in two daughter cells from 
the chromosomes of the parental cell. Meiosis or reduction division occurs only 
in the formation of gametes. The number of chromosomes in each daughter cell 
is reduced to the haploid number.
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Mitosis
The average duration of the mitotic cell cycle is 24 hours. Each chromosome 
replicates itself during the S stage of the cell cycle, and one copy of each 
chromosome is transferred to each of the two daughter cells during mitosis. 
Mitosis can be divided into five stages: prophase, prometaphase, metaphase, 
anaphase, and telophase (Fig 1.4).
i) Prophase
The chromosomes appear as long thin threads. In middle to late prophase the 
chromosomes are changing gradually to a shortened and thickened state to form 
chromatids. During prophase, the nucleolus cannot be detected under the light 
microscope. In the cytoplasm, the centrioles begin to move to opposite poles of 
the cell and to form the microtubules that make up the mitotic spindle.
ii) Prometaphase
This stage is between prophase and metaphase. The nuclear membrane disperses 
and disappears, releasing the chromosomes into the cytoplasm. The 
chromosomes show nearly maximum condensation, and collect on the 
metaphase plate. At this time the spindle fibres are not yet attached to the 
kinetochore to which they later anchor for chromatid separation.
iii) Metaphase
At metaphase, the centrioles are in place at opposite poles and the mitotic 
spindle is accomplished. The chromosomes become aligned at the metaphase 
plate with the spindle fiber attached to each kinetochore, and the kinetochores 
are facing opposite poles of the cell. At metaphase, the chromosomes become 
the most condensed state and are also metabolically inactive.
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Medical Genetics, 1995)
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iv) Anaphase
Anaphase begins with the division of the centromeres and consequently starts to 
separate the chromatids. The spindle fibers drag the sister chromosomes to 
opposite ends of the cell.
v) Telophase.
The final stage of mitosis is telophase. In telophase, the chromosomes uncoil, 
become less distinct, and the individual chromosomes become indiscernible 
again. The nucleolus and the nuclear membrane reappears, the spindle fibers 
disappear. During or immediately after telophase, the cytoplasm is divided by the 
formation of new cell membranes in a process called cytokinesis, and finally the 
cell division is completed. The mitosis results in two daughter cells, each with a 
complete and identical set of genetic information.
1.4.2 The Cell Cycle (Normal)
The cell cycle consists of a series of two major events which result in DNA 
duplication and cell division. The eukaryotic cell cycle consists of the M 
(mitotic) period and interphase. Interphase is further divided into G, (Gap 1), S 
(Synthetic), and G2 (Gap 2) phases (Fig 1.5).
An interphase cell is not in the dividing state but is active in metabolism. DNA 
replication takes place during S-phase. Although the length of the cell cycle 
varies considerably from one species and tissue to another, the average 
mammalian cell cycle takes 18 hours, with nine hours for Gb five hours for S, 
three hours for G2, and one hour for M.
Gj phase is the period for preparing to synthesize DNA and for synthesis of both 
RNA and proteins. Although DNA replication occurs during S phase, some 
DNA will replicate early, and other DNA will replicate late. A given part of the 
chromosome will almost always replicate at a certain time in the S period. 
During G2 phase, cells are preparing for mitosis. At the beginning of Gj the cell 
may start into a new cycle immediately, or enter a non-cycling stage known as 
G0 In G0 phase, the cell remains in a transient quiescent state until stimulated
15
to return to the cell cycle or terminally differentiated state (Lawce and Barch, 
1991; Bradley et al., 1995; Carr, 1996)).
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Fig 1-5 Cell cycles (Adopted from Bradley et al.; Lecture notes on molecular 
medicine, 1995)
1.5 Progression of Human Cytogenetics
1.5.1 Brief history of development in human cytogenetics
One o f  the oldest parts o f  genetics is cytogenetics which is a study o f  the 
chrom osome itself
The first important development in human cytogenetics was the discovery o f  the
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exact number of the diploid human chromosomes in somatic cells as forty-six by 
Tjio and Levan in 1956. This discovery using cultured embryonic lung cells, 
made use of the earlier discovery (Hsu, 1952) that hypotonic treatment improved 
the spreading of metaphase chromosomes. In the same year, Ford and Hamerton 
(1956) studied meiotic chromosomes in spermatocytes and observed 23 
bivalents.
The major technical development of the use of phytohemaggutinin (PHA) to 
stimulate the peripheral blood T lymphocytes to divide (Moorhead et al., 1960) 
provided a more accessible source of suitable metaphases available for 
cytogenetic analysis. Colchicine was first used in cytogenetic studies during the 
1950s (Clark and Wall, 1996).
In 1959 the first chromosome aberrations in man were described; the presence of 
an additional chromosome 21 in patients with Down Syndrome was shown by 
Lejeune et al. (Lejeune et al., 1959). Turner syndrome was associated with a 
45,X chromosome constitution (Ford et al., 1959) and the 47,XXY karyotype of 
Klinefelter’s syndrome was demonstrated by Jacobs and Strong (Jacobs and 
Strong, 1959).
Initially chromosomes were uniformly stained by Feulgen or Orcein and 
attempts at identification were based on overall chromosome size and arm ratio. 
The development of the first banding technique, Q banding (Casperson et al., 
1968) allowed identification of individual chromosome pairs and chromosome 
regions. G-banding described by Seabright (1970) allowed chromosome 
identification without the use of fluoresence. Since then more than a dozen 
chromosome banding methods have been introduced (Verma and Babu, 1995). 
These developments led to the description of many more chromosome 
abnormalities, and to the detailed genotype/phenotype correlations which are the 
basis of diagnostic cytogenetics.
1.5.2 General Banding techniques
Since the development of fluorescent banding by Caspersson’s group, many 
banding methods have been developed, such as G-banding, R-banding, Q-
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banding.
G-banding is the most popular banding method in the diagnostic cytogenetics 
laboratory. Chromosomes treated with methanol-acetic acid fixation are 
morphologically best for this method. G-banding of chromosomes is a two-stage 
process including pretreatment using trypsin and staining with Giemsa or 
Leishman’s stain or Wright stain. Enzymatic digestion using trypsin is damaging 
to the protein content but not to the DNA of the chromosomes. Chromosomes 
are divided into light and dark bands by G-banding. G-light bands were shown to 
replicate in the first half of S phase followed by replication of G-dark bands in 
the last half of S phase (Holmquist et al., 1982).
In diagnostic cytogenetics, approximately 400 to 2000 G-bands can be produced 
on each haploid chromosome set. Chromosomes are divided into three types 
depending on the position of the centromere: metacentric, acrocentric, and 
submetacentric. By standard nomenclature of the human karyotype, p is for the 
short arm of a chromosome, q for the long arm of a chromosome. Bands are 
numbered outwards from the centromere, using an agreed classification of 
regions and bands.
R-banding, reverse-banding, gives essentially the same information as G- 
banding and Q-banding. R-banding is particularly useful for the study of 
structural changes involving chromosome ends that might be difficult to detect 
by G-banding due to normally light staining with G-banding in those regions. 
One interesting finding about R-dark (G-light) bands is that they mainly contain 
the housekeeping genes of the cell and about half of the tissue-specific genes, 
are rich in GC and have CpG islands. On the other hand, dark staining regions 
were found to be 3.2% richer in A and T than G-light bands (Holmquist et al., 
1982) and have relatively few active genes, implying a structural 
compartmentalization of the genome (Benn and Perle, 1992; Clark and Wall, 
1996).
C-banding reveals regions of constitutive heterochromatin, which are situated at 
the centromeres of all chromosomes, at the pericentromeric regions of 
chromosome 1, 3, 9, 16 and at the distal end of the long arm of the Y. The
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distribution of C-bands is very species-specific or even individual-specific 
(Clark and Wall, 1996). C-banding can be a useful method for detecting whether 
such variants are due to heterochromatin or are of clinically significant 
euchromatin.
Q-banding with certain fluorescent dyes gives a banding pattern similar to G- 
banding with Q bright bands corresponding to G dark bands, and Q dull bands to 
G light bands.
There are also a number of banding techniques staining a specific area of the 
chromosome such as RE staining, in situ hybridization banding, D-banding, and 
AgNOR banding.
1.5.3 Types of chromosomal aberrations
Chromosome aberrations are chromosomal changes caused by mutation, which 
are large enough to be visible under the light microscope and are divided into 
two categories: numerical abnormalities and structural abnormalities. Both of 
them may involve either the autosomes or the sex chromosomes.
Numerical aberrations (polyploidy, aneuploidy)
Aneuploidy is usually caused by the failure of paired chromosomes or sister 
chromatids to disjoin at anaphase (non-disjunction) or delayed movement of a 
chromosome at anaphase (anaphase lag). Aneuploidy can occur during meiosis 
or mitosis, and meiotic non-disjunction may occur at the first or the second 
meiotic divisions.
Triploidy is usually caused by fertilization with two sperm (dispermy) or by 
failure of one of the maturation divisions of the egg or the sperm.
Tetraploidy usually occurs due to failure to complete the first zygotic division.
Structural aberrations
Structural aberrations occur due to chromosome breakage and then the unstable 
ends of the chromosomes induce translocation, deletion and ring chromosomes, 
duplications, inversions, isochromosomes, and centric fragments (Fig 1.6).
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Fig 1.6 Diagram of structural aberrations (adopted from Therman and Susman, Human 
chromosomes, 1993)
(a) breaks in one chromosome, (b) broken chromosome; (c) centric ring and acentric 
fragment; (d) acentric ring and centric fragment; (e) chromosome with pericentric 
inversion; (f) breaks in two chromosomes; (g) dicentric chromosome and acentric 
fragment; (h) balanced reciplocal translocation; (i) Robertsonian translocations
i) Translocation
The exchange of chromosomal material between chromosomes is caused by 
breakage of both chromosomes with repair in an abnormal arrangement, or 
accidental recombination between non-homologous chromosomes during 
meiosis. There are three types of translocation - reciprocal, centric fusion 
(Robertsonian), and insertional. Where no chromosomal material is missing 
translocations may have no phenotypic effect on the individual carrying them but 
have consequences in the risk of abnormal offspring.
ii) Deletions
A deletion is a chromosomal mutation involving the loss of a segment of a 
chromosome. The missing region of chromosome may be interstitial or terminal. 
The consequence of the deletion depends on the genes or part of the genes which 
have been lost.
iii) Ring chromosome
It is caused by breakage of long and short arms of the same chromosome with 
rejoining and loss of material beyond the breakpoints. Depending on the amount 
lost, it may have phenotypic consequences. Topological problems in replication 
may be caused by different alignments of rejoining.
iv) Isochromosome
After misdivision or breakage of the centromere, sister chromatid rejoining 
immediately adjacent to the centromere leads to production of a chromosome 
with formation of two long arms or two short arms of the same chromosome.
v) Inversion
In inversion, part of a chromosome has been rotated through 180°. Inversions are 
not necessarily harmful, but may cause problems in the pairing of homologous 
chromosomes in meiosis. Where the centromere is involved it is called a 
pericentric inversion; where both breakpoints are in the same arm this is called a 
paracenric inversion.
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vi) Duplication
This, an additional copy of a segment of a chromosome, may result from unequal 
crossing over during meiosis and meiotic events in a parent with a translocation, 
inversion or isochromosome.
1.5.4 Limitation of chromosome banding technique
Chromosome banding techniques have been able to identify specific human 
chromosomes and chromosomal aberrations. However they have some 
limitations as a diagnostic or research tool. Chromosome banding techniques 
need high quality metaphase spreads from actively dividing cells but these are 
sometimes very difficult or impossible to prepare from certain cell types or 
tissues, especially hematological malignancies and solid tumours. Although 
particular chromosomal bands can be recognized by their position in a 
chromosome, small chromosomal aberrations less than a few megabases of DNA, 
such as microdeletions, and inversions, do not always have sufficient 
characteristic bands for precise identification.
Conventional cytogenetic techniques also sometimes have difficulty in 
identifying the composition of abnormal chromosomes present in complex 
karyotypes such as derivative chromosomes or marker chromosomes.
The interpretation of chromosome banding patterns is often technically difficult, 
especially with respect to detection of minor structural changes and when 
analyzing complex karyotypes, such as those of highly aneuploid tumor cells 
(Lichter et al., 1988).
1.6 Fluorescence In Situ Hybridisation
The basic principle of in situ hybridisation is that when a DNA probe is applied 
to a cytological preparation under the optimal conditions, it will find and 
hybridise to its complementary sequences in the cell or chromosome. It was
22
devised and first used as a method for gene mapping by Pardue and Gall (1969) 
and independently by John et al. (1969). Initially it was limited to highly 
repeated probes until the advent of recombinant technology enabled the cloning 
and purification of any DNA sequence. At first, visualization was by means of 
incorporation of radioisotopes, but this method had several disadvantages such 
as long exposure time, short shelf life because of half-life of isotopes, decreased 
banding resolution, inconvenience and lack of safety (Dyer and Meyne, 1991). 
Because of these disadvantages ISH moved to other methods for recognition of 
gene localization of which the most popular is the use of fluorochromes. These 
can either be incorporated directly into the probe DNA (FITC or rhodamine etc.) 
or detected indirectly via use of biotin or digoxigenin.
The development of FISH allowed diagnostic applications to evolve to 
supplement classical cytogenetic banding techniques leading to the development 
of molecular cytogenetics. It is particularly useful in detecting the origin of small 
derivative chromosomes and demonstrating the presence of deletions beyond the 
limit of resolution of the light microscope. This method can not only study 
metaphase chromosomes but also interphase cells and paraffin-embedded 
sections. FISH in interphase is mainly useful in detection of aneuploidy of 
specific chromosomes but may also demonstrate the presence of some specific 
translocations, mainly in malignancies.
1.6.1 Basic Principles of FISH
The FISH technique is based on the double-stranded nature of the target and 
probe DNAs, which are rendered single stranded DNA after denaturation. The 
probe DNA will anneal with their complementary sequences in metaphase 
preparation or interphase nuclei under suitable conditions. A general outline of 
the in situ hybridisation procedure is presented in Fig 1.7.
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Fig 1.7 Schematic illustration of FISH (adopted from Lichter and Cremer, Chromosome 
analysis by non-isotopic in situ hybridisation; In Human cytogenetics A practical 
approach vol. 1, 1992)
Target
The first requirement for successful FISH is target material of high quality to 
maximize probe hybridisation efficiency and to decrease the signal-to-noise ratio. 
A chromosome preparation should contain minimal cytoplasm and other cellular 
debris because these reduce the signal intensity and produce high levels of 
background. The chromosomes should also be well spread to allow accurate 
analysis.
Probes
DNA sequences in target DNA are usually detected using labelled DNA probes. 
These probes are usually cloned sequences in vectors such as plasmids, cosmids 
or YACs, and are normally double-stranded. Synthetic oligonucleotides are 
made using a DNA synthesizer and PCR also is able to amplify DNA sequences 
(up to 4 kbp in length) as probes.
Labelling
i) Labels
A wide variety of non-radioactive labels have been used in recent years. There 
are two main types of labelling.
a) Direct labelling- In this approach a detectable molecule (reporter) has been 
incorporated into the probe and can be visualized directly after hybridisation to 
the target nucleic acid. Some fluorochromes (e.g. FITC, rhodamine) can be 
detected directly.
b) Indirect labelling- the reporter molecules are incorporated into the probes 
using nick translation, then after hybridisation, they are detected by binding with 
fluorescent affinity reagents. The two most frequently used reporter molecules 
are biotin and digoxigenin. Biotin is vitamin H found in egg white, usually
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incorporated in form of biotin-11-dUTP, and detected via either anti-biotin 
antibody or biotin-streptavidin system for which it has a strong affinity. 
Digoxigenin is a steroid found in Digitalis purpura and D. Lanata, incorporated 
as digoxigenin-11-dUTP, and is detected via antibodies.
ii) Labelling Method;
a) Enzymatic labelling by nick translation (Fig 1.8)
Biotin, digoxigenin and fluorochromes can be incorporated into probe DNA 
using enzymatic labelling systems of which the most popular is nick translation. 
This reaction uses two enzymes, DNase 1 and DNA polymerase 1. The DNase 1 
produces single strand nicks in the double stranded DNA of the probe to expose 
a free 3'-OH group. The 5' to 3' exonuclease activity of DNA polymerase 1 
deletes mononucleotides at the 5' side of the nick to synthesize a copy of the 
template strand. The function of polymerization of DNA polymerase catalyses 
the incorporation of new dNTPs from solution at the 3'OH end of nick. The ideal 
size of probe for maximizing specific hybridisation and decreasing background 
signals is about 200-400 bp (Trask, 1991). This can be achieved by adjusting 
incubation time or ratio of enzyme mixture (DNase : DNA polymerase 1).
b) Chemical labelling
AAF (Acetylaminofluorene), sulfone groups, and mercury can be chemically 
introduced into double stranded and single stranded DNA, and RNA and 
detected by immunochemistry.
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Fig 1.8 Diagram o f  nick translation (Adopted from Nicholl; An Introduction to 
Genetic engeneering, 1994).
Hybridisation;
i) Conditions for the denaturation
The labelled DNA is then hybridised to metaphase chromosomes or interphase 
nuclei after the denaturation o f  both the DNA o f  the target cells and the labelled 
probe DNA. Double stranded DNA o f  both target and probe sequences need to 
be denatured to single stranded DNA by dissociation o f  hydrogen bond between 
two complementary nucleic acids strands. There are several factors affecting the 
stability o f  the hybrid nucleic acid -the proportion o f  guanine and cytosine, the 
length o f  hybrid nucleic acid, the environment o f  the nucleic acid hybrids, and 
the presence o f  mismatched hybrids. The degree o f  denaturation for the target 
D N A  is more critical than that for the probe because o f  the narrow w indow 
between adequate denaturation and DNA loss.
ii) Conditions for the reannealing
Hybridisation depends on the ability o f  denatured DNA to reanneal with 
complementary sequences. For binding to complementary sequences in the 
target, the hybridised slides are incubated overnight at 37°C, which is usually 
about 20-25°C below the melting point. The Tm is the temperature at which half  
the DNA is present in a single stranded form. The Tm value is different for
genomic DNA isolated from various organisms. The rate of hybridization 
depends on the probe length, complexity of sequence and concentration.
Post-hybridisation washing
Non-specifically bound probes can be dissociated by washing at various 
stringencies. The stringency of the washes can be adjusted by changing the 
formamide concentration, salt concentration and temperature.
Post hybridisation washes are usually carried out in 50% formamide (v/v)/2x 
SSC and 2x SSC at 42-45°C to remove weakly bound probe leaving absolutely 
perfectly or mostly perfectly matched nucleotides in the duplex.
Detection of the probe
To produce a fluorescent signal at the site of probe hybridisation, different 
haptens, including biotin and digoxigenin, can be detected with 
immunochemicals linked to different fluorochromes. In the indirect method, 
slides are treated with immunofluorescent reagents such as fluorochrome- 
conjugated avidin or anti-biotin antibodies for biotinylated probes. Detection of 
hybridised digoxigenin probes is mediated by high affinity anti-digoxigenin 
antibodies conjugated to alkaline phosphatase, peroxidase, fluorescein or 
rhodamine (Fig 1.9). When probes are too small to make strong signals properly, 
several cycles of amplification can be applied (Fig 1.9).
Visualization of the signals
After mounting in an anti-fade solution containing DAPI, the slide is evaluated 
using a fluorescence microscope equipped with an UV mercury lamp and 
appropriate excitation and emission filters.
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Fig 1.9 Immunochemical detection and signal-generating system for non-radioactive 
probes, a) One step detection system b) Two-detection system, (adopted from Leich et 
al., In situ hybridization, 1994)
1.6.2 Types of probes and their applications
Probes for FISH include repetitive element probes, whole chromosome paint 
probes, single-copy probes, and species-specific total genomic DNA probes.
Whole chromosome libraries (paints)
Whole chromosome paint probes are derived from flow-sorted chromosomes or 
from somatic cell hybrids that contain only a single human chromosome. They 
are cloned in lambda phage vectors (Van Dilla et al., 1986) or in pBS plasmid 
vectors (Fusco et al., 1989; Collins et al., 1991) or by the PCR amplification of 
flow-sorted chromosomes.
These probes are composed of sequences representing loci along the length of an 
entire chromosome. Because these probes usually contain interspersed repetitive 
sequences such as the Alu and Kpnl elements chromosomal in situ suppression 
hybridisation is needed to suppress cross hybridisation with common repetitive 
sequences by using appropriate competitor DNAs. The suppression hybridisation 
technique utilizes a partial reannealing step to block binding by the non-specific 
repetitive DNA present in all human chromosomes. The labelled probe 
fragments and a competitor DNA are denatured together and then incubated at 
37°C for a given period of time (usually up to an hour) to allow preannealing 
(Lichter and Cremer, 1992).
Whole chromosome paints are useful for detection of chromosome 
rearrangements such as translocations, duplications, and possibly marker 
chromosomes in some constitutional chromosome abnormalities, the acquired 
chromosomal changes of leukemia and other malignancies (Leversa, 1993). A 
limitation for this probe is the difficulty of detecting abnormalities in cryptic 
regions, and also structural changes within the same chromosome (Yung, 1996). 
Detection of small deletions and small chromosomal rearrangements is also 
difficult.
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Chromosome-specific repetitive element probe
These probes usually consist of highly repetitive sequences, approximately 
present in 100 to 5000 copies in specific chromosomal regions such as near 
centromeres, telomeres, or heterochromatic regions on specific chromosomes. 
There are thus various kinds of probes with repetitive sequences such as alpha- 
satellite centromeric probes and telomeric probes (Trask, 1991).
The most informative chromosome-specific repetitive element probes are 
chromosome specific centromeric probes, composed of alphoid DNA repeats. 
These probes are widely used to identify numerical abnormalities in metaphase 
spreads or interphase nuclei in prenatal diagnosis, and cancer genetics (Lichter, 
1991).
Single-copv probes (chromosome specific unique sequence probes)
These probes show a variable range of size depending on the vector 
(plasmid—»cosmid-»yeast). Single copy probes can be used to detect 
complementary unique sequences in metaphase and interphase cells. These 
probes have great advantages for identification of structural abnormalities such 
as micro-deletions (eg. Williams syndrome; Yung, 1996), inversions such as 
inv(16) found in AML (Trask, 1991; Dauwerse et al., 1993)), and translocations 
(eg. bcr/abl, Tkachuk et al., 1991; Bentz et al, 1994a). The hybridisation efficacy 
of these probes depends on the size of probe applied. As probe size becomes 
larger, the hybridisation efficacy increases, ranging from 20-50% with plasmid 
probes containing 2 kbp of target sequences to more than 90% using large-insert 
probes such as cosmid or YACs (Yeast Artificial Chromosomes) (Trask, 1991).
Species-specific total genomic DNA probes
Total genomic DNA (consisting of the entire DNA complement of an organism’s 
genome) can be used as a probe to identify individual chromosomes in cell 
fusion hybrids.
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Discrimination between two genomes is greatly improved when the genomic 
probe is hybridised in the presence of an excess concentration of unlabelled total 
genomic DNA from the other genome (blocking DNA) as CISS.
Interphase FISH
Fluorescent in situ hybridisation is especially useful for the detection of 
chromosomal aneuploidy and the investigation of chromosomal organization in 
interphase nuclei. FISH on metaphase spreads is sometimes limited by a lack of 
sufficient mitoses for analysis. Interphase FISH is independent of metaphase 
cells by hybridising directly to non-dividing cells. Thus there is no requirement 
for lengthy cell culture and this is particularly important in malignancies where 
chromosomal changes not present in the original tumour might arise.
FISH to nuclei is particularly useful in situations where the number or quality of 
metaphase chromosome preparations is inadequate for full analysis as can be the 
case in some types of leukemia and is enormously useful in assessing the success 
of bone marrow transplantation. It is also valuable where results are required 
quickly (e.g. prenatal diagnosis of common aneuploidies) or where prolonged 
culture time might lead to abnormalities arising in vitro.
In prenatal diagnosis, centromeric probes are used to screen for chromosome X 
and 18 in uncultured amniocytes or fetal cells isolated from maternal blood 
(Leversa, 1993). Unfortunately there is cross hybridisation between the 
centromeric probe for 13 and 21, thus the 13/21 shows 4 signals in normal cells 
and five in cells with aneuploidy making scoring difficult. In these cases, 
complex probes such as genomic fragments (without clustered repeats) cloned in 
cosmids, PI, YACs, or similar vectors are applied. Good results are obtained with 
chromosome specific plasmid clones (Lichter et al., 1988b) or YACs for 
chromosome 21 (Chumakov et al., 1992).
Probes specific for alpha satellite DNA can also be used to look for aneuploidy 
of specific chromosomes in malignancies where they allow many cells to be 
screened, for examples, hyperdiploidy in ALL (Moorman et al, 1996), trisomy 
12 in CLL (Escudier et al., 1993). In solid tumours, aneuploidy can be detected
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by tissue in situ hybridisation.
Single copy probes may also be used in interphase cells to look for specific 
abnormalities eg. bcr/abl for the Philadelphia chromosome (Bentz et al, 1994a), 
t ( l5; 17) (Warrel et al., 1993), inv(16) in AML (Trask et al., 1991; Gray et al., 
1992; Dauwerse et al., 1993) and deletion of the human erythrocyte ankyrin gene 
on chromosome 8 associated hereditary spherocytosis (Lux et al., 1990). 
Chromosome specific libraries are unsuitable for detection of aneuploidy in 
interphase cells. It has been shown that each chromosome occupies as specific 
domain in the interphase nucleus and consequently the signal obtained from 
FISH using chromosome libraries is diffuse, overlapping and confusing to 
interpret (Tkachuk et al., 1991).
1.6.3 Additional applications of FISH
Reverse chromosome painting
The principle of this procedure is that labelled DNA from various sources is 
hybridised to metaphase chromosome spreads from normal cells by in situ 
suppression hybridisation. This approach can be applied to investigate the 
chromosomal content of interspecies hybrid cells, to identify the origin of 
marker chromosomes (Carter et al., 1992) and to recognize unbalanced 
chromosomal material of entire genomes by using the whole genomic DNA as a 
probe (Joos et al., 1993).
MicmrFISH
Micro-FISH is a composite procedure involving microdissection of an aberrant 
chromosomal region, amplification by degenerate oligonucleotide primed-PCR 
and labelling of the dissected DNA, and subsequent FISH to normal metaphase 
chromosome (reverse chromosome painting).
Micro-FISH can be used for the analysis of chromosomal aberrations, especially 
in malignant cells and de novo mutations, which often remain incompletely
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resolved because of the limitations of routine banding and staining techniques in 
the identification of small and complex chromosome rearrangements.
The micro-FISH technique has also been called reverse chromosome painting, 
originally described by Carter et al. (1992) as opposed to forward chromosome 
painting. With this method, cytogenetically unknown origin of the marker 
chromosomes, balanced or unbalanced translocations, duplications, interstitial 
deletions, and insertions can be directly identified even without any clue from 
the conventional cytogenetic method (Meltzer et al.,1992; Xu et al., 1995; 
Muller-Navia et al., 1996). Although this method is very sensitive and 
straightforward, it still requires reasonable banded patient metaphases for 
chromosome microdissection and is difficult to optimize because it involves 
several techniques, all of which are critical.
Fibre-FISH
This visual high-resolution genome mapping technique is based on FISH of 
probes to free chromatin fibres derived from lysed cells (Heiskanen et al., 1995). 
To achieve better resolution, FISH is performed on extended single DNA fibres. 
There are several methods for extending single DNA fibres, which are 
collectively referred to as Fibre FISH (Florijn et al., 1995). These methods have 
been employed in ordering of overlapping and adjacent probes in the range 1 - 
lOOkb (Parra and Windle, 1993; Senger et al., 1994). Fibre-FISH may also be 
very useful for high resolution physical mapping, and contig evaluation, and for 
detecting genetic aberrations, such as microdeletions, translocations, inversions, 
and small duplications (Wiegant et al., 1992; Parra and Windle, 1993), with an 
accuracy far superior to that possible by traditional FISH techniques.
Multicolour-Primed in situ labelling
The Primed In Situ Labelling (PRINS) technique is an alternative to traditional 
FISH methods for detection of nucleic acids in situ. Multi PRINS is a fast and 
simple method by which allows simultaneous probing of multiple repetitive
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sequences. The basic principle of PRINS is that an unlabelled oligonuceotide 
probe is used as a primer for chain elongation in situ, using labelled 
deoxynucleotides as substrate for a DNA polymerase. The target chromosomal 
DNA acts as a template for the chain elongation. Newly synthesized DNA can 
be identified by fluorescence detection (Hindkjaer et al., 1994,1996).
In comparison with FISH, PRINS is a very fast procedure; less than 1 hour is 
required with repetitive DNA sequences and less than 3 hours with unique DNA 
sequences. Gosden et al., (1991) showed high quality chromosome R-banding 
could be produced by PRINS with Alu oligonucleotides as primers. Koch et al, 
(1991) applied direct incorporation of fluoresein-12-dUTP to the PRINS to avoid 
the time consuming immunocytochemical steps to detect the labelled probe. 
PRINS can be used to simultaneously visualize multiple sequences, both in 
metaphase and interphase chromosomes. Multi- PRINS is a valuable tool to 
identify unambiguous chromosomal aberrations and aneuploidies from a small 
number of suitable metaphases.
Chromosomal bar codes
After many attempts to devise a more specific and flexible way of chromosome 
banding, the term bar was developed to distinguish such a chromosome 
subregion more clearly than the natural chromosome bands. Any combination of 
bars can be applied to mark chromosomes at multiple, selected sites and 
consequently produce a chromosomal bar code (CBC). For applications of CBCs 
as a general diagnostic tool, large number of probes and improved hybridisation 
efficiency would be required (Lengauer et al., 1993).
Although multi-colour CBCs are definitely not enough to screen whole 
chromosomes for unknown aberrations, a specific CBC can provide 
comprehensive information in a single FISH experiment for identification of the 
suspected translocations, insertions, deletions, and inversions by a change in a 
sequence of differently coloured bars spaced along the chromosomes of interest 
(Lengauer et al., 1993).
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1.6.4 Approaches to Whole Genomic Screening
Multicolour FISH
Although FISH can identify some chromosome abnormalities with a high degree 
of specificity, it is usually used with some prior knowledge or suspicion of the 
abnormality likely to be present, and usually not more than two probes with 
different fluorochromes are applied simultaneously. One approach to obtaining a 
global analysis using FISH was developed to multicolour FISH. At the 
beginning, Nederlof et al. (1989b) developed a three-colour FISH for the 
simultaneous detection of multiple nucleic acid sequences using three 
fluorochromes.
Multicolour FISH was developed to identify each of the 22 human autosomes 
and the two sex chromosomes with distinctively different colours. It is possible 
to obtain a unique spectral colouring on each chromosome by using a 
hybridising set of chromosome specific DNA probes labelled with a different 
combination of fluorescent dyes. Two strategies enable detection of targets 
beyond the number of fluorochromes; one is called combinatorial labelling, 
where each target is identified by probe labelled with a defined combination of 
fluorochromes: the other is called ratio labelling, where each target is recognized 
by a combination of fluorochromes at different ratio (Reid et al.,1992a,b; Le 
Beau, 1996). In multicolour FISH, multiplex FISH (M-FISH) and spectral 
karyotyping (SKY) are two major approaches (Speicher and Ward, 1996). M- 
FISH depends on digital images obtained separately for each of the five 
fluorochromes (FITC, Cy3, Cy3.5, Cy5, Cy7) using a CCD camera. Then special 
software system analyses these by generating a composite image in which each 
chromosome is pseudo-coloured based on its fluorochrome composition. In the 
SKY system, an interferometer is used to analyse the spectrum of fluorescence 
wavelength for each pixel of the CCD chip. The special computer software 
identifies the components of this spectrum by applying a classification algorithm. 
These two methods have advantages and also disadvantages. Applications of M- 
FISH and SKY have not yet been established, but these methods provide
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comprehensive screening of whole karyotypes for detecting chromosomal 
aberrations in a single FISH experiment. Multicolour FISH is particularly 
valuable for identification of the origin of marker chromosome, especially in 
solid tumours and for the detection of balanced chromosomal aberrations. Proper 
metaphase preparations are an essential part of multicolour FISH, but they are 
difficult to obtain from many tumour samples especially hematologic 
malignancies. Decreasing mitotic cells or displacement with another clone 
during cell culture are another problem of metaphase preparations. Multicolour 
FISH showed limitations in the detection of paracentric inversions, some 
pericentric inversions, insertions involving a single chromosome arm, small 
duplications and small deletions. Also, the sensitivity in detecting cryptic 
telomeric translocations was not established. Now, attempts are being made to 
apply multicolour FISH to interphase nuclei for visualization of all chromosome 
domains simultaneously (Speicher and Ward; 1996).
1.6.5 Microscopy
Fluorescence Microscopy and filters
The basis of fluorescence microscopy lies in the fact that a photon of a particular 
wave- length (excitation wavelength) excites an electron in the fluorochrome and 
the excited electrons become unstable, and on returning to a stable state lose 
energy which is emitted as light (Leitch et al., 1994). Although the average 
wavelength of emitted fluorescence is longer than the average excitation 
wavelength for any given fluorochrome, there is in fact some overlap for many 
commonly used fluorochromes.
To generate and observe flurorescence, it requires a fluorochrome bound to a 
molecule, a light source, and a detection system with appropriate optical filter 
for the particular fluorochrome to produce and to detect various excitation and 
emission wavelengths.
Excitation filters are used to select the correct wavelengths of the light for the 
specific fluorochrome and other wavelengths are either absorbed or reflected by
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this filter. The emission or barrier filter is also required for separating 
unabsorbed excitation light from the fluorescence emission light because most of 
the excitation light is not absorbed by the fluorochrome. Filter sets vary 
according to the amount of light which they permit to pass such as long band­
pass filters, narrow band-pass filters, and dual- and triple band-pass filters enable 
to simultaneously visualize two or three fluorochromes.
Light sources
The light source for fluorescence microscopy is a mercury lamp. Mercury lamps 
can be chosen by desirable excitation intensities that correspond to bulb wattage 
(50W or 100W). Brighter excitation intensity produces more intense 
fluorescence and therefore a shorter exposure time for photographs. A 100 W 
bulb also has a longer operating life than a 50 W bulb. Mercury bulbs should not 
used >200 hr because of a risk of explosion that can damage the microscope.
1.7 Comparative Genomic Hybridisation (CGH)
CGH, which was first developed by Kallioniemi et al in 1992, is a 
comprehensive method for detection of DNA sequence copy number changes 
(deletions, gains, and amplifications) on a genome-wide scale in a single 
hybridisation using extracted test DNA as a probe.
Unlike FISH, CGH analysis does not need previous information about 
cytogenetic aberrations, nor does it require a series of probes to fully evaluate 
the extent of genetic gains or losses in a test sample. Conventional cytogenetics 
is hardly used in the analysis of solid tumours because of technical difficulties in 
culture. CGH was developed as a method of overcoming this limitation since it 
allows analysis of tumour DNA without requiring chromosome preparations 
from malignant tissue.
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1.7.1 Basic principles of CGH
CGH is based on competitive binding of test and control DNA to normal 
metaphase chromosomes. The DNAs are differentially labelled with different 
fluorochromes (green and red) and co-hybridised to a normal metaphase under 
suppression conditions (Fig 1.10). The basic assumption in CGH is that the 
hybridisation kinetics of the test and control DNA are independent, so the ratio 
of the binding of the DNA to a specific locus is proportional to the ratio of the 
copy numbers of the sequences in the two DNAs. The relative intensities of both 
differently labelled genomic DNAs (test and control) to normal metaphase 
chromosomes reveals the region of changed copy number. Ratios of the signals 
can be quantified along the length of each homologue and provide a copy 
number karyotype of the test DNA (Kallioniemi et al., 1992; du Manoir et al., 
1993).
Cohybridisation of differentially labelled normal DNA (control DNA) provides 
an internal standard, which allows differentiation between variation in signal 
intensities due to differences in DNA copy number and variations due to signal 
inhomogeneities. This is caused by several experimental parameters which 
include differential denaturation of chromosomal regions with different base 
composition, and chromatin packaging as well as different target accessibility of 
probe sequences (Bentz et al., 1994b).
At present CGH is applied to detect genetic aberrations in a wide spectrum of 
cancers. The use of the CGH technique in cytogenetic analysis of solid tumours 
has expanded rapidly in particular where archival formalin fixed paraffin- 
embedded sections are used as starting material. Paraffin block studies are 
especially useful in many tumour types in which fresh tissue is usually not 
available, for example, skin melanoma (Isola et al., 1994).
Paraffin block CGH provides a powerful research tool to study the pathogenesis 
of cancer by evaluating genetic progression from pre-malignant to fully 
malignant lesions, or by comparing genetic aberrations in primary tumours and 
their metastases.
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1.7.2 Preparation for CGH experiments
Normal metaphase preparations for CGH
Normal metaphase chromosomes prepared from phytohaemaggulutinin (PHA)- 
stimulated, synchronised peripheral blood lymphocytes from a karyotypically 
normal healthy donor are used as hybridisation targets in CGH.
The quality of metaphase preparations is crucial to obtaining an optimal CGH 
image. It is desirable to prepare several batches of slides at once before selecting 
a suitable one. The hybridisation characteristics of several slides from each batch 
of slides are tested using labelled DNAs from a control cell line. When high 
quality hybridisation cannot be achieved, the entire batch has to be abandoned. 
The best quality of metaphase preparation contains reasonably straight 
chromosomes with minimal overlapping, adequate length of chromosomes and a 
high mitotic index with little cytoplasmic residue.
Isolation of DNA for CGH
The CGH analysis of disease processes requires the extraction of test DNA from 
a sample of blood, bone marrow, or a variety of tissue preparations including 
fresh and paraffin embedded tissue.
The technique for the extraction of DNA from cytologic preparations and fresh 
tissue is already well established. Fixation and paraffin embedding of tissue is a 
procedure that has a profound effect on its molecular arrangement. The DNA of 
frozen tissue sections is still present as high molecular weight DNA and good 
quality CGH can be achieved even after DOP-PCR with direct, standard cell 
lysis protocols. In contrast, the formalin fixation of tumour tissues leads to 
extensive cross-linking of nuclear proteins and formation of tight complexes 
between proteins and DNA, in addition to fragmentation of DNA; therefore 
formalin fixation is the major limiting factor for the DNA analysis of archival 
material (Isola et al., 1994). The success of a CGH study using fixed, paraffin
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embedded materials depends on several factors, including the fixative used in the 
tissue processing, the duration of the fixation, the age of the paraffin block, and 
the length of the DNA fragment to be amplified. Several technical modifications 
to improve the yield of high molecular weight DNA from paraffin embedded 
tissues have been suggested, such as modifying proteinase K application, 
changing the extraction buffer, or incorporating an additional incubation step 
with sodium thiocyanate after the dewaxing (Speicher et al., 1993). From a 
literature review, it appears that prolonged proteinase K treatment can improve 
the DNA extraction efficacy in relatively thick tissue sections. Although the 
underlying mechanism remains unknown, this effect may be related to partial 
reversal of fixation induced cross-links in aqueous buffer during proteinase K 
digestion (Isola et al., 1994). In very small volumes of microdissected samples, 
single-step cell lysis method may be used for DNA extraction because the 
number of cells is too small to extract by the standard method (Zhuang et al., 
1995). Another problem of DNA extraction is contamination of malignant cells 
with normal cells from the surrounding tissue and with necrotic cells, resulting 
in decreased specificity of CGH results.
Probe labelling
Probe labelling for CGH is carried out by nick translation in the same way as for 
FISH. In CGH experiments with very small amounts of test DNA, DOP-PCR 
labelling is also performed during the amplification process.
Nick translation
The length of the probe molecules after labelling is a crucial factor for good 
quality CGH. In CGH it is important to adjust not only the optimal length of the 
fragments but also to produce a similar length (quality) for test and reference 
DNA.
During the nick translation process, probe size can be modified by adjusting the
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ratio of DNase 1 to DNA polymerase 1 in the reaction solution and/or the 
incubation time. The optimum size for ideal CGH is between 500 to 2000 bp 
(Kallioniemi et al., 1994). As with FISH, labelling may be by direct or indirect 
methods. In the indirect method, biotin and digoxigenin are used commonly as 
reporter molecules owing to their sensitivity and commercial availability. In 
direct labelling, directly fluorochrome-conjugated nucleotides, such as FITC-11- 
dUTP and TexasRed-5-dUTP are used.
Denaturation, Hybridisation and Washing
Basic theory for denaturation and hybridization is the same as in FISH. For 
DNA.DNA in situ hybridisation both the probe and target sequences need to be 
denatured to make them single stranded prior to in situ hybridisation. In CGH 
the normal metaphase slides as target DNA are denatured at 72-74°C for 3 
minutes in 70% formamide/2x SSC (Kallioniemi et al., 1994), but optimal 
denaturation time and temperature varies from one batch of slides to another. 
After denaturation, slides should be checked for chromosome morphology to 
obtain the optimal denaturation time.
In some papers, proteinase K treatment after denaturation is recommended (du 
Manoir et al., 1993; Kallioniemi et al., 1994). Although pretreatment of the 
specimen by proteolytic digestion can improve the probe accessibility to 
specimen, the effect is controversial because such a treatment may also result in 
a higher granularity of the signal by the genomic DNA.
Probes, which are mixtures of equal amounts (120-200 ng) of test and control 
DNA with Cot-1 DNA (5-10 ug), are also denatured at 70°C for 5 minutes 
(Kallioniemi et al., 1994).
Hybridisation essentially follows the steps used in chromosome suppression in 
situ hybridisation with unlabelled Cot-1 DNA to block binding of the labelled 
repetitive sequences in both genomes. For accurate assessment of chromosomal 
imbalances by variations in the fluorescence intensity ratio, suppression must be 
as complete as possible.
43
Hybridisation is carried out under a coverslip in a moist chamber at 37°C to 
39°C for 2-3 days. The temperature and duration of incubation can be changed 
depending on test DNA conditions.
Post-hybridisation washing is carried out as standard FISH protocols. When 
indirectly labelled probes are used, washing procedure is performed as in 
standard dual colour FISH protocol with immunochemical staining with avidin- 
FITC and anti-digoxigenin rhodamine (Kallioniemi et al., 1992, du Manoir et al., 
1993).
Image acquisition and Analysis of CGH
For proper CGH analysis, there are two basic requirements; one is hardware for 
image acquisition and the other is software for image analysis. For hardware, a 
conventional epifluorescence microscope with 50W or 100W mercury lamp, 
appropriate excitation and emission filter sets, and camera are employed. 
Although a cooled CCD (Charge Coupled Device) is not needed, it has many 
advantages including digital readout, high spatial resolution, high sensitivity, low 
noise, and high dynamic range (du Manoir et al., 1995b).
Software for image analysis of CGH is developing continuously. Image analysis 
can be achieved by two methods. One is global analysis which involves 
examining individual metaphases at the level of individual picture elements 
(pixels) calculating the fluorescence ratio and coding to various colours 
according to the magnitude. The other is axial analysis which is a method of 
calculating the average red:green ratio along a defined line, calculating the 
average intensity value for a specific pixel width at right angles (orthogonal) to 
the line, generating a graph and painting the abnormal regions. Finally the 
fluorescence ratios over six metaphases are collected and represented in a CGH 
Karyogram.
For proper CGH analysis, several steps of analysing procedure are performed in 
addition to assessment of image quality. These are background correction; 
segmentation to separate the chromosomes; identification of the chromosomes
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by the banding pattern of the DAPI image; normalisation of the fluorescence 
intensities from the test and reference DNA; measurement of the ratio of test and 
reference signals along lines perpendicular to the chromosome axis; averaging of 
fluorescence ratio from multiple chromosomes; and interpretation of the ratio 
profiles.
i) Assessment of image quality
For reliable CGH analysis, six or more metaphase spreads are selected in each 
experiment. Every metaphase should be assessed by objective criteria including 
degree of suppression of repeat sequence in the hybridisation, intensity of the 
hybridisation signals, signal to background ratio, homogeneity of the 
hybridisation, homogeneity of the image, and granularity of the hybridisation to 
increase the quality of CGH images (du Manoir et al., 1995b)
ii) Correcting the background
Local background fluorescence and residual uneven illumination can be 
corrected by subtracting the interchromosomal fluorescence intensity from the 
chromosomal fluorescence.
iii) Segmentation of images
Chromosome segmentation is for defining accurate chromosomal boundaries by 
pre-filtering in the image through a top-hat filter, or by basing segmentation on 
the combined DAPI and reference DNA image or possibly by using a different 
counterstain with better telomere staining properties. Segmented images are 
created by setting zero value for pixels that are outside the chromosome masks, 
eventually it will be used to retain all material within the green area.
iv) Identification of chromosomes
Specific chromosomes could be identified visually based on the R-banding 
pattern in the DAPI image. Actually DAPI banding does not show a very distinct 
banding pattern to allow definite identification. Identification could be facilitated 
using grey scale DAPI component by enhancing the banding pattern and
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displaying using an inverted lookup table.
v) Normalisation of the fluorescence intensity (Fluorescence equalisation)
To compare information among different copies of the same chromosome type in 
different metaphases and in different experiments, some sort of normalisation or 
standardisation procedure is required. This procedure produces approximately 
equalised median intensities of the test and reference images in all metaphases. 
Thus the corrected median test/median reference ratio is approximately equal to 
1.0 for each metaphase and fluorescence ratio of the chromosomal area 
corresponding to the normal part of the test DNA will become approximately 1.0 
in all images.
vi) Determining of ratio profile
Test and reference fluorescence intensity profiles are obtained by combining the 
pixel value along slices orthogonal to the chromosome axis. The chromosome 
axis is calculated using a standard skeleton operator. Point by point division of 
the intensity profiles yields the ratio profile.
v) Profile averaging
Averaging of ratio profiles to reduce random noise and give better estimation of 
copy number differences is required. A minimum of 5-10 examples of each 
chromosome is needed to obtain average ratio profiles. Chromosome length 
standardisation is required before averaging ratio profiles. Then, average ratio 
profiles are calculated by combining the individual ratio profiles from multiple 
images and displaying the averaged ratio profiles together with a measure of 
variability on CGH Karyogram (du Manoir et al., 1995a,b).
vi) Identifying regions of copy number gains or loss
Determination of threshold is also an important step in detecting DNA copy 
number changes accurately. CGH analysis procedures result in measurements of 
relative copy number only. Most interpretations are based on whether the mean 
profile at a locus, or the mean ratio value for an entire chromosome arm, is either
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higher than an upper threshold, or less than a lower threshold. Upper thresholds 
of between 1.10 and 1.25 and lower thresholds between 0.75 and 0.90 are 
currently used. Particularly the wider threshold (0.75-1.25) is the theoretical 
threshold for monosomy and trisomy in cases where a chromosomal imbalance 
is present in 50% of cells (du Manoir et al, 1995b). However it may be 
insufficiently sensitive in cases where a chromosome imbalance is present in 
only a small proportion of the cells contributing the test DNA. Alternative 
thresholds using statistical distribution of the average ratio value for balanced 
chromosomal regions in tumour sample also can be applied. Confidence 
intervals (95% or 99%) express the error estimated, which is directly 
proportional to the standard error. By using these statistical justifications, 
sensitivity for detection of small regions of DNA copy number change may be 
increased (du Manoir et al., 1995b).
Limitation and difficulties of CGH
Generally CGH is limited by resolution of affected chromosome regions. In a 
digital image system, deletion is less detectable than gain of copy numbers.
CGH can only detect genetic aberrations that involve true losses or gains of 
DNA sequences. Thus balanced translocations or inversions, point mutations and 
small intragenic rearrangements cannot be detected. Also CGH can only detect 
relative DNA sequence copy number changes, so that diploid cells cannot be 
differentiated from true triploid or tetraploid cases by using the ordinary method 
of analysis. Peri-centromeric and heterochromatic repeat regions, notably the 
centromeric region of 1, 9, 16, and Y and acrocentric short arms, cannot be 
reliably evaluated by CGH as they are blocked to various extents by the 
unlabelled Cot-1 DNA in the hybridisation and there are no unique sequence 
hybridisation signal in these area. The ratio changes at or near these regions 
should be analysed carefully because these DNA sequences are highly 
polymorphic in copy number between individuals. Telomeric regions should also 
be carefully investigated because of the fall off in the hybridisation signal at the
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very end of chromosomes. Some regions of chromosomes, for example GC rich 
regions such as lp32-pter, 16p, 19 and 22, occasionally show widely variable 
intensity ratios and this is thought to be related to the structure of those 
chromosomes. Another frequent problem for CGH is caused by mosaicism 
involving two different cell lines, or in the case of tumours with contamination 
of normal cells. If the normal cell contamination is greater than 50% of the total 
DNA content, reliability of CGH is decreased. In bi- or multi clonal tumours, it 
is difficult to detect the different genetic aberrations present in the individual 
clones because CGH detects the average copy number of sequences in all cells 
included in the specimen.
1.8 Development of the CGH Technique using Whole Genome 
Amplification
1.8.1 Polymerase Chain Reaction (PCR)
Specificity and Fidelity of PCR
PCR is designed to selectively amplify specific target DNA sequence or 
sequences within a heterogeneous collection of DNA sequences.
The efficacy of PCR can be measured by its specificity, yield, and fidelity. 
Although an ideal PCR aims to get a product with high specificity, yield, and 
fidelity, adjusting conditions for maximum specificity may not be compatible 
with high yield. Likewise, optimising for the fidelity of PCR may result in 
reduced efficiency. The buffer conditions, the PCR cycling regimen (i.e., 
temperature and duration of each step), and DNA polymerase would affect the 
success of PCR.
i) Template
Suitable substrates for PCR include all kinds of DNA and RNA such as genomic,
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plasmid, and phage DNA, previously amplified DNA, cDNA, and mRNA. In 
general, the efficiency of PCR is greater for smaller-size template DNA than for 
high-molecular-weight (undigested eukaryotic genomic) DNA. PCR can be used 
to amplify as little as a single molecule of template, although great care has to be 
taken when performing such experiments, particularly in the avoidance of 
contamination.
ii) Primer design
An ideal set of primers should hybridise efficiently to the target sequence with 
minimum hybridisation to other related sequences that are present in the sample. 
Primers are generally 15-30 nucleotides in length with an approximately equal 
number of each of the four bases. Primer pairs should also be designed so that 
there is no complementarity of the two bases at extreme 3' ends either inter or 
intra individual primers to reduce the incidence of primer-dimer formation 
(Newton and Graham, 1994). The specificity of amplification depends on the 
specificity of primer hybridisation to the target site with respect to different 
target DNA sequences, which are not intended to be amplified. Primers which 
take part in nonspecific extension in PCR not only reduce the concentration of 
primer available for the correct amplicon but can also lead to artifactual products, 
or false positive or negative results.
iii) Reaction Mixture
The standard buffer for PCR with Taq polymerase contains 50mM KC1, 10 mM 
Tris-HCl (pH 8.3 at room temperature), and 1.5 mM MgCl2 Although the 
standard buffer works well for a wide range of templates and oligonucleotide 
primers, the buffer for a particular PCR should be optimised depending on the 
target, the primer sequences, and the concentration of other components in the 
reaction such as dNTP and primers. Optimisation of the concentration of M g^is 
very important whenever a new combination of target and primers is first used or 
when the concentration of dNTPs or primers is changed. dNTPs are a major 
source of phosphate groups in the reaction, and any change in their concentration 
affects the concentration of available Mg^ (Cha and Thilly, 1995).
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iv) Primer and dNTP
The ratio between the primer and template is an important factor, which affects 
the specificity of PCR. If the ratio is too high, PCR is more prone to generate 
nonspecific amplification products, and primer-dimers are also produced. 
However, if the ratio is too low (<0.1% of the standard condition for the genomic 
DNA PCR), the efficiency of PCR is greatly decreased. Unincorporated primers 
are completely dependent on the amount of target sequences generated, on the 
other hand unincorporated dNTPs depends not only on the number of target 
sequences generated, but also on the size of the target sequence. Thus, for 
amplifying a large target sequence, a higher concentration of dNTP is 
recommended (Keohavong et al., 1988).
v) PCR Cycle
A standard PCR cycle consists of three steps: (1) a denaturation step (1-2-minute 
incubation at > 94°C); (2) a primer annealing or hybridization step (1-2-minute 
incubation at 50°-55°C); and (3) an extension step (1-2-minute incubation at 
72°C).
Although higher annealing temperature and shorter time of extension step 
improve the specificity of PCR, large fragments (>1 kb) of template DNA are 
needed to increase the duration of each step to get efficient amplification (Kwok 
et al., 1990).
vi) Exponential phase of PCR
An understanding of the kinetics of specific product accumulation during PCR is 
necessary for an informative and analytical PCR. The desired blunt-ended 
duplex fragments start from the third cycle of the PCR, and then this product 
accumulates exponentially according to the formula, Nf = N0 (1+Y)n, where Nf is 
the final copy number of the double-stranded target sequence, N0 is the initial 
copy number, Y is the efficiency of primer extension per cycle, and n is the 
number of PCR cycles under conditions of exponential amplification 
(Keohavong et al.; 1988). In most cases, after the final copy number of the
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desired fragment (Nf) reaches about 1012, its efficiency per cycle (Y) drops 
dramatically due to limitation of enzyme action. Continuing PCR beyond this 
point often produces amplification of nonspecific bands, the appearance of small 
deletion mutant bands, and the disappearance of the specific product in certain 
instances (Cha and Thilly, 1995). Because each specific PCR amplification has a 
different efficiency, an accurate quantitative analysis should be carried out to 
determine the efficiency of the particular PCR.
Method to reduce PCR Contamination
PCR is especially susceptible to contamination because PCR produces an 
abundance of amplified DNA product from a small amount of DNA. There are 
three sources of contamination such as DNA from other test samples, DNA from 
experimental materials such as recombinant clones, or DNA generated by 
previous PCR amplification of the same target sequences (carryover 
contamination).
To avoid contamination during PCR, experiments should be set up in a laminar 
flow cabinet or in a separate laboratory. Equipment and reagents for PCR should 
be kept separately from general laboratory equipment. Reagents which can be 
autoclaved should be sterilized in an autoclave. Disposable gloves and lab coat 
should be worn at all times.
i) Ultraviolet irradiation to reduce PCR contamination
UV irradiation of dry DNA or DNA in solution acts as a tool to prevent PCR 
contamination. Most UV-induced DNA damage occurs via the formation of 
cyclobutane rings between neighboring pyridine bases, thymidine or cytidine 
because the cyclobutane rings produce intrastrand pyrimidine dimers that inhibit 
polymerase-mediated chain elongation (Cone and Fairfax, 1995). Three- 
dimensional objects, such as pipettes, cannot be effectively decontaminated by 
UV light because only a fraction of the surface actually exposes the light source. 
Although UV irradiation provides an additional margin of safety for keeping the 
PCR laboratory contamination-free, meticulous technique remains the most
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important method for preventing contamination. In particular, UV irradiation 
cannot be substituted for the physical separation of sample preparation in pre- 
and post PCR experiment.
Generally, UV irradiation for more than 10 min with 100pJ min'1 at 254 nm in a 
UV crosslinker should be recommended for reaction tubes and the reaction 
mixture (except the sample DNA, primer and DNA polymerase) (Newton and 
Graham, 1994).
Various kinds of Enzyme for PCR amplification
i) DNA polymerase 1 from E.coli
This heat labile enzyme was the first polymerase to be identified and has the 
function of polymerization of DNA in a 5'—>3' direction, 5'—>3'exonuclease 
activity for nick translation , 3'->5' exonuclease activity for proofreading.
ii) Taq/AmpliTaq DNA polymerase
The thermostable DNA polymerase from Thermus aquaticus has been the most 
widely used enzyme in PCR. Taq DNA polymerase has an optimal extension rate 
of 35-100 nucleotides per second at 70°-80°C which is the optimum temperature 
range for the enzyme. Taq DNA polymerase has a 5' to 3' exonuclease activity, 
which removes nucleotides ahead of the growing chain. But this enzyme has no 
3 '—>5' exonuclease activity to perform a proofreading function. The fidelity of 
Taq (2 x 10-4 error/bp per duplication) is the lowest among DNA polymerases 
whose fidelity has been measured.
Since AmpliTaq is recombinant, the purity and reproducibility of this enzyme 
are higher than Taq DNA polymerase. AmpliTaq LD is a recombinant, 
thermostable 94kDa DNA polymerase encoded by a modified form of the 
Thermus aquaticus DNA polymerase gene which has been inserted into an 
Escherichia coli host. This enzyme is identical to AmpliTaq DNA polymerase 
but is further purified through a proprietary process to reduce bacterial DNA 
introduced from the environment. This product is especially useful for PCR
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amplifications of low copy number bacterial target sequences (<1000 bp) 
because of the low level of DNA in the preparations.
A modified version of the recombinant AmpliTaq DNA polymerase (Stoffel 
fragment) is also available which has a deletion of 289 amino acids from the N 
terminus. This version has twofold higher thermostability, no intrinsic 5' to 3' 
exonucease activity compared to the Taq or Amplitaq DNA polymerases, 
exhibits optimal activity over a broader range of magnesium concentrations.
iii) Topoisomerase 1
Topoisomerase 1 catalyzes unwinding superhelical structures from covalently 
closed circular double-stranded DNA by transient breakage and rejoining of 
phosphodiester bonds (Sambrook et al., 1989).
iv) T7 Sequenase
T7 Sequenase (version 2.0 DNA polymerase) is derived from bacteriophage T7 
DNA polymerase but chemically or genetically modified to improve its 
properties for sequencing. These properties include heat-labile, high processivity, 
low 3' to 5' exonuclease activity. T7 DNA sequenase acts well at the low 
temperature at which the random primer complexes become stable and it has 
strand displacement synthesis capabilities which can synthesize long stretches of 
DNA by displacing other primers that have already annealed to the DNA 
(Bohlander, 1992; Guan et al., 1993).
v) Pfu DNA polymerase
This polymerase is isolated from the hyperthermophilic marine archaebacterium 
Pyrococcus furiosus and has both 5' to 3' DNA polymerase activity and 3' to 5' 
exonuclease proofreading activity. The 3' to 5' exonuclease activity enhances the 
fidelity of DNA synthesis as it will excise incorrectly added, mismatched 3 
terminal nucleotides from the primer/ template and then incorporate the correct 
nucleotide. The fidelity of DNA synthesis is 12-fold higher than that of Taq 
DNA polymerase (Newton and Graham, 1994).
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vi) Pwo DNA polymerase
Pwo DNA polymerase is isolated from Pyrococcus woesei and possesses 3' to 5' 
exonuclease activity but no 5' to 3' exonuclease. This enzyme also has 
proofreading activity as Pfii DNA polymerase. This enzyme has a half life of 2hr 
at 100° C and is useful for high temperature primer extension reactions, DNA 
cycle sequencing and blunt-ending cloning (Newton and Graham, 1994).
1.8.2 Whole Genome Amplification (WGA) from a very small amounts of 
DNA
Molecular or molecular cytogenetic analysis of very small amounts of DNA is 
limited because of insufficient material to perform more than one independent 
PCR amplification or CGH. To solve this problem, there are several methods to 
generate a non-specific amplification of all genomic sequences (whole genome 
amplification) such as primer extension preamplification, degenerate 
oligonucleotide primed PCR, alu-PCR, tagged PCR and ligation-mediated PCR. 
Successful whole genome amplification requires that the fidelity of the 
sequences be maintained and that the extent of amplification is not significantly 
biased. Degenerate oligonucleotides are used as primers in PCR to induce 
polymerase extension randomly at multiple sites in total genomic DNA template 
to reach these requirements.
The reliability of whole genome amplification, particularly in a single or a few 
microdissected formalin-fixed and paraffin-embedded solid tumour cells, has not 
yet been systematically evaluated. Also the limiting cell number of 
microdissected tissue sections has likewise not yet been systematically 
investigated for CGH experiment. There are many problems in achieving 
properly amplified samples. First, when tissue sections are microdissected and 
used for DNA analysis by PCR (WGA), the diminished volume of the cell and 
nucleus by cutting may represent loss of chromosomes or part of chromosomes, 
probably leading to false negative CGH results (Speicher et al., 1995). Another 
problem is intrinsic error rate of Taq polymerase (error rate: KWbp), which is
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prone to introduce AT-to-GC transitions as well as to generate deletion mutations 
due to secondary structures of the DNA template (Cha and Thilly, 1995). Proof­
reading polymerases (e.g. Pfu polymerase) have not yet been fully evaluated for 
the sequence accuracy. Thus there is a potential risk of getting incorrectly 
amplified sequences during whole genome amplification when concentration of 
template DNA is extremely low.
Primer Extension Preamlification (PEP)
basic primer:
15-base oligonucleotides (NNNNNNNNNNNNNNN)
The primer is composed of a mixture of 415 (1 x 109) sequences.
Primer extension preamplification (PEP) is an in vitro procedure developed to 
amplify a large fraction of the genome from limited amounts of DNA, such as 
that derived from a single cell and from microdissected paraffin-embedded tissue 
sections.
PEP was first developed by Zhang et al. (1992). PEP involves repeated primer 
extension using a mixture of 15-base random oligonucleotides and the Taq DNA 
polymerase. It is one of the universal genomic amplification methods which 
have been developed to overcome limitations of PCR analysis in very small 
amount of DNA. Several groups have used PEP, with minor modification such as 
different concentration and size of primer, changing enzyme or changing cycles, 
especially in preimplantation genetic diagnosis (Xu et al., 1993; Kristjansson et 
al., 1994; Snabes et al., 1994). It is estimated that PEP can cover at least 78% of 
the genomic sequence in a single human haploid cell and can amplify any 
sequence in the genome to a minimum of 30 copies. Because of the random 
nature of the primers, it is also unlikely that any one primer-extension product 
will be involved in primer extension at a subsequent cycle more than any other 
primer extension product (Zhang et al., 1992).
When PEP was applied to a single diploid cell or very small cell free DNA 
samples, careful consideration had to be given to the size of each aliquot and the
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number of aliquots taken from the PEP reaction because of the missing allele in 
the aliquot (Zhang et al., 1992). In the case of paraffin-embedded samples, 
whole genome amplification using PEP was not easy because of inadequate 
amount and the poor quality of template DNA which was cross-linked with 
proteins and already nicked to relatively short fragments. Although PEP 
amplification of the whole genome, coupled with subsequent locus-specific 
amplification by PCR, represents a significant improvement over PCR alone for 
the genetic analysis of a single cell, the application of PEP for CGH was still 
under investigation.
Degenerate Oligonucleotide-Primed PCR (DOP-PCR)
Basic primer;
5'-CCG ACT CGA GNN NNN NAT GTG G-3'
DOP-PCR was designed by H. Telenius, 1992 as a simple PCR technique to 
produce general amplification of target DNAs by multiple locus priming without 
restriction using a partially degenerate sequence as a primer. This degeneracy, 
combined with a PCR protocol with a low initial annealing temperature, leads to 
multiple priming at evenly dispersed sites within a given genome. Furthermore, 
the method appears to be species-independent because efficient amplification is 
achieved from the genomes of all species tested using the same method. Thus, 
for the general amplification of target DNA, DOP-PCR proved more effective 
than interspersed repetitive sequence PCR (IRS-PCR), which relies on the 
appropriate position of species-specific repeat elements (Telenius et al., 1992). 
During the DOP-PCR, several cycles of low temperature annealing and 
extensions can anneal at many sites in the human genome. During the first few 
cycles, the annealing temperature usually does not exceed 30°C, since this 
facilitates annealing of the short sequences specified by the 3' end of the 
oligonucleotides used, hence allowing sufficient priming to initiate DNA 
synthesis at frequent intervals along the template. Six random bases can yield 46
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primers of different sequences as opposed to the single sequence of a non­
degenerate primer, thus making its applicability universal. After several cycles of 
low temperature annealing and extensions, the annealing temperature is 
increased to bind more specific priming sites on 6-bp 3' end and specific 10-bp 
5' end. It will allow specific hybridisation to the tagged-genomic sequences only, 
and exponential increase in DNA will take place until Taq DNA polymerase is 
exhausted. While it is possible that higher amounts of Taq DNA polymerase may 
improve the overall yield, this can produce an increased amount of primer 
related products.
Although DOP-PCR amplified exponentially with lower starting DNAs, 
genomic DNA below certain level produces an increased chance that a given 
locus will not be represented in the DOP-PCR product.
DOP-PCR can be used to achieve several hundred-fold amplification of virtually 
all sequences in the human genome with sufficient starting template genomic 
DNA. The product amplified by DOP-PCR cannot represent the whole genomic 
sequence of the starting genomic DNA and universally DOP-PCR amplified 
one-third as well (Cheung and Nelson, 1996). This is thought be caused by non­
specific priming and consequently creating non-specific DNA, which has no 
relation to the human genome and by overlapped sets of DNA fragments. 
Additionally, over-represented highly repetitive DNAs may be related (Cheung 
and Nelson, 1996).
The CGH technique in association with DOP-PCR allowed large retrospective 
prognostic studies of genetic aberrations as well as studies on genetic 
progression from premalignant lesions to advanced lesions in solid tumours by 
application of the CGH technique to the DNA obtained from very small amounts 
of paraffin embedded tissue samples.
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1.8.3 Probe Labelling
P QP-PCR labelling
Degenerate oligonucleotide primer PCR may also be useful for labelling 
genomic DNA. This method is another version of PCR labelling by employing a 
heat stable DNA polymerase. The cycle of denaturation, primer annealing, DNA 
synthesis is repeated up to 40 times. The heat stable DNA polymerase has been 
shown to accept modified nucleotides (digoxigenin or biotin labelled nucleotides, 
directly fluorochrome-conjugated nucleotides) as substrates. The PCR can be 
used not only to amplify DNA but also to produce large quantities of labelled 
probe DNA suitable for CGH.
Purification of labelled probe
After labelling procedure, final product in the mixture includes labelled probe 
and unincorporated labelled nucleotides. These unincorporated nucleotides are 
better to be removed to avoid non-specific background signals.
The High Pure PCR Product Purification Kit (Boehringer Mannnheim) is made 
for the efficient and convenient isolation of PCR products without primer, 
mineral oil, salts, unincorporated nucleotides and the thermostable polymerase 
from amplification products. The High Pure PCR Product Purification Kit 
(Boehringer Mannnheim) is based on the principle that nucleic acids bind 
specifically to the surface of glass fibers or silica materials in the presence of a 
chaotropic salt. The binding reaction occurs within seconds by the disruption of 
the organized structure of water molecules and the interaction with the nucleic 
acids. Since the binding process is specific for nucleic acids, the bound material 
can then be separated and purified from impurities (e.g. salts, free nucleotides 
and proteins) by a simple washing step. The small oligonucleotides and 
dimerized primer from PCR products are also selectively removed by synergistic 
process for requiring minimum lengths of the DNA fragment.
58
Rapid Labelling Assay
One of the critical problems associated with non-radioactive labelling is the 
question of how much labelled probe has been produced because it is difficult to 
monitor incorporation of labelled nucleotide. In this rapid assay, the labelled 
probe is dotted onto a membrane (Hybond-N + nylon or whatman DE 81), the 
unincorporated nucleotide is eliminated in a 20 minutes wash at 60°C. The 
remaining bound probe is visualized by a UV transilluminator or by eye in the 
dark room and compared with diluted original fluorochrome as known standards 
(100%, 75%, 50%, 25%, 12.5%, 6.25%).
1.8.4 Validation of the CGH results
There is a potential risk of false copy number changes being introduced during 
whole genome amplification by methods such as PEP or DOP-PCR. Many 
efforts have been made to validate CGH with other cytogenetic methods. 
Comparison of CGH results with those obtained by karyotyping, FISH, and 
molecular method (e.g. microsatellite assay or loss of heterozygosity) has clearly 
indicated that CGH reliably detects DNA sequence copy number aberrations of 
solid tumour (Kallioniemi et al.; 1994).
To obtain reliable detection of chromosome gains and losses, careful controlling 
of the quality of hybridisation is required. This can be evaluated by the signal 
strength, the smoothness of the signal distribution along the chromosome, the 
lack of accentuated banding, the efficient blocking of the centromere, and the 
absence of artifactual ratio variations. One of the important ways of verifying the 
CGH results is to include normal and positive controls in each experiment.
Inverse labelling CGH and tissue in situ hybridisation are also used for 
validation (Isola et al., 1994; Speicher et al., 1995).
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Inverse labelling CGH (Reverse CGH)
To further improve the accuracy of the CGH, inverse-labelling can be applied. 
Inverse labelling means that test samples are labelled with Texas-Red and 
hybridised with FITC-labelled normal reference DNA to control for differences 
in hybridisation of FITC versus Texas-Red labelled probes. Comparison between 
these two hybridisation methods confirmed the presence of copy number 
aberrations at almost all loci (Isola et al., 1994; Speicher et al., 1995).
Tissue In Situ Hybridisation
FISH has become a well-established technique to confirm CGH results. 
Particularly in solid tumors where fresh cells or freshly prepared fixed cell 
preparations were not available, paraffin-embedded tissue can become an 
alternative source of material for FISH (Schofield et al., 1992; Kim et al., 1993). 
Paraffin-embedded tissue can be analysed as a suspension of disaggregated, but 
intact, nuclei or as an intact section of tissue. The advantages of performing 
studies on suspensions of intact nuclei are that numerical abnormalities for a 
given chromosome can be detected even in a small population of cells. The main 
disadvantage is loss of the spatial relationships of one cell to another. The main 
advantage of analysing tissue sections is preservation of the spatial relationship 
between cells and possibility of identification of numerical abnormalities in 
subpopulation of cells. The major drawback to this method is that exact counting 
of abnormal cells is very difficult because of the three dimensional structure of 
the cells and the existence of partial nuclei rather than intact nuclei in a given 4 
to 6-um-thick tissue section. To increase the accuracy of the test, many nuclei 
must be counted and statistically analysed to determine whether an abnormal 
population of cells exists.
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1.9 Genetic Changes in Cancer Development
Cancer is caused by disruption of the genetic mechanisms that control the 
normal cellular growth, location and mortality of cells. In most of cancer, the 
genetic mutations are not inherited and arise in somatic cells during adulthood as 
a result of exposure to environmental carcinogens (Connor and Ferguson-Smith, 
1993) or of spontaneous genetic changes but some individuals have an inherited 
mutation in a gene which induces a genetic predisposition for development of 
cancer (Hodgson and Maher, 1993). Mutation in three broad categories of genes 
including proto-oncogenes, tumour suppressor genes, and genes coding for DNA 
repair enzymes probably leads to disruption of normal control mechanism by 
changes in cell surface protein expression, protein secretion and cell motility 
(Fig 1.11). Cancer development is associated with an inter-relation between 
susceptibility to cancers and an impaired ability of cells to repair DNA damage. 
It suggests that cancers develop not only from deregulated proliferation but also 
from disorganized control of the programmed cell death or apoptosis. Growth 
arrest process associated with aging (senescence) may become useless as a 
further consequence of the activation of oncogenes or the loss of tumour 
suppressor genes. Senescence is usually associated with shortening the length of 
telomeres which are composed of short, tandem repeats of the hexanucleotide 5'- 
TTAGGG-3' at the end of each chromosome. Telomerase, which is responsible 
for synthesis of the telomere, is active in many tumours but is not common in 
normal tissue (Hesketh, 1995).
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1.9.1 Cell cycle regulation and pathogenesis of cancer
Tumour progression is related to genomic changes represented by chromosomal 
aberrations, translocations and aneuploidy, which arise by cumulative genetic 
changes resulting from loss of cell cycle control. In other words, cancer can be 
described as a disease of the cell cycle.
There are two major control points within the cell cycle- one near the end of G]5 
known as the restriction point (G,-S) and the other at the initiation of mitosis 
(G2-M). During the G] phase, cells responding to extracellular signals progress to 
either continuing toward another division cycle or withdrawal from the cycle 
into a resting state (G0). The decision about division occurs as cells pass a 
restriction point late in G,, after which they become refractory to extracellular 
growth regulatory signals and then carry out the autonomous program that 
commits them to the division. Although G, progression can normally be 
stimulated by mitogens or blocked by antiproliferative cytokines, cancer cells are 
not affected by these controls and are likely to stay in cycle. Consequently 
because cell cycle exit can facilitate maturation and terminal differentiation, 
these processes are also destroyed. The usual function of the G2-M control point 
seems mainly to confirm that the DNA is completely replicated, undamaged and 
ready to be separated at mitosis (Carr, 1996; Sherr, 1966).
The progression of the cell cycle is checked for DNA damage at the G,-S and 
G2-M boundaries. Normal cells with DNA damage remain at either of these 
checkpoints during appropriate DNA repair. At the G,-S checkpoint any damage 
sustained by cellular DNA is repaired with great fidelity. The second checkpoint 
occurs at the G2-M boundary where cells can be arrested if they have damage not 
previously corrected after entering into the S-phase.
Many of the proteins that coordinate and control the cell cycles are identified. 
Various cyclin-dependent protein kinase complexes act as key regulators of cell 
cycle progression at the different stages of the cell cycle to integrate the 
independent events that constitute the cell cycles. In mammalian cells, a series of 
signalling pathways interact with the cyclin-dependent kinase and hold or 
stimulate entry into the cell cycle when it is appropriate. When errors develop,
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either in the genetic material itself or through a conflict in signalling processes, 
eukaryotic cells are blocked up advancing through the cell cycle or lost 
completely by programmed cell death (Carr, 1996).
Activating mutations in oncogenes and inactivating mutations in tumour 
suppressor genes induce carcinogenesis. Activated oncogenes ultimately 
promote activation of CDK complexes and subsequently uncontrolled cell 
proliferation occurs. The checkpoint pathways become useless by inactivating 
mutations in tumour suppressor genes.
1.9.2 Oncogenes
Some tumour viruses such as retroviruses contain genes that are able to cause 
tumours. These genes are called viral oncogenes, v-oncogenes. In the human 
genome, there are normally genes with DNA sequences very closely related to 
the viral oncogenes.
Proto-oncogenes are normal cellular genes, which encode protein involved in 
normal cell division and differentiation (Bradley et al., 1995). The functions of 
protein products of proto-oncogenes in normal cells may include growth factors, 
growth factor receptors, signal transducers, and nuclear proto-oncogenes and 
transcription factors (Hodgson and Maher, 1993; Hesketh, 1995).
When a proto-oncogene becomes mutated, it may function as an oncogene. 
There are several mechanisms to induce mutation of proto-oncogenes: 
translocations, point mutations, deletions, and gene amplification. An oncogene 
is a gene whose action stimulates uncontrolled cell proliferation by losing 
control of normal cell growth and division.
1.9.3 Tumour suppressor genes
In normal cells there are gene products that have the ability to suppress the 
uncontrolled cell proliferation which is characteristic of malignant cells. The 
genes involved are called tumour suppressor genes, recessive oncogenes or 
growth suppressor genes.
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While the normal products of tumour suppressor genes possess an inhibitory 
function in cell growth and division, this function is lost when tumour 
suppressor genes are inactivated and consequently this leads to unprogrammed 
cell proliferation.
Although inactivation of tumour suppressor genes has been linked to the 
development of a wide variety of human cancer, the two best understood tumour 
suppressor genes are the retinoblastoma {RBI) gene and TP53. Retinoblastoma 
provides the classical model for a recessive tumour suppressor gene in that both 
paternal and maternal copies of RBI must be inactivated for tumour to develop. 
For TP53 and some other tumour suppressor genes, mutation at one allele may 
be sufficient to give rise to the altered cell phenotype (Hodgson and Maher, 
1993).
1.9.4 Apoptosis
Apoptosis, or programmed cell death, is a natural physiological process which 
normally controls the lifespan of cells, occurring in embryonic development, 
differentiation and morphogenesis. It acts as a pathway of control of growth by a 
selective elimination of cells as another pathway of regulation of growth control. 
Apoptosis is also induced by exposure of cells to various agents and aberrant 
physiological conditions.
Cells undergoing apoptosis are characterized by distinctive morphological 
changes involving the condensation of nuclear chromatin and shrinkage of the 
cytoplasm, and the fragmentation of nuclear DNA. The apoptotic bodies are 
rapidly phagocytosed by neighbouring cells but this is not accompanied by an 
inflammatory response. The major biochemical feature of the apoptotic process 
is the fragmentation of nuclear DNA by Ca2+ -Mg2+ - dependent endonucleases 
which cleave the DNA at internucleosomal sites (Cohen and Duke, 1984; Caron- 
Leslie et al., 1991).
Several genes that are closely related with cell proliferation and neoplastic 
development are also associated with the apoptotic pathway. This indicates that 
the regulation of these processes may be interlinked and deregulation of
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apoptosis may induce tumorigenesis and deregulation of cell cycle control would 
affect the cells into apoptotic pathway
1.9.5 DNA Repair
DNA repair mechanisms are present to correct DNA damage due to 
environmental mutagens and accidental base misincorporation at the time of 
DNA replication. Inherited defects of either system result in an increased 
frequency of cancer (Connor and Ferguson-Smith, 1993).
The recognition and repair of DNA damage occurs before the cells enter the S- 
phase of the cell cycle and cells are held in the G1 phase until the repair process 
is completed.
Replication errors which are not corrected by the proofreading activity of DNA 
polymerase may be amended by a process called mismatch repair. This process 
includes the recognition of mismatched bases or single base insertion or 
deletions in the newly replicated strand followed by correction of the error. Four 
human DNA mismatch repair gene loci in humans have been identified, MSH2, 
MLH1, PMS1, PMS2 (Hesketh, 1995) and these gene products act with each 
other to achieve mismatch repair in normal cells. Mutations in mismatch repair 
genes result in an overall increase of the mutation rate and predispose to cancer 
development.
1.9.6 Double minutes (DMs) and Homogeneously staining regions (HSRs)
These structures are amplifications of specific genetic material and are generally 
correlated with resistance to various drugs especially anti-metabolite drugs. They 
are also associated with many human cancers, frequently appearing in tumour 
cell lines, and are particularly associated with the progression of many tumours 
from benign to highly aggressive (Alitalo and Schwab, 1986).
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Double minutes (DMs)
DMs are small spherical structures like minute chromosomes that each consist of 
approximately 1000-2000 kb of DNA. They do not participate in regular division 
at mitosis, segregating in a random fashion and producing an unequal 
distribution in the daughter cells (Clark and Wall, 1996).
Homogeneously staining regions (HSRs)
HSRs are large regions of non-banding amplified material within a chromosome. 
HSRs stain uniformly with G or Q banding with intermediate range of intensity. 
The size of the HSR is related to the length of the sequence amplified and the 
number of times it is multiplied. Multiple HSRs can occur in cells as a result of 
several amplification events or breakage and translocation of the original HSR.
1.9.7 Chromosomal Abnormalities in Malignancies
The probability that chromosome abnormalities were a cause of malignant 
transformation was suggested by Boveri in 1914 (Therman and Susman, 1993; 
Hodgson and Maher, 1993). Nowell and Hungerford identified the Philadelphia 
chromosome in chronic myeloid leukemia as the first consistent chromosomal 
abnormality in 1960. Then a large number of numerical and structural 
chromosome aberrations were discovered in wide range of cancers. Wide 
spectrum of chromosomal aberrations were found including numerical changes 
(from near haploid to polyploid, monosomy or trisomy), structural changes 
(partial monosomy or trisomy, unbalanced or balanced translocations, 
isochromosomes, isodicentrics, ring chromosomes), amplications (HSR, DMs), 
and marker chromosomes.
Although cytogenetic information from solid tumours was scarce because of 
technical difficulties, recent advances in culture techniques and in molecular- 
cytogenetic techniques has made possible remarkable progress in the analysis of 
solid tumours.
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Chromosome aberrations in human cancer may be categorized into primary and 
secondary events. Primary chromosome aberrations occuring early in the 
development of the tumour are directly related to the genesis of cancer and are 
frequently found in particular tumours as a sole abnormality and show a highly 
nonrandom nature. Secondary chromosome aberrations tend to show more than 
one abnormality and are accompanied by primary changes. Secondary 
abnormalities may be additional phenomena during the progression of tumour or 
may have a role in the subsequent biological behaviour of the tumour, including 
invasion, metastasis and response to therapy (Hodgson and Maher, 1993). 
Chromosome aberrations such as deletions of part of or an entire chromosome 
may induce inactivation of tumour suppressor genes. Translocations may 
activate an oncogene or inactivate a tumour suppressor gene. Gains of 
chromosomal material can lead to over-expression of oncogenes (Hodgson and 
Maher, 1993).
Leukemia
Leukemia accounts for about 2% of all human cancers and shows two peaks in 
the age incidence- in childhood and in the elderly (Hodgson and Maher, 1993). 
Despite the increased incidence of leukemia in congenital syndromes, most 
leukemia is likely to be an acquired condition. Most cases of leukemia reflect a 
stem cell disorder and the pathogenesis is often multi-step. Etiology is usually 
unknown, but may result from the interaction of endogenous factors such as 
inherent chromosome instability, abnormal DNA repair and altered immune 
function or exogenous factors such as radiation, chemicals and viruses.
i) Cytogenetic aspects of acute lymphoblastic leukemias
The identification of the chromosomal aberrations in acute lymphoblastic 
leukemia is particularly important to establish the exact diagnosis, to predict 
prognosis and to monitor the effects of therapy or bone marrow transplantation. 
Clonal chromosomal abnormalities at diagnosis have been reported in between
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44% and over 90% of patients analysed. The success of a cytogenetic analysis 
for detection of abnormal clone is dependent on optimal sample and culture 
conditions (Pui et al., 1990; Seeker-Walker, 1994).
Importance of cytogenetics in ALL still continues as an independent prognostic 
indicator in spite of continuous adjustment to treatment regimens. An ever- 
increasing understanding of the genetic consequences of translocations and other 
chromosomal aberrations is extending the role of metaphase and interphase 
cytogenetics both in patient management and in increasing our understanding of 
the biology of the disease.
The convergence of cytogenetics and molecular techniques has now become a 
powerful method for understanding the events that predispose to, and result in, 
human ALL (Look, 1985).
ii) Established chromosomal aberrations of ALL
There are now at least 36 structural and 8 numerical abnormalities established in 
association with ALL (Seeker-Walker, 1994).
Although the incidence of chromosomal aberrations may vary according to the 
patient’s age, geographic location and the exact nature of the leukemia examined, 
the most common changes are t(9;22), t(4;ll), and del(6q) followed by t(8; 14), 
t ( l ; 19) and del(9p) (Downing and Look, 1995).
a) Structural abnormalities
ALL with t(4; 11 )(q21 ;q23) is often observed in patients with ALL-Llor L2, is 
sometimes associated with congenital leukemia and has a poor prognosis similar 
to ALL with t(9;22). ALL with t(9;22) is observed in 6% of childhood and 17% 
of adult ALL. It is of pre B-cell or B-cell lineage and has an poor prognosis. B- 
cell ALL with t(8; 14), t(2;8), or t(8;12) also has a very unfavourable prognosis 
and high incidence of CNS involvement at presentation possibly because of the 
very high cell proliferative rate of this disease (LeBeau, 1991; Kurzrock and 
Talpaz, 1995; Look, 1995). Other structural abnormalities including t( 1; 19),
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t(8;22), del(6q), del(9p), t/del(12p) have not been demonstrated to have any 
prognotic significance (Seeker-Walker, 1994).
b) Numerical changes - ploidy groups
Hypodiploidy;
Hypodiploidy, clonal loss of one or more chromosomes occur in 5%-8% of 
reported series in children and 9% of adults. There is little consistency in the 
clinical features of these cases. Prognosis for this group is variable.
Near-haploidy 23-36 chromosomes;
Near-haploidy is marked by the gain from haploidy (23 chromosomes) chiefly of 
chromosomes 10, 14, 18, 21 and the presence of both sex chromosomes, XX or 
XY. The reported incidence ranges from 0.7% to 2.4% and is more frequent in 
adolescent girls. This group has a particularly unfavourable prognosis with a 
median survival of 11 months.
Pseudodiploidy;
Pseudodiploidy describes a clone with a false dipolid complement of 46 
chromosomes. The vast majority of pseudodiploid clones are accompanied by 
chromosomal translocations. Prognosis is usually unfavourable.
Low hyperdiploidy 47-50 chromosomes;
The most frequent gains are of chromosomes 21, X, 8 and 10 together with 
structural changes which often include abnormalities of lq, 6q, 12p and 19p. The 
incidence in childhood leukaemia ranges from 11% to 15% and in adults 
between 8% and 11%. The prognosis is variable due to the heterogeneous nature 
of the group.
High hyperdiploidy 51-65 chromosomes;
Chromosomal gain in high hyperdiploidy is nonrandom with an excess gain of 
chromosomes X, 4, 6, 14, 17, 18 and 21. The incidence in childhood series (16%
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to 27%) is at least 6 times greater than in adults (4%-5%). Usually patients with 
51-60 chromosomes have had the most favorable prognosis (Pui et al., 1990; Van 
der Plas et al., 1992). There is some evidence that, within this subgroup, patients 
with trisomy 6 or with trisomies 4 and 10 have the best prognosis (Jackson et al., 
1990; Harris et al., 1992). One characteristic which distinguishes patients with 
high hyperdiploidy is their response to the folate antagonist methotrexate (MTX) 
used in all treatment regimens. Improved survival has been demonstrated in 
patients whose lymphoblasts have the ability to accumulate high levels of 
methotrexate and methotrexate polyglutamate in vitro. This ability has been 
shown to be greatest in the lymphoblasts from children with hyperdiploidy 
(Whitehead et al., 1992). By combining metaphase cytogenetics with interphase 
cytogenetics using chromosome-specific centromeric probes, it becomes 
possible to demonstrate heterogeneity both in the mitotic index of the clone and 
in the elimination of the clone after 28 days of treatment. This technique will 
detect approximately 1/1000 clone cells.
Triploidy/tetraploidy;
Cases with >65 chromosomes represent a minority of cases in ALL with an 
incidence in childhood of approximately 1%.
Cytogenetic aspects of Acute myeloid Leukemia
AML is characterized by proliferation and accumulation of malignant 
myeloblasts and other immature myeloid cells. Infiltration of the marrow with 
these cells causes anemia, granulocytopenia and thrombocytopenia.
The classification of AML is based on the clinical presentation, cellular 
morphology, cytochemistry and immunology. The French-American-British 
(FAB) type, which is a morphological classification, serve as an important guide 
in prognosis and therapy of the individual leukemias and can act as a pointer to 
the likely chromosome abnormality which may be found.
Numerical or structural chromosomal aberrations in AML may occur alone or 
together. The frequency of chromosome abnormalities detected in AML at
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diagnosis is variously reported as 60 to 90% depending on length of time in 
culture, banding techniques and referral patterns of reporting centres. With 
improved banding techniques, a chromosomal abnormality in at least 70% of 
cases could be detected (Walker et al., 1994).
The most frequently observed numerical abnormalities in all FAB types of AML 
are trisomy 8 and monosomy 7. Rarely observed are trisomies of chromosomes 4, 
11, 13, 21 and 22. Numerical aberrations are seen in 15-20% of the 
cytogenetically abnormal AML cases (Downing and Look, 1995).
There are a number of common specific chromosome rearrangements which 
include translocations, inversions and deletions. t(8;21)(q22;q22) is the most 
common structural abnormalities in AML, seen in 10-15% of all M2 and some 
M4 cases, has a favorable prognosis with an uniformly high complete remission 
rate. t( 15; 17)(q22;q21) is detected in at least 70-90% of M3 cases and associated 
with good prognosis. inv(16)(pl3;q22), which are associated with AML M4Eo. 
This subtype shows high complete remission rate with standard AML 
chemotherapy, which may be followed by subsequent CNS involvement, often 
with intracranial masses.
A poor prognosis is associated with several chromosomal aberrations in AML 
such as rearrangement of 3q21-q26, -5 or del(5q), -7 or del(7q), t(6;9), t(llq23), 
and del/t(12p).
Secondary AML
Secondary AML is usually defined as AML resulting from treatment with 
cytotoxic drugs and/or radiotherapy, or from exposure to environmental toxic 
agents. The most common abnormalities are —5/del(5q) and -7/del(7q) which are 
often present in the same clone. Other common cytogenetic aberrations are +8, - 
17, -18, +21, -21 and abnormalities of 3q, 6p, llq , 12p, 17p and 21q. Complex 
and hypodiploid karyotypes are a common feature.
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Well Differentiate Liposarcoma (WDLPS)
Liposarcoma is one of the most common types of soft tissue sarcoma in adults. 
WDLS is one of the histological subtypes of this malignant tumour including 
myxoid, round cell, and pleomorphic liposarcoma.
The characteristic cytogenetic findings of WDLPS are supernumerary rings, 
giant rod-like marker chromosomes and telomeric associations (Szymanska et al., 
1996). These marker chromosomes may be derived material from chromosome 
12q as well as material from chromosome 1, 4, 8 and 16 (Pedeutour et al., 1994). 
SAS and MDM2, well known to be amplified in liposarcomas, are located in 
chromosomal bands 12ql3-14 (Nilbert et al., 1994; Pedeutour et al., 1994). In 
addition to amplification band on 12q 14-21, chromosome 1 q21-24 is often 
amplified (Szymanka et al., 1996).
Malignant Melanoma
Melanoma is one of the commonest human malignancies and one of the most 
malignant of all cancers. Epidemiologically, the incidence of melanoma is 
showing an increasing trend, especially among whites.
During early gestation, melanocytes migrate from the neural crest to the skin, 
mucous membranes, uveal tract and meninges. So melanoma can arise at any 
sites where tissue of neural crest origin is found and includes the epidermis, hair 
bulbs, leptomeninges and retina.
Most melanoma occurs in the skin. When it has invaded into the deeper dermis 
or fat, it metastasizes frequently to local regional lymph nodes or to other organs. 
In the early stages of melanoma, it is difficult to detect genetic alteration using 
molecular analysis because by current isolation methods it is difficult to obtain 
malignant cells without contamination with other cells. By several cytogenetic 
studies, malignant melanoma has shown to have structural abnormalities 
affecting chromosomes 1, 6, 7 and numerical abnormalities as +1, +5, +7, -9 and 
-10. In metastatic melanomas, additional nonrandom abnormalities have been 
shown on chromosomes 1, 2, 6, 7, 9, and 11 (Ozisik et al., 1994). By means of
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cytogenetic studies of cutaneous malignant melanoma, 9p and lOq were seen to 
be involved in earliest stage of melanoma tumorigenesis although there is some 
controversy whether chromosome 10 is involved in the earliest stage or not. The 
incidence of loss of chromosome 10 (especially lOq) was very high. It suggests 
that putative tumour suppressor genes are probably located on chromosome lOq. 
It is of interest that loss of lOq has also been found in other neural crest derived 
tumours such as glioma (Karlborn et al., 1993; Indsto et al., 1998).
1.9 Aims of this project
The first aim of this project was to assess the usefulness of interphase FISH in 
the cytogenetic analysis of hematological malignancies, especially acute 
lymphoblastic leukemia, and then to evaluate whether CGH would be an 
approach to help identify chromosomal aberrations in hematological 
malignancies. The second aim was to assess the applicability of CGH to fresh 
frozen solid tumours. Finally, the aim was to optimise several procedures of 
whole genome amplification for analysing very small amounts of DNA using 
CGH, to evaluate the limiting amount of test DNA required for analyzable CGH 
images and to apply these optimized techniques on paraffin-embedded sections 
from samples of melanoma.
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CHAPTER 2.
MATERIALS and
METHODS
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2. Materials and Methods
2.1 Safety
Laboratory coat and gloves were worn at all times during the experiments. 
Handling of human blood, bone marrow, and other biological materials was 
carried out in a appropriate safety cabinet. All glassware and where appropriate 
solutions were sterilized using an autoclave. If it was needed, some solutions 
except for primer, plastic equipment, microcentrifuge tubes, tips, and pipettors 
were exposed to UV irradiation. Toxic and carcinogenic agents were handled 
with care in a special fume hood according to safety guidelines.
2.2 Samples
There were two major sources of material for the investigations in this study. 
The first was the diagnostic laboratories of the Department of Medical Genetics. 
Blood and bone marrow samples remaining after diagnostic analysis were 
supplied by the cytogenetics laboratory as was the fresh frozen tissue from 5 
cases of liposarcoma. The molecular genetics laboratory provided paraffin- 
embedded sections of ovarian tumour. The Cytogenetics laboratory also supplied 
the results of their diagnostic tests. In the later part of the study both fresh frozen 
samples and paraffin sections of melanoma were provided by the Dermatology 
Department of the Western Infirmary.
For the CGH study, control DNA was extracted from normal male and female 
peripheral blood.
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2.3 Basic solutions for experiment
1. Tris-acetate (TAE, 50x)
242 gram Tris base
57.1 ml glacial acetic acid
100 ml 0.5 M EDTA (pH 8.0), dissolve in 1000 ml of distilled water, store at 
room temperature
2. T.B.E. buffer (5x)
54 gram Tris base
27.5 gram Boric acid
40 ml 0.5 M EDTA (pH 8.0), dissolve in 1000 ml of distilled water, store at 
room temperature
3. T.E. buffer (pH 8.0)
10 mM Tris-HCl (pH 8.0)
1 mM EDTA (pH 8.0)
4. Phosphate-buffered saline (PBS)
10 Dulbecco PBS tablets in 1000 ml of distilled water, adjusted pH to 7.4 with 
HC1, sterilize by autoclaving and store at room temperature.
5. 1 M Tris HC1
Dissolve 121.1 g of Tris base in 800 ml of distilled water, adjust the pH to the 
appropriate value by adding concentrated HC1. Allow the solution to cool to 
room temperature before making final adjustments to the pH. Adjust the 
volume of the solution to 1000 ml with distilled water, and sterilize by 
autoclaving.
6. 5 MNaCl
292.2 g of NaCl in 1000 ml of distilled water, sterilized by autoclaving
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7. 0.5 M EDTA (pH 8.0)
Add 186.1 g of disodium ethylenediaminetetra-acetate.2H20  to 800 ml of H20. 
Stir vigorously on a magnetic stirrer. Adjust the pH to 8.0 with NaOH and 
sterilize by autoclaving.
8. 10% sodium dodecyl sulfate (SDS)
Dissolve 100 g of electrophoresis-grade SDS in 900 ml of distilled water. Heat 
to 68°C to assist dissolution. Adjust the pH to 7.2 by adding a few drops of 
concentrated HC1. Adjust the volume to 1 litre with distilled water. Dispense 
into aliquots.
9. 3 M sodium acetate
Dissolve 408.1 g of sodium acetate.3H20  in 800 ml of distilled water. Adjust 
the pH to 7.0 with dilute acetic acid. Adjust the volume to 1000 ml with 
distilled water. Dispense into aliquots and sterilize by autoclaving.
10.10 M ammonium acetate (protein precipitating solution)
770 g of ammonium acetate in 1000 ml of distilled water, sterilize by 
filtration.
11. 20x SSC
Dissolve 175.3 g of NaCl and 88.2 g of sodium citrate in 800 ml of distilled 
water. Adjust the pH to 7.0 with a few drops of a 10 M solution of NaOH. 
Adjust the volume to 1000ml with distilled water. Sterilize by autoclaving. 
Store at room temperature.
12. 2x SSC
Dilute 20x SSC to 1/10 concentration, for example 50 ml of 20x SSC mix 
with 450 ml of distilled water. Store at room temperature.
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13. 4x SSCT (4x SSC, 0.05% Tween-20)
Add 250 pi of Tween-20 into 100 ml of 20x SSC, adjust the volume to 500 
ml with distilled water. Store at room temperature.
14. 1 kb ladder
100 pi of stock ladder solution are mixed with 200 pi of loading mix and 800 
pi of distilled water.
15. Loading mix
Mix 30% glycerol with 0.25% bromophenol blue in distilled water.
2.4 Chromosome preparation from cultured peripheral blood 
cells
2.4.1 Culture and Metaphase harvest of peripheral blood
Materials
Heparinized whole blood 
Iscoves Medium
100 ml Iscoves medium (Imperial Labs Prod.)
1 ml Heparin (5,000 units/ml: LEO Laboratories)
1 ml Glutamine (Gibco BRL)
2 ml PHA (Gibco BRL)
1 ml Penicillin/Streptomycin (Gibco BRL)
10 pg/ml Colcemide (Gibco BRL)
75 mM KC1 (0.56 g in 100 ml H20; store <2 weeks at room temperature) 
Fixative: 3:1 absolute methanol/ glacial acetic acid
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Procedure
1. Add 0.5 ml of heparinized whole blood to 4.5 ml of culture medium using 
an aseptic technique.
2. Mix the contents of each culture tube by gently inverting several times.
3. Incubate for 72 hours with tubes tilted at 45° in a humidified 37°C 
incubator.
Harvest culture
1. Initiate harvest by adding 0.1 ml of Colcemide. Mix by gently shaking the 
tube and incubate at 37°C for 45 minutes.
2. Centrifuge the tube at 1200 rpm for 7 minutes, room temperature. Discard 
the supernatant using pipette into a container of 10% Chloros.
3. Add 10 ml of 75 mM KC1 (prewarmed at 37°C) and gently resuspend pellet.
4. Incubate the tubes at 37°C for 10 minutes.
5. Centrifuge the tubes at 1200 rpm for 7 minutes. Then discard the supernatant 
into a container of 10% Chloros.
6. Resuspend the pellet by adding 10 ml of fresh fixative.
7. Centrifuge the tubes at 1200 rpm for 7 minutes and remove the supernatant
8. Resuspend the pellet in 10 ml of fixative. Centrifuge the tubes at 1200 rpm 
for 7 minutes and pipette off the supernatant.
9. Resuspend the pellet by adding 5 ml of fresh fixative and place the tubes in 
the refrigerator (+ 4°C) for a minimum 30 minutes.
10. Centrifuge the tubes at 1200 rpm for 7 minutes and pipette off the 
supernatant.
11. Remove the supernatant and resuspend the pellet in 0.5 to 1.0 ml of fresh, 
cold fixative to produce a light milky suspension.
12. Prepare slides and analyse chromosome spreads.
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2.4.2 Culture and Harvest by chromosome elongation methods
Materials
Culture medium
100 ml Iscoves medium (Imperial Labs Prod.)
1 ml Heparin (5,000 units/ml)
1 ml Glutamine (Gibco BRL)
2 ml PHA (Gibco BRL)
1 ml Penicillin/Streptomycin (Gibco BRL)
10pg/ml Colcemid solution
37.5 mM KC1 (hypotonic solution)
Thymidine solution (30 mg/ml: Sigma)
10 ml distilled water 
300 mg Thymidine
2-deoxycytidine stock solution (2.27 mg/ml: Sigma)
20 ml distilled water 
45.4 mg 2-deoxycytidine 
Store frozen as 1 ml aliquots 
2- deoxycytidine working solution (0.227 mg/ml)
9 ml distilled water 
1 ml 2-deoxycytidine stock solution
Procedure
1. Add 1.0 ml heparinised whole blood to 9 ml of culture medium using an 
aseptic technique
2. Incubate for 48 hours with tubes tilted at 45° in a humidified 37°C, 5% C 02 
incubator.
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3. Add 0.1 ml thymidine solution to each 10 ml culture tube, (final 
concentration: 0.3 mg/ml)
4. Incubate the cultures for a further 18 hours in same conditions as above.
5. Add 0.1 ml of 2-deoxycytidine working solution to each 10ml culture, (final 
concentration: 10 pmol/ml)
6. Incubate the cultures for a further 3 hours and 55 minutes at 37°C.
Harvest culture
1. Add 0.1 ml colcemid to each 10 ml culture, mix by gently shaking the tube
and incubate for an additional 20 minutes, (final concentration: 0.1 pg/ml)
2. Centrifuge the tubes at 1200 rpm for 7 minutes.
3. Discard the supernatant into 10% Chloros, leaving approximately 1 ml and 
resuspend the pellet by gently tapping the side of the tube.
4. Add 9 ml of 37.5 mM KC1 solution (pre-warmed to 37°C) into above 
resuspended pellet. The first 0.5 ml should be added drop by drop whilst 
gently tapping the side of the tube.
5. Centrifuge the tubes at 1200 rpm for 7 minutes.
6. Discard the supernatant into 10% Chloros, leaving approximately 1 ml and 
resuspend the pellet by gently tapping the side of the tube.
7. Add 9 ml of cold, fresh fixative. The first 0.5 ml should be added drop by 
drop whilst gently tapping the side of the tube.
8. Centrifuge the tubes at 1200 rpm for 7 minutes and discard the supernatant.
9. Repeat steps 7 and 8.
10 Resuspend the pellet in 5 ml of cold, fresh fixative and place the tubes in the 
refrigerator (+ 4°C) for a minimum of 30 minutes.
11. Centrifuge the tubes at 1200 rpm for 7 minutes and discard the supernatant.
12. Add 0.5 to 1.0 ml of cold, fresh fixative solution to resuspend the pellet.
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2.4.3 Slide Preparation
1. Clean microscope slides by soaking in Decon overnight and rinse with 
running tap water for at least 2 hours. Stored the clean slides in 70% ethanol.
2. Remove the slides from ethanol and rinse with running water until the 
ethanol has gone and a thin, uniform film of water cover the slides. Keep the 
slides inside water at + 4°C at least for 30 min.
3. Centrifuge the tubes containing the cell suspension at 1200 rpm for 8 
minutes and discard the supernatant, resuspend the pellets in 0.5-1 ml of 
fresh cold fixative solution. Place 3-4 drops of the cell suspension onto cold, 
grease free, wet slides.
4. For G-banding, place the slides on a hotplate to dry and evaluate under a 
light microscope (phase contrast). For FISH or CGH, allow the slides to air 
dry.
2.5 Chromosome banding technique
2.5.1 Giemsa banding
Materials
Sorensons Buffer
1000 ml of distilled water
9.48 g Disodium dihydrogen phosphate
9.08 g Potassium dihydrogen phosphate
Trypsin solution
1000 ml of Sorenson’s buffer 
1.2 gDifco Trypsin (1:250)
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Staining solution
2000 ml of methanol 
3 g of Leishmans powder 
Filter this solution before use. For staining purposes dilute this solution with 
buffer (pH 6.8) in the ratio 1 part stain to 3 parts buffer.
Procedure
1. Age the slides by placing them in a dry oven at 80°C for two hours.
2. Immerse the slide in trypsin solution solution for 10 to 15 seconds.
3. Rinse with saline and stain with Leishmans solution for two minutes.
4. Place the slide on the hotplate to dry.
2.6 Fluorescence In Situ Hybridisation
In this study, test materials for FISH were peripheral blood or bone marrow, 
paraffin-embedded tissue. In the early part of this study, FISH was performed 
with chromosome specific centromeric probes and whole chromosome libraries 
to become familial with FISH technique, then mono- or dual colour FISH using 
alpha-satellite, chromosome-specific probes was carried out for the study of 
hematologic malignancies. Finally FISH was performed on paraffin-embedded 
tissue using unique sequence probes.
2.6.1 Labelling of Probes by nick translation
In the first part of this study probes were labelled indirectly with biotin or 
digoxigenin where probes were commercially unavailable.
In this method, digoxigennin or biotin were used as reporters instead of directly 
fluorochrome coupled nucleotides. Biotinylation was carried out by nick 
translation using biotin-11-dUTP.
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Material
A) For nick translation
Biotin-dUTP or Digoxigenin-dUTP (Sigma)
DNA to be labelled
Nick translation system (Gibco BRL)
B) For ethanol precipitation 
3M sodium acetate
Glycogen (Boehringer Mannheim)
80% cold ethanol (filtered)
Procedure:
1. Prepare the solution to a final volume of 50 pi solution containing 1 pg of the 
DNA to be labelled, 5pi of solution A4 (dATP, dCTP, dGTP), 3 pi of biotin- 
11-dUTP, 5 pi of DNA polymerase 1/DNase 1 enzyme mixture, and distilled 
water.
2. Mix the content by inverting the tube and incubate at 15°C for 90 minutes.
3. Stop reaction by adding 5 pi of stop buffer (solution D).
Ethanol precipitation to remove unincorporated nucleotides
4. Add 5 pi of 3 M sodium acetate, 1 pi of glycogen, and 122pl of ice-cold 85% 
ethanol to the probe.
5. Mixed the content by inverting the tube, placed at -70°C for 30 minutes or -  
20°C for overnight and then centrifuge at 14000 rpm for 30 minutes.
6. Discard the supernatant.
7. Allow the pellet to air dry, and then dissolve in 20 pi of lx TE buffer.
For labelling with digoxigenenin, all procedures are the same as for biotinylation 
except for substitution of 3pl of biotin-11-dUTP for 2pl of digoxigenin-dUTP.
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2.6.2 FISH to metaphase chromosomes, interphase nuclei
Materials
A) For preparation of target metaphase and probe
Slides containing metaphase chromosomes or interphase nuclei of interest 
Non-isotopically labelled DNA probes (chromosome specific libraries, 
centromeric probe)
Hybridisation buffer (50%formamide/2x SSC)(Hybrisol V I1; Oncor)
B) For denaturation of target DNA
Denaturation solution: 70% (v/v) formamide/2xSSC (pH 7.0)
50%, 70% (ice-cold), 70%, 90%, 100% ethanol 
Water bath (70°C)
C) For Hybridisation 
Water bath (42°C)
22-mm2 coverslips 
Rubber cement
D) For Post-hybridisation washing and detection 
50% (v/v) formamide/2x SSC
2 x SSC 
4 x SSCT
Blocking agent (850pl of 4 x SSCT + 150pl of 15% human AB serum; Sigma) 
Biotin detection: Antiavidin -FITC, Avidin -FITC (Vector Laboratories) 
Digoxigenin detection: Anti-digoxigenin FITC, Anti-sheep FITC (Vector 
Laboratories)
70%, 90%, 100% ethanol
DAPI or propidium iodide staining solution (Sigma Chemical Co)
Appropriate antifade mounting solution (Citiflour)
Water baths (42°C, 37°C)
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22-mm2 coverslips
Nail polish
E) Visualization
Epifluorescent microscope with appropriate filter
CCD camera and computer with Smartcapture software
Procedure
A) Preparation of target metaphases
1. Examine the slide, select the region with best metaphases and mark the slide 
using diamond pen.
2. Dehydrate the aged slide by soaking in the series of ethanol(50%-70%-90%- 
100%) for 2 minutes
B) Denaturation of DNA in target metaphases and probe
3. Soak slide containing metaphase chromosomes for 3 min in 70% formamide 
in a Coplin jar in a 70°C water bath.
4. Rinse slide for 2 min in ice-cold 70% ethanol in Coplin jar to stop 
denaturation. Then continue dehydration by soaking slide for 2min in room 
temperature in 70%, 90%, and 100% ethanol. Allow the slide to air dry.
5. Check denatured chromosome preparation with a phase-contrast microscope.
6. If probe is a centromeric probe, 1-1.2 pi of probe is mixed with 10 pi of 
hybridisation buffer. If probe is whole chromosome library, 15 pi of probe is 
used.
7. Heat for 10 min at 70°C to denature the probe. Then, if probe is a 
centromeric probe, an suppression step is not needed. If probe is a whole 
chromosome library, incubate the probe for 1 hour at 37°C.
C) Hybridisation
8. Place denatured probe mix on marked area of target metaphase slide. Cover
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with a 22 mm2 coverslip, remove any air bubbles with gentle pressure, seal 
with rubber cement, and incubate overnight (about 16 hrs) in a water bath at 
42°C to hybridise.
D) Post-hybridisation washing and detection
9. Remove the coverslip by soaking in 2 x SSC carefully, having first removed 
the cement. Wash the hybridized slide in two changes of 42°C pre-warmed 
50% formamide/2x SSC wash solution 5 minutes each, in 42°C 2 x SSC 5 
minutes twice, then in room temperature 4 x SSCT for 5 minutes once.
10. Take off slide, place it flat and blot excess buffer. Do not allow slide to dry at 
any point in the procedure.
11. Add 100 pi of blocking solution to the slide and cover with parafilm. 
Incubate for 15 minutes on a tray in a water bath at 37°C.
12. Add 100 pi of detecting reagent to hybridized chromosome preparation on 
slide and cover with parafilm. Incubate for 30 min on a tray in a water bath at 
37°C.
Preparation of detecting reagent:
In cases with biotin labelled probe:
498 pi of blocking agent + 2 pi of fluorescence Avidin
496 pi of blocking agent + 4 pi of fluorescence Anti-Avidin
Mix above solutions in two separate tubes, leave at room temperature for 10
min, spin at 14000 rpm for 10 min, mix supernatant together in one tube, and
incubate in a 37°C water bath at least 15 min.
In cases with digoxigenin labelled probe:
Mix 500 pi of blocking agent + 0.75 pi of Anti-digoxigenin FITC + 0.75 pi 
of Anti-sheep FITC in one tube, leave at room temperature for 10 min, spin 
at 14000 rpm for 10 min, transfer supernatant to another tube and incubate in 
a 37°C water bath at least 15 min.
In cases with biotin/digoxigenin labelled probe (dual colour):
Mix 995 pi of blocking agent with 2.5 pi of Avidin FITC and 2 pi of Anti- 
digoxigenin rhodamine, continue with remaining procedure as digoxigenin. 
In this case, there is no need for incubation.
13. Rinse slide sequentially in Coplin jars containing 4 x SSCT at room 
temperature for 3 min three times. Then continue dehydration by soaking 
slide 2min in room temperature 70%, 90%, and 100% ethanol and allow 
slide to air dry.
14. Add 10 pi ofDAPI (O.lpg/ml) with antifade solution to stained slide and add 
a coverslip. Seal with nail polish.
D) Visualization
15. Examine the slide using a fluorescence microscope with an appropriate filter 
set with or without a CCD camera and computer equipped with 
SmartCapture software system.
2.6.3 FISH to paraffin-embedded tissue
Materials
Paraffin-embedded tissue of interest
Histoclear
50%, 70%, 90%, 100% ethanol
Protein digestion enzyme solution (from Tissue Kit of Oncor)
Tissue pretreatment solution (from Tissue Kit of Oncor)
1 xPBD
2 x SSC
10 to 12 ng biotin- or digoxigenin- labelled centromeric DNA probe
10 pi of unique sequence probe (p53 DNA probe, Oncor) or 1 pi of unique
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sequence probe (LSI p53 Spectrum Orange, Vysis)
Hybridization solution: 70% (v/v) formamide in 2 x SSC
Procedure
A) Sample preparation
Tissue should be cut into 4 jim thickness sections and applied to silanized slides
and after attaching sections to slide, allowed to air dry. The slides were then
baked at 65°C for 6 hours.
In this study, these slides were prepared at the Dermatology department.
B) Tissue sample preparation
1. Place up to four slides in a Coplin jar containing 50 ml of fresh histoclear. 
Allow the slides to soak at room temperature for 15 minutes twice.
2. Transfer the slides to a Coplin jar containing 100% ethanol. Soak the slides 
for 10 minutes at room temperature. Pour off the ethanol and add fresh 100 % 
ethanol to the jar containing the slides and soak for another 10 minutes.
3. Remove the slides from the ethanol and allow to air dry.
4. Place up to four slides into pre-warm (45°C) pretreatment solution and 
incubate at 45°C for 10 minutes.
5. Rinse the slides by placing them in a Coplin jar filled with fresh 2 x SSC and 
agitating for 5 to 10 seconds
6. Place up to four slides into the pre-warm (45°C) protein digesting solution
7. Incubate the slides for 16 minutes at 45°C.
8. Rinse the slides by placing them in a Coplin jar filled with clean 2 x SSC and 
agitating for 5 to 10 seconds.
9. Dehydrate slides in 70%, 90%, 100% ethanol series at room temperature for 1 
minute each. Allow slides to air dry.
10. Check the degree of pretreatment and protein digestion by applying with 
Propidium iodide counterstain.
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C) Probe preparation
Co-hybridisation of satellite probe with unique sequence probe (Oncor: indirect
labelled):
1. Combine lpl of satellite probe and 9pl of hybridization buffer with I O jliI of 
unique sequence probe and mix well.
2. Pre-warm probe mix for 5 minutes at 37°C.
Co-hybridization of satellite probe with unique sequence probe (Vysis; direct
labelled):
1. Mix lpl of satellite probe, Ipil of unique sequence probe, lpl of distilled 
water, and 7pi of hybridization buffer.
2. Centrifuge shortly and vortex and centrifuge again.
D) Hybridisation
1. Place the probe mix on each slide, cover with a coverslip and seal with rubber 
cement.
2. Denature the probe and target DNA simultaneously by placing the slide in 
74°C oven or slide warmer for 5 minutes.
3. Incubate slides overnight in a 37°C water bath.
E) Post- hybridisation wash and detection
Indirect labelled probe:
1. Pre-warm 50 ml of 2 x SSC in a glass Coplin jar to 72°C-74°C in a water 
bath.
2. Remove the coverslip carefully.
3. Immerse slides in pre-warmed 2 x SSC for 5 minutes.
4. Transfer slides to a Coplin jar containing 50 ml of lx PBD for 2 minutes.
5. Remove slides from lx PBD and blot excess fluid from the edge.
6. Apply 60 pi of blocking agent (same as FISH on metaphase) to each slide and 
place parafilm over the solution. Incubate slides for 10 minutes in a 37°C
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water bath.
7. Apply 60 p.1 of the detection reagent to each slide and place a parafilm over 
the solution. Incubate slides for 15 minutes in a 37°C water bath. For 
detection reagent of dual colour, use same method as FISH on metaphase.
8. Carefully remove the coverslip and wash slides 3 times for 2 minutes each in 
50 ml of lx PBD at room temperature.
9. Remove slides from lx PBD and blot excess fluid from the edge.
10. Apply 10 (j,l of the appropriate counterstain. Cover with a glass coverslip and 
seal with nail polish.
11. Evaluate slides with an epi-fluorescence microscope.
Direct labelled probe:
1. Pre-warm 50 ml of 0.4 x SSC with 75 til of tween 20 in a glass Coplin jar in 
a 73 °C water bath.
2. Remove the coverslip carefully.
3. Immerse slides in pre-warmed 0.4 x SSCT for 2 minutes.
4. Wash slides in 2 x SSC for 2 min.
5. Allow slides to air dry.
6. Apply 10 p.1 of the appropriate counterstain. Cover with a glass coverslip and 
seal with nail polish.
7. Evaluate slides with an epi-fluorescence microscope.
2.6.4 Microscopy and Image analysis
Light Microscope
Phase contrast microscope is used for identifying the best part of slide for FISH. 
Fluorescence Microscopy
Fluorescence microscopy takes advantage of the fact that many dyes absorb light 
energy and subsequently emit part of this energy at a different wavelength.
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Examination of signals is performed either by using lOOx Plan-achromatic 
objective of epifluoresence microscope (Zeiss Axioplan) or by using 
epifluorescence microscope equipped with CCD camera and computer with 
SmartCapture software system.
Light sources
The light source for epi-fluorescence microscopy is a mercury lamp (50W or 
100W).
Mercury bulb is changed every 200 hr because there is a risk of explosion that 
can damage the microscope.
Filters
Choice of filters for fluorescence microscopy is determined by the fluorochrome 
and counterstain used in sample preparation. Dual- and triple band-pass filters 
are used to permit simultaneous visualization of dual or triple fluorochrome 
combinations.
2.7 Comparative Genomic Hybridisation
2.7.1 Preparation of normal target metaphase slides
High quality of human metaphase preparations is critical step for successful 
result of CGH.
Metaphase spreads were prepared as previously mentioned in 2.4.3. Slides were 
kept at room temperature to dry and used after 1-2 days.
Although it was best to use metaphases from a male donor, sometimes the donor 
was matched to patient sex for further careful analysis of sex chromosomes. 
Before using for CGH, over 100 metaphase slides were made at once to
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minimize inter-experimental fluctuation and several slides from each batch were 
checked for high quality of metaphases. Differently labelled normal versus 
normal hybridisation was applied to a test slide from each batch of metaphase 
spread preparations. If quality of slides was acceptable, the remaining slides in 
the same batch were used for further CGH experiments. If not, the entire batch 
was discarded. After starting experiments with DNA from paraffin-embedded 
tissue, slides made commercially (Vysis Ltd) were used to increase objectivity.
2.7.2 Preparation of Genomic DNA for CGH
Isolation of genomic DNA from peripheral blood and bone marrow
Materials
RBC lysis solution 
155 mM Ammonium Chloride 
10 mM Potassium Hydrogen Carbonate 
1 mM EDTA
Cell Lysis:
25 mM EDTA 
2% SDS
Proteinase K (20mg/ml) (Gibco BRL)
10 mM Ammonium acetate
Isopropanol
Ethanol (70% v/v)
TE buffer
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Procedure
1. Collect the blood or bone marrow into a vacutainer containing EDTA
2. Add 3 volumes of RBC lysis solution to one volume of blood or bone 
marrow sample.
3. Invert the sample several times to mix and keep at room temperature for 20 
minutes before being centrifuged at 2000 g for 7 minutes (large sample) or at 
14,000 g for 20 seconds (small sample).
4. Discard the supernatant until approximately 10-20 pi liquid with white cell 
pellet remains.
5. Resuspend cell pellet with remaining liquid by vortexing, add 1 volume of 
cell lysis solution, and vortex again.
6. Add 1/3 volume of protein precipitation solution, vortex, and centrifuge at 
3000 g for 20 minutes (large sample) or at 14,000 g for 3 minutes in 
microcentrifuge (small sample).
7. Transfer supernatant to clean tube containing 1 volume isopropanol and mix 
thoroughly to form DNA precipitate.
8. Spool out DNA using sealed Pasteur pipette, and wash in 70% ethanol. If the 
sample is small, spin down the DNA.
9. Dry the DNA pellet, and dissolve in various amount of TE buffer depending 
on size of pellet.
Isolation of genomic DNA from fixed cells 
Procedure
1. Add 5ml of 2 x SSC to the fixed cell pellet to wash off the methanol/acetic 
acid and spin for 10 minutes at 1000 rpm.
2. Discard the supernatant and repeat step 1 again.
3. Discard the supernatant and add 5 ml of cell lysis buffer to remaining pellet.
Remaining steps (from No 6) are the same as above.
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Isolation of genomic DNA from fresh frozen tissue
Material
Cell lysis solution
Proteinase K solution (20mg/ml, GibcoBRL)
RNase A solution (Sigma)
Protein precipitation solution (10 M Ammonium acetate)
Isopropanol
Ethanol (70% v/v)
Procedure
1. Chill a 1.5 ml tube containing 600 pi cell lysis solution on ice. The solution 
will turn cloudy.
2. Add 10-20 mg of fresh or frozen tissue to the cooled cell lysis solution, and 
quickly homogenize using pestle. Keep homogenized samples on ice.
3. Transfer lysate to 1.5 ml eppendorf tube and incubate lysate at 65°C for 15-
60 minutes. Then add 3 pi Proteinase K solution (20 mg/ml) to the lysate and
incubate at 55°C for 3 hours or until tissue has dissolved.
4. Add 3 pi RNase A solution to the cell lysate.
5. Mix the sample by inverting the tube 25 times and incubate at 37°C for 15-
60 minutes.
6. Cool sample to room temperature.
7. Add 200 pi 10 M ammonium acetate to the RNase A-treated cell lysate.
8. Vortex vigorously at high speed for 20 seconds to mix the lOmM ammonium 
acetate evenly with cell lysate.
9. Centrifuge at 14000 g for 3 minutes.
DNA precipitation
1. Transfer the supernatant containing the DNA into a clean eppendorf tube (1.5
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ml) containing 600 pi 100% isopropanol.
2. Mix the sample by inverting gently 50 times until the white threads of DNA 
form a visible clump.
3. Centrifuge at 14000 g for 1 minute: the DNA will be visible as a small white 
pellet.
4. Discard the supernatant carefully, add 600 pi 70% ethanol, and invert the 
tube several times to wash the DNA pellet.
5. Centrifuge at 14000 g for 1 minute. Discard the ethanol taking care not to
loose the DNA pellet.
6. Drain the tube on clean absorbent paper and allow sample to air dry.
7. Resuspend in TE buffer.
8. Keep DNA at room temperature overnight or heat at 65°C for 1 hour to 
dissolve DNA.
Isolation of genomic DNA from paraffin-embedded tissue
A) Method 1:
Materials
Histoclear
100% ethanol
Proteinase K (20mg/ml, Gibco BRL)
10 M Ammonium acetate
70% Phenol: chloroform (1:1) saturated in H20
TE buffer
Procedure
De-paraffinizing step:
1. Centrifuge tissue to the bottom of the 1.5 ml tube for 5 seconds.
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2. Add 1ml of histoclear and gently vortex to loosen the paraffin from the 
bottom of the tube. Leave at room temperature for 10 minutes.
3. Centrifuge for 2 minutes at full speed in a microfuge.
4. Remove supernatant (histoclear) carefully.
5. Repeat steps 2-4.
6. Add 0.5 ml of 100% ethanol to the tube and mix well, centrifuge for 2 
minutes and carefully remove ethanol.
7. Repeat step 6.
8. Air dry.
Proteinase K digestion:
1. Add 500 pil of lysis buffer (500 pi nuclei lysis buffer, 0.5% SDS) to the tube 
containing de-waxed tissue pellet and mix well.
2. Add 0.4 mg/ml Proteinase K and incubate at 55°C for 10 hr with frequent 
tapping.
Phenol/chloroform extraction:
1. Add I volume of 1:1 phenol/chloroform to the proteinase K digested DNA 
sample, and mix to form an emulsion.
2. Incubate at room temperature for 10 minutes.
3. Microcentrifuge for 2 min at maximum speed at room temperature.
4. Transfer supernatant (DNA in the top layer) to clean microcentrifuge tube.
Ethanol precipitation:
1. Add 1/3 volume of 10 M Ammonium acetate to the DNA sample to be 
precipitated.
2. Add 2 to 2.5 volume (calculated after addition of 10 M Ammonium acetate) 
of ice cold 100% ethanol. Mix well. Incubate 15 to 30 minutes in dry ice.
3. Microcentrifuge 10 minutes at maximum speed.
4. Discard the supernatant carefully, add 1 ml of ice-cold 70% ethanol. Mix and 
microcentrifuge for 5 minutes at maximum speed.
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5. Allow the pellet to air dry.
6. Dissolve in TE buffer, pH 8.0.
B) Method 2
Deparaffinizing step:
Same as Method 1
Proteinase K digestion:
1. Suspend the samples in 200 pi DNA extraction buffer (0.3 mg/ml proteinase 
K, 100 mmol/L NaCl, 10 mmol/L Tris-HCl pH 8, 25 mmol/L EDTA pH 8, 
and 0.5% sodium dodecyl sulfate). Incubate at 55°C overnight.
2. Add additional proteinase K (5 pi from 20 mg/ml stock solution) 24 hours and 
48 hours later for a total incubation time up to 96 hours.
3. Inactivate enzyme by heating at 94°C for 10 minutes or 85°C for 15 minutes.
Phenol/chloroform extraction:
Same as method 1
Ethanol precipitation:
Same as method 1
C) Method 3
Deparaffinization and Proteinase K digestion
1. Suspend the samples in 20 pi of lx PCR buffer ll(10mM Tris-HCl, pH 8.3,
50mM KCL; Perkin-Elmer, Norwalk, CT, USA).
2. Heat at 95°C for 10 min under paraffin oil with periodic mixing to aid 
deparaffinization.
3. Add proteinase K (2mg/ml) to the samples and incubate at 65°C for 90 min,
then inactivated at 85°C for 15 min.
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4. Directly use crude DNA for whole genome amplification without 
phenol/chloroform extraction.
2.7.3 Preparation of labelled probes for CGH
Direct labelling method 
Materials
1 pg of test or control DNA in 38 pi double distilled water 
5 pi 10 x A4 mixture (0.2 mM dATP, dCTP, dGTP in 500 mM Tris-HCl(pH 7.8), 
50 mM MgCl2 100 mM P-mercaptoethanol, lOOpg/ml BSA)
1 pi (>1 nmol) FITC-12-dUTP (Dupont, Boston, MA) or Fluorescein-11-dUTP 
(Amersham) for test DNA
1 pi (>1 nmol) Texas Red-5-dUTP (Dupont, Boston, MA) or rhodamine-4-dUTP 
(Amersham) for control DNA
5 pi enzyme mixture containing DNA polymerase 1 (>2 U) and DNase 1 (>200 
pg) (Gibco BRL, Gaithersburg, MD)
1 pi (>10U) DNA polymerase 1 (Promega, Madison, WI)
Procedure
1. Mix all above solutions in a microcentrifuge tube.
2. Incubate 45-90 minutes at 15°C depending on quality of DNA.
3. Stop reaction by 10 minutes incubation at 65°C.
4. Run a double stranded 1% agarose gel to check the probe fragment
distribution. Adjust incubation time and amount of enzyme mixture for 
obtaining ideal size of fragment (600-2000 bp)
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Indirect labelling method
Materials
1 jLXg of test or control DNA
10 x A4 mixture; 0.2 mM each of dATP, dCTP, dGTP, in 500 mM Tris-HCL (pH 
7.8), 50mM MgCl2, lOOmM 2-mercaptoethanol (Gibco BRL)
0.4.mM biotin-11-dUTP or 0.35 mM digoxigenin-ll-dUTP
DNA polymerase 1 /DNase 1 mix: 0.5 U/ul DNA Polymerase 1, 0.4 mU/pl 
DNase 1 in 50 mM Tris-HCl (pH 7.5), 5 mM Mg-acetate, 0.1 mM PMSF, and 
50% (v/v) glycerol, 100 pg/ml nuclease-free BSA 
Stop buffer: 0.5 M EDTA (pH 8.0)
Procedure
1. Mix with 5 pi of A4 solution, lpg of DNA, 3 pi of biotin-11-dUTP or 2 pi of 
digoxigenin-11-dUTP, add water up to 45 pi of total volume.
2. Add 5 pi of DNA polymerase 1/DNase 1 mixture, mix gently, and centrifuge 
briefly.
3. Incubate at 15°C for 90 minutes
4. Add 5 pi of Stop buffer or heat at 68°C for 10 minutes.
2.7.4 Preparation of probe mixture for hybridization
Materials
labelled test DNA
labelled control DNA
Cot-1 DNA (lpg/ pi, Gibco-BRL)
3 M sodium acetate 
100% cold ethanol
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Hybridisation buffer (50% formamide, 10% dextran sulfate, pH 7, Phamacia)
Procedure
1. Mix 400-800 ng of test DNA, control DNA, and 20-40 fig of human Cot-1 
DNA in a 1.5 ml microcentrifuge tube. In test DNA from fresh samples, 
equal amounts of test and reference DNA were used. In test DNA from 
paraffin-embedded tissue, test DNA was used 2 or 2.5 fold of reference DNA 
and amount of human Cot-1 DNA was also increased.
2. Add 1/10 volume of 3 M sodium acetate, mix, then add 2.5 volume of 100%
ethanol and mix again for precipitation of DNA.
3. Microcentrifuge 30 minutes at maximum speed.
4. Discard the supernatant and vacuum dry for 15 minutes.
5. Add 10 pi hybridisation buffer (50% formamide, 10% dextran sulfate, pH 7) 
and resuspend pellet gently.
6. Denature the probe mix for 5 minutes at 70°C immediately before use.
2.7.5 Preparation of target metaphase slides
1. Mark the area of the slide containing metaphases with a diamond pen.
2. Denature metaphase slides for 3 minutes at 72°C-73°C in a denaturation 
solution (70% formamide, 2x SSC, pH 7).
3. Plunge slides into 70% ice-cold ethanol.
4. Dehydrate in a series of ethanol (70%, 90%, 100%), 2 minutes each.
5. Allow slides to air dry.
Optimisation of denaturing time for CGH was checked after denaturation step at
the beginning of each new batch of slides.
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2.7.6 Hybridisation, Post-hybridisation washing, and Detection
Direct labelling method:
1. Apply 10 pi of hybridisation mixture to the slide, cover with a 22mm2 
coverslip and seal with rubber cement.
2. Incubate for 2-3 days in a 37°-40°C water bath.
3. Remove coverslip and wash slides twice in a washing solution (50% 
formamide, 2x SSC, pH7) at 45°C for 15 minutes each.
4. Wash in 2 x SSC at 45°C for 5 minutes once.
5. Wash in 1 x SSC at 45°C for 5 minutes once.
6. Wash once in 4 x SSC at 45°C and again at room temperature, 5 minutes
each.
7. Dehydrate in a series of ethanol (70%, 90%, 100%), 2 minutes each.
8. Allow slides to air dry and mount in an antifade solution containing 0.1-0.2 
pM DAPI.
Indirect method:
Same as washing and detection method with dual-colour FISH
2.7.7 CGH with inverse labelling
Usually, test DNA is labelled with FITC-12-dUTP, control DNA with TexasRed- 
5-dUTP. In case of reverse CGH, test DNA is labelled with TexasRed-5-dUTP, 
control DNA with FITC-12-dUTP.
2.7.8 Microscopy, Imaging, and Image analysis for CGH
Direct visual inspection
Metaphases spreads hybridised by CGH are examined using an epifluorescence 
microscope with lOOx oil-immersion lens and appropriate filter sets for the
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fluorochromes used. Differences in relative intensities of the two fluorochromes 
can be visualized by using a dual-band-pass filter that transmits red and green 
fluorescence simultaneously, along with a filter for the DAPI counterstain. 
Although certain sequence copy number changes such as gene amplification (> 
10 to 20 fold) and changes that include a large region may be visually detected, 
small regions of gain or deletion (<10 to 20 Mb) may not be visible to the human 
eye.
Microscope
Epiflurescence microscope equipped with high-numerical-aperture, plan- 
corrected, and chromatically corrected objectives are used for acquisition of 
high-quality images with minimal aberrations.
Optical filter
Appropriate filters in which are matched to the fluorochromes are used.
Camera
For image acquisition, epifluoresence microscope (Axioplan: Zeiss, Germany) 
equipped with a cooled CCD camera (Photometries) and computer (Mackintosh) 
was used. This camera was controlled by an image analysis system installed in 
computer.
Digital image analysis
A) Image capture
Capturing of image was performed using an epifluorescence microscope 
(Axioplan: Zeiss, Germany) equipped with a cooled CCD camera (Photometries) 
controlled by SmartCapture™ V2.1 software (Digital Scientific, Cambridge, 
UK).
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1. After identification of ideal metaphase using DAPI filter under the 
epifluorescence microscope, activate Alias of IP Lab in the Apple Menu 
items.
2. Select Capture from the Extension Menu.
3. Click More Options and set up optional menu (normalization, exposure time, 
gain, binning), camera, and filter.
4. Click Done to close the window for remembering this setting.
5. Select Expose and then the three excitation frequencies yellow (rhodamine), 
blue-green (FITC) and blue (DAPI) appeared sequentially. Composite image 
from the three colour components and colour normalisation window came up 
on the screen after a brief pause.
6. Same Normalisation setting was kept on during analysis of the same patient 
sample.
7. For saving image, choose Save As with PICT format in a allocated folder.
8. Five to ten images were captured and saved in the same way.
B) Image analysis
For proper CGH analysis, 7 steps of analysing procedure were performed in 
addition to assessment of image quality.
After image capture, image analysis was performed two ways-SmartCapture 
system and Quips CGH analysis system. By using SmartCapture system, all 
procedures were performed manually, while using Quips CGH analysis system 
the procedures were carried out automatically.
C) SmartCapture System
i) Correcting the background
For correct quantitation, CGH images are first background corrected by applying 
a top hat filter.
1. Select Background Remove from the Extension Menu and set filter size to 27 
on red, green and blue filter with better quality.
2. Select New Window and click OK.
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ii) Segmentation of image
Software used in this study produced a segmentation mask where each pixel was 
identified as a foreground or background pixel and contiguous clusters of 
foreground pixels make up chromosomes.
1. Choose Script for segmentation in script folder and then select 
Segmentation from Analyse Menu. Check the binarise box, green inside 
and choose Show ROI histogram.
2. By moving line, choose a value of size and extent of the chromosomes.
3. Click on Continue after recovering the script.
iii) Identification of chromosomes
Identification of specific chromosomes is possible visually based on the R- 
banding pattern in the DAPI image. Identification can be facilitated using gray- 
value morphology filtering to enhance the banding pattern and by displaying 
using an inverted lookup table.
iv) Normalisation of the fluorescence intensity
It is necessary to normalise the intensities of the hybridisation signals to 
calculate ratios and to combine information from different metaphase spreads. 
Normalisation is accomplished by equalising median intensities of the test and 
reference DNA images.
Normalisation is achieved after running Script for colour (fluorescence) 
equalisation in script folder.
v) After normalisation, detection of relative copy number changes can be 
detected by Global method and Axial analysis. In the Global method, individual 
metaphases are examined at the level of individual picture elements (pixels) and 
calculating fluorescence ratio and coding this to various colours according to the 
magnitude (FR >1; green represents gain, FR=1; white balanced state, FR<1; red 
represents loss). Global method is useful to detect hypotriploidy/tetraploidy. 
Axial method is replaced by automatic Quips CGH analysis program.
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D) Quips CGH analysis system
In this system, usually Quips CGH/Karyotyper and Quips Interpreter were used. 
Quips CGH/Karyotyper is for editing and analysing a metaphase image to 
generate a karyotype and CGH ratio profiles. Quips Interpreter is for editing and 
analysing ratio profile data from several metaphases in a CGH experiment. 
Sequence of analysis and features of this system are presented in Fig 2.7.1 and 
Table 2.7.1.
i) Image analysis by using Quips CGH/Karyotyper
1. Choose New from the File Menu and then new document window come up on 
the screen.
2. Select CGH Analysis and click OK.
3. Select the appropriate file where images with ICS-format file from IP Lab 
were saved.
4. By using Display Options, Tools, Image selection, and Reference, images are 
produced by appropriate automatic karyotyping and displayed CGH profiles 
automatically. Errors in karyotyping were corrected manually.
5. Select Save As from the file menu and save as a PICT file in allocated folder.
ii) Interpreting multiple CGH ratio profiles
1. Choose New from the file menu.
2. Select CGH Interpretation from the File Type menu on the dialog box that 
appears.
3. Select the appropriate file from the list.
4. Click Open.
5. Select an image analysed.
6. Click Add and repeat as needed to add images to the interpretation.
7. Click Done and then ratio profile appears on the screen.
8. Adjust the threshold to obtain accurate CGH result.
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DATABASE
(Enter information on Case Study card.)
I
CAPTUR&COLOR CAPTURE 
(Acquire metaphase images for analysis.)
I
DATABASE
(Update Images Folder list with image acquisition tiles.)
\
CGH ANALYSIS
(Analyze metaphase image to generate karyotype and ratio profiles.)
I
DATABASE
(Update Images Folder list and enter results of CGH analysis on Case 
Study card.)
\
KARYOTYPE
(Print report with images and data from Case Study card.)
\
DATABASE
(Start a new case study.)
Figure 1-2. Using the Quips Suite to Analyze Case Study Data
Fig 2.7-A Diagram of the sequence using Quips system (adoped from Quips CGH 
analysis user guide)
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Software Features
Quips Karyotyping Capture and visualize images from the microscope
using a digital CCD camera or images captured using 
SmartCapture FISH.
Segment chromosomes automatically, with manual 
correction.
Edit metaphase and karyotype using tools and an 
interface that is intuitive.
Examine selected chromosomes on a karyotype in the 
metaphase spread.
Classify G-. R-. Q-, and DAPI-banded chromosomes 
automatically, with manual correction.
Enhance metaphase or selected chromosomes in the 
karyotype.
Generate classifiers from your metaphases appropriate 
for your laboratory preparations.
Display ideograms.
Annotate images with text, arrows, and boxes.
Organize and print reports.
Enter and manage case study information.
Quips CGH Analysis' Contains features of Quips Karyotyping.
Use multicolored images from the microscope 
obtained by Quips SmartCapture FISH.
Correct localized background automatically
Normalize fluorescent intensities automatically.
Enhance DAPI banding automatically.
Display metaphase as individual color plane or 
composite color.
Display karyotype as individual color plane or 
composite color.
Compute chromosome symmetry axis and CGH ratio 
profiles automatically.
Optionally include chromosomes in karyotype out 
not in profile analysis.
Display ideograms with karyotype and ratio profiles. 
Display individual or average ratio profiles.
Compute regions of DNA copy number gam or loss.
Table 2.7.1 Quips software system (adoped from Quips CGH analysis user guide)
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Data interpretation
Data interpretation is a very important and continually developing aspect of 
CGH. A normal (test)-versus-normal (control) hybridization should be run with 
each experiment as a control. For deciding threshold, this could be fixed or could 
be set for each experiment by comparing normal versus normal hybridization 
and test vs. reference hybridization. Upper thresholds of between 1.10 and 1.25, 
and lower thresholds between 0.75 and 0.90, are currently accepted. In the early 
part of this work, these were often justified by experiment with normal versus 
normal hybridization. Later, limits were set at a lower threshold of about 0.8 and 
upper threshold of around 1.2 by comparing normal versus normal hybridization. 
And also statistical justification (standard deviation, 95% or 99% confidence 
value) was added for increasing the sensitivity of experiment. Centromeric and 
heterochromatic regions, as well as the p arms of acrocentric chromosomes were 
excluded from interpretation because regions rich in repetitive sequences show 
wide variability in the CGH ratio. The interpretation of the GC-rich regions at 1 
pter, 16p, 19, and 22 should be carefully performed. Telomeric regions were also 
carefully examined because of the decreasing hybridisation signal at the very 
ends of chromosomes. All regions mentioned above, as well as centromeric and 
telomeric regions of all chromosomes, can give false ratio changes if the probe 
sizes or hybridisation conditions are not optimal, and careful interpretation is 
necessary.
Analysing method of CGH with hypotriploidv/tetraploidy
CGH analysis results only can represent the relative DNA sequence copy 
number, so diploid tumors cannot be differentiated from tetraploid because there 
is no difference in the relative fluorescence ratio along chromosomes.
When information can not be obtained from other diagnostic tools including 
conventional cytogenetics or FISH, CGH analysis for triploidy/ tetraplidy is 
impossible.
In cases with hypotriploidy/hyperdiplody or near tetraploidy, based on the
110
conventional karyotyping result or interphase FISH results, chromosomes with 
known ploidies are identified and use as the standard chromosome for CGH 
normalisation process. In a global analysis using the SmartCapture system, the 
standard chromosome which is known ploidy is normalised by equalising the 
fluorescence intensities to the balanced state. Then green to red ratios along the 
remaining chromosomes are calculated under the previous fixed normalisation 
state. Repeat this single chromosome normalisation method until the ploidy state 
of each chromosome is fully evaluated.
2.7 Whole Genome Amplification
Comparative Genomic Hybridization (CGH) of amplified DNA isolated from 
formalin-fixed, paraffin-embedded tissue can be difficult because of the poor 
quality of template DNA for amplification. In samples after the formalin fixation 
process, DNA is complexed with proteins and is often nicked already. The DNA 
concentration is too low to perform the CGH experiment. To overcome these 
drawbacks, universal amplification is applied to very small amounts of DNA 
isolated from paraffin-embedded tissue.
In this study, two kinds of whole genome amplification method were applied: 
primer extension pre-amplification (PEP) and degenerate oligonucleotide-primed 
PCR (DOP-PCR).
2.8.1 Microdissection of the specimen
7 pm and 3 pm thickness sections were prepared at Dermatology department. 
One of the sections was stained with hematoxylin and eosin and used as a 
control. The adjacent 7 pm and 3 pm sections were used for microdissection. 
Unstained tissue sections on glass slides were deparaffmized twice with 
histoclear, washed twice with 100% ethanol. Cells on the same site comparing 
with H-E stained slide were selected and microdissected under the inverted
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microscope using 25G needle and cells were put straight into the buffer. 
Microdissected areas were 2mm2 x 3pm, 9 mm2x 3 pm, 18 mm2x 3pm, 9 mm2x 
7 pm.
2.8.2 Primer Extension Pre-amplification (PEP)
Primer
The advantage of the PEP protocol depends on random nature of primer. The 
primers used for PEP are a random 12 mer and a 15 mer oligonucleotides, which 
are made by Cruachem. Primers were already purified.
For estimation of primer concentration, 5 pi of primer was added to 995 pi of 
dH20  in a 1.5-ml microcentrifuge tube, and mixed well by vortexing. Optical 
density of DNA was measured at A260 using UV spectrophotometry and the 
concentration was calculated as follows:
1 OD unit of a single stranded oligonucleotide consists of about 33 mg, by mass. 
One molar (1 M) of oligonucleotide has a number of OD units equal to lOx the 
number of bases.
The gram molecular weight in 12 mer oligonucleotides = 12x 10x33 = 3960 g 
1 M = 3960 g/L
200 pmol corresponded to 792 ng/pl
The gram molecular weight in 15 mer oligonucleotides = 15x 10x33 = 4950 g 
1 M = 4950 g/L
200 pmol corresponded to 990 ng/pl 
PEP reaction solution
200 pmol of random 12- or 15 mer oligonucleotides 
200 pM of each dNTP (Pharmacia Biotech)
5 mM MgCl2 (Perkin Elmer)
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lx  PCR buffer 11 (Perkin Elmer)
10 jal of DNA template
5 U AmpliTaq DNA polymerase or AmpliTaq LD (Perkin-Elmer)
Add dH20  up to 60 pi of total volume
Thermal cycler
OMN-E thermal cycler (Hybaid) was used during amplification process. 
Procedure
DNA was isolated from formalin-fixed paraffin-embedded tissue sections of 
unknown fixation method or fixation time by the DNA isolation method No. 4, 
9-2, 10, 11, 12 (Table 3.5.2).
To briefly mention again the basic method of DNA isolation, transfer samples 
into 20 pi of lx PCR buffer 11 (Perkin-Elmer, Norwalk, CT, USA), heat at 95°C 
for 10 minutes under paraffin oil with periodic mixing to aid deparaffinization. 
Samples were digested with proteinase K (2mg/ml) at 65°C for 90 minutes, then 
the enzyme was inactivated at 85°C for 15 minutes.
In parallel experiments, 5 U of AmpliTaq LD or 3.6 U of EHF PCR system, EL 
Template PCR system were used as an enzyme for PEP amplification instead of 
AmpliTaq DNA polymerase, and the concentration of MgCl2 was applied with 5 
mM or 2.5 mM for comparing the results. In some experiments, primer 
concentration was reduced to 100 pmol. Negative control (water blanks) were 
included for checking contamination in each experiment.
113
The basic thermal cycling program (Faulkner et al.,1998) was carried out as 
follows:
Cycle tempreature Time Cycles
92°C 4 min 1 cycle
92°C 1 min 40 cycles
25°C 2 min the ramp between 25°C and
30°C 30 sec 30°C steps at 0.25°C/sec
35°C 30 sec
40°C 30 sec
72°C 2 min
72°C 15 min 1 cycle
In amplification with Pfu DNA polymerase, extension time was changed from 
72°C for 2min to 72°C for 4min.
When EHF PCR system or ELT PCR system was used as an enzyme for PEP, 
thermal cycling program was changed as follows:
Cycle temperature Time Cycles
94°C 1 min 50 cycles
37°C 2 min the ramp between 37°C and
55°C 4 min 55°C at 0.1°C/sec
68°C 30 sec
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2.8.3 Degenerate Oligonucleotide primer-PCR (DOP-PCR)
Primer
A degenerate oligonucleotide primer of 22 nucleotides in length with the
sequence (Telenius, 1992) as follows:
5'-C C G A C T C G A G N N N N N N A T G T G  G-3'
The primer was synthesized by a 391 Synthesizer PCR-MATE (Applied
Biosystem). Oligonucleotide deprotection was then carried out with ethanol
precipitation of primer.
Oligonucleotide deprotection
1. Connect a polypropylene syringe containing 1 ml of ammonium hydroxide 
(40 mM) to the end of the column (primer).
2. Attach an empty syringe to the other end.
3. Gently push the ammonium hydroxide through the column, consequently the 
barrel of the other syringe was displaced.
4. Push ammonium hydroxide back and forth through the column, 2 to 3 times, 
for 2-3 hrs. The column should be filled with liquid, which will decolourise 
from yellow to white.
5. Withdraw the ammonium hydroxide and transfer into small Nunc tube.
5. Add ammonium hydroxide up to 2.5 ml, tighten the cap and incubate in a 
55°C water bath overnight.
7. Store at -  70°C.
Ethanol precipitation of oligonucleotides
1. Aliquot 450 pi of the deprotected primer into a 1.5 ml microcentrifuge tube.
2. Add 50 pi of 3M sodium acetate and 2 volumes of 95% ethanol and mix
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gently for 30sec to 1 min.
3. Incubate the primer at -70°C for 1 1/2 hrs and centrifuge at 12000 rpm for 
20 min.
4. Remove the supernatant carefully, wash the pellet with 85% ethanol and 
centrifuge at 12000 rpm for 2 min.
5. Discard the ethanol and allow the pellet to air dry.
6. Resuspend the pellet with 200 pi of TE buffer and store at -20°C.
Calculation method of DOP-primer concentration
For estimation of primer concentration, 5 pi of primer is added to 995 pi of 
dH20  in a 1.5 ml microcentrifuge tube, mixed well by vortexing. Optical density 
of DNA is measured at A260 using UV spectrophotometry and the concentration 
is calculated as follows:
1 OD unit of a single stranded oligonucleotide consists of about 33 mg, by mass. 
One molar (1 M) of oligonucleotide has a number of OD units equal to lOx the 
number of bases.
The gram molecular weight in 22 oligonucleotides = 22 x 10 x 33 = 7260 g 
1 M = 7260 g/L
100 pmol corresponded to 726 ng/ul
Solutions for DOP-PCR
1 Ox PCR buffer 11 (Perkin Elmer)
100 mM Tris-HCl, pH 8.3 (at 25°C)
500 mM KC1
lOx EHF PCR system buffer (Boehringer Mannheim)
Enzymes:
Topoisomerasel (lU/pl, Promega)
T7 sequenase (13 U/pl, Amersham-Life Science)
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Thermosequenase (32 U/|al, Amersham-Life Science)
AmpliTaq DNA polymerase LD (5U/pl, Perkin Elmer)
Expand High Fidelity PCR System (3.5U/pl, Boehringer Mannheim)
Stock Solution 
25 mM MgCl2
1 M Tris-HCl 
0.5 MEDTA 
5 M NaCl 
1MKC1
100 pM DOP-PCR primer
2 mM each dNTP
The thermal controller-cycler
OMN-E thermal cycler (Hybaid) was used during amplification process. 
Procedure
In this experiment, basically three kinds of DOP-PCR methods were used.
A) The first method by Guan et al.
First DOP-PCR amplification
1. Pipette 2 pi of PCR mix into 0.2 ml microcentrifuge tube.
40 mM Tris-HCl (pH 7.5)
2 mM MgCl2 
50 mM NaCl 
0.2 mM dNTP 
7 pmol DOP-primer 
dH20
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2. Add 3 il of template DNA
3. Turn on the PCR thermal cycler and set the appropriate program
4. Add 0.1 pi of Topoisomerase 1 (1 unit) and incubate at 37°C for 30
minutes in the thermal cycler
5. Heat at 95°C for 10 minutes for inactivation of Topoisomerase 1.
6. Start 7 cycles of first low annealing temperature cycle by adding 0.2 pi (~
0.3 units) of T7 sequenase (diluted 1:8) before starting each cycle.
94°C for 1 min 
30°C for 1 min 30 sec 
37°C for 2 min x 7
7. After finishing 7 cycles, add 45 pi of PCR mixture and mix well.
10 mM Tris-HCl 
50 mM KC1 
2 mM MgCl2 
75 pmol DOP-primer
0.2mM dNTP 
dH20
8. Heat at 95°C for 3 minutes as a denaturation step in the thermal cycler.
9. Pause the thermal cycler.
10. Add 0.8 pi of AmpliTaq LD.
11. Start again first high annealing temperature cycles.
94°C for 1 min 
56°C for 1 min 
72°C for 3 min x 35
72°C for 10 min x 1
Second DOP-PCR amplification
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1. Add 7 pi of first DOP-PCR product into the second PCR mixture.
lx PCR buffer 11
2.5 mM MgCl2 
0.2 mM dNTP 
150 pmol DOP-primer 
dH20  (up to 50 pi)
2. Denature at 95°C for 3 minutes in the thermal cycler
3. Add 0.7-0.8 pi of AmpliTaq LD in to the mixture
4. Start the second DOP-PCR thermal cycles
94°C for 1 min 
56°C for 1 min 
72°C for 3 min x 30
72°C for 15 min x 1
B) The second method by Kuukasjarvi et al. (1997)
First DOP-PCR amplification
1. Add 3 pi of template DNA into the 2 pi of the PCR mixture prepared 
(total volume; 5 pi).
20 mM Tris-HCl
60 mM KC1
2 mM MgCl2
0.2 mM dNTP
5 pmol DOP-primer
0.5 ul of thermosequenase
dH20
2. Start the first low annealing temperature cycles in thermal cycler.
94°C for 1 min
25°C for 1 min with 3 min ramp from 25°C to 74°C 
74°C for 2 min x 4
119
3. After finishing 4 cycles, add 20 pi of PCR mixture into the previous 
product.
10 mM Tris-HCl (pH 8.4)
10 mM KC1 
1.5mM MgCl2
0.2 mM dNTP 
50 pmol DOP-primer
0.5 pi of AmpliTaq LD 
dH20
4. Start the first high annealing temperature cycles in the thermal cycler.
94°C for lmin 
56°C for 1 min 
72°C for 2 min x 30
Second DOP-PCR amplification 
Repeat the above step 3 and 4.
(template DNA ; product from first high temperature cycles)
C) The third method 
First DOP-PCR amplification
1. Prepare 49.2 pi of PCR mixture in the 0.2 ml microcentrifuge tube.
lx PCR buffer 11
1.5mMMgCl2
0.2 mM dNTP
100 pmol DOP-primer
10 pi of template DNA
dH20
2. Denaturate the PCR mixture at 96°C for 8 minutes.
3. Add 0.8 pi of AmpliTaq LD.
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4. Start the first low annealing temperature cycles in thermal cycler.
93°C for 1 min
30°C for 1 min with 3 min ramp from 30°C to 72°C 
72°C for 3 min x 8
5. Continue the high annealing temperature cycles without interruption.
93°C for 1 min 
60°C for 1 min 
72°C for 3 min x 28
72°C for 15 min x 1
Second DOP-PCR amplification
1. Prepare 50 |il of second DOP-PCR mixture in the 0.2 ml microcentrifuge 
tube
lx PCR buffer 11
2.5 mM MgCl2
0.2 mM dNTP 
150 pmol DOP-primer 
lp.1 of AmpliTaq LD
10 (il of first DOP-PCR product as a template DNA 
dH20
2. Start the thermal cycles in the thermal cycler.
93°C for 1 min 
60°C for 1 min 
72°C for 3 min x 28
72°C for 15 min x 1
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2.8.4 Gel electrophoresis of the amplification product
The length of the probe molecules can be checked by gel electrophoresis.
1. Weigh out 0.6 g of agarose and added to 60 pi of TAE or TBE buffer.
2. Dissolve it by boiling in the microwave oven for 3 minutes.
3. Allow to cool down to 70°C, and add 2 pi of ethidium bromide to the 
dissolved agarose solution inside the hume hood.
4. Pour the gel prepared (1 %) onto the electrophoresis gel casting unit.
5. Mix 4 pi of probe with 1 pi of loading mix and load on the gel.
6. Run the gel at 15V/cm for 30 minutes and take photographs under ultraviolet 
illumination.
The amount of loading mix and probe can be changed depending on size of well. 
Every time, ladder is loaded on the gel.
2.8.5 Measurement of probe concentration
The concentration of the DNA probe is estimated by measuring the optical 
density (O.D.) at A260 nm in a spectrophotometer. 5 pi of the probe DNA is 
added to 995 pi of dH20, mixed well by vortexing and then measured. The 
concentration of the probe is calculated according to the formula below:
Cone = OD A260 x dilution factor (200) x 50 = concentration of probe pg/ml or 
ng/pl
A260: Absorbance at 260 nm wavelength
50: a Constant corresponding to 50 pg DNA per ml at 260 nm per 1 unit OD
2.8.6 Probe labelling with amplified probe
There are two labelling methods after amplification namely DOP-PCR labelling 
and nick translation.
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In this study, products of PEP amplification were usually labelled by nick 
translation, products of DOP-PCR amplification were labelled by DOP-PCR 
labelling.
DOP-PCR labelling.
During the second DOP-PCR amplification, fluorochrome (5 fil of FITC-12- 
dUTP for test DNA and 5 pi of TexasRed-5-dUTP for control DNA; Du Pont or
2.5 pi of FITC-ll-dUTP for test DNA and 2.5 pi of rhodamine-4-dUTP; 
Amersham) was put into PCR reaction mixture for labelling.
After finishing second DOP-PCR amplification, labelled products were subject 
to a purification step to remove any unincorporated nucleotides. But CGH results 
with amplified product using DOP-PCR were rarely affected by purification.
Nick translation
Same as labelling method in CGH experiment
2.8.7 Purification of labelled probe
At first, purification of labelled probe was carried out using High Pure PCR 
Product Purification Kit.
High Pure PCR Product Purification Kit fBoehringer Mannheim!
Materials 
Binding buffer
3 M guanidine-thiocyanate
10 mM Tris-HCl
5% ethanol (v/v), pH 6.6 (25°C)
Wash buffer
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20 mM NaCl
2 mM Tris-HCl, pH 7.5 (25C)
Elution buffer
10 mM Tris-HCl 
1 mM EDTA, pH 8.5 (25C)
High Pure filter tube
Collection tube
Procedure;
1. Add 500 pi binding buffer to a 100 pi PCR reaction and mix well.
2. Combine the High Pure filter tube and the collection tube and transfer 
sample to the upper reservoir.
3. Centrifuge for 30 seconds at maximum speed in a standard table top 
centrifuge.
4. Discard the flow through and combine the filter tube again with the same 
collection tube.
5. Add 500 pi wash buffer to the upper reservoir and centrifuge for 30 sec at 
maximum speed.
6. Discard the wash buffer flow through and combine the filter tube again with 
the same collection tube. Add 200 pi wash buffer, centrifuge as in step 3.
7. Discard the collection tube and insert the filter tube in a clean 1.5 ml reaction 
tube.
8. Use 50-100 pi elution buffer or redistilled water for the elution of DNA. Add 
elution buffer or water to the filter tube and centrifuge at maximum speed for 
30 sec.
2.9 PCR with specific primers
PCR for sex determination; a 30 mer derived from pseudoautosomal sequences
(C) in combination with 30 mer from Y-specific and X-specific regions
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Sequence of primers
X CTGCAGAAACAAGCTCATCAGCGTGACTAT 
Y GTACTACCTTTAGAAAACTAGTATTTTCCC 
C GAATTCTTAACAGGACCCATTTAGGATTAA
The thermal controller-cycler
OMN-E thermal cycler (Hybaid) was used during amplification process.
Procedure
1. Prepare the primer mix according to C:Y:X at a ratio of 50:75:5 using 10 pM 
stocks of each primer.
2. Prepare the PCR beads (two in one tube: Amersham Pharmacia biotech) and 
add 25 pi of distilled water, 2 pi of template DNA (100 ng), and 23 pi of 
primer mix.
3. Start the thermal cycles in the thermal cycler
94°C for 5 min
54°C for 1 min
72°C for 2 min x 1 cycle
94°C for 1 min
54°C for 1 min
72°C for 2 min x 30 cycles
72°C for 5 min x 1 cycle
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CHAPTER 3. RESULTS
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3. RESULTS
3.1 Fluorescence In Situ Hybridisation
In order to become familiar with the techniques of Fluorescence In 
Situ Hybridisation (FISH), a number of control experiments were 
carried out using libraries to whole chromosomes (including suppression), 
centromeric probes to chromosomes and centromeric probes to nuclei.
3.1.1 Interphase Fluorescence In Situ Hybridisation
Conventional G-banding analysis of childhood ALL is technically more difficult 
than in other leukemias. For detection of structural aberrations or numerical 
abnormalities, high quality chromosome preparations from bone marrow are 
required. But malignant clones of the B-cell lineage can be obtained only by 
rapid harvesting because of rapidly decreasing malignant cells during 
prolonged in vitro culture (Karhu et al., 1997b). In practice, between 23 and 
33% of cases cannot produce adequate or sufficient metaphases to identify 
hyperdiploidy (Jackson et al., 1990b; Harris et al., 1992; Moorman et al., 1996). 
Moorman et al. (1996) indicated the potential of interphase FISH in this situation 
and recommended a sequence of probes based on the involvement of specific 
chromosomes in hyperdiploidy (Fig 3.1-A).
The first objective of this project was to try to detect hyperdiploidy when 
conventional karyotyping had failed, or hidden hyperdiploidy in ALL 
patients using interphase FISH with Moorman’s strategy. The second aim of this 
experiment was to classify the cases studied into one of the three ploidy 
subgroups; low hyperdiploidy with 47-50 chromosomes, high hyperdiploidy with 
51-68 chromosomes and tripoidy/tetraploidy with >68 chromosomes.
This study was carried out on cells which had been cultured for diagnostic 
chromosome analysis. The probes were selected specific chromosome alpha- 
satellite probes, in a step-wise pattern according to Moorman’s strategy, for 
chromosomes known to be frequently involved in hyperdiploidy (Fig. 3.1-A).
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Fig 3.1-A Probes for detection of hyperdiploidy in ALL according to Moorman et al. 
(adopted from Moorman et al, Genes, Chromosomes & Cancer 16:40-45, 1996).
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For the 22 samples studied, conventional karyotyping and interphase FISH were 
carried out independently.
At least 100 interphase nuclei were analysed for each probe on each 
sample. Every experiment was carried out in parallel with a control sample and 
the results of test and normal control samples were compared. When the signals 
were located close together with the same intensity and of similar size, they were 
scored as one signal. When size and intensity of signals were different and there 
was more one signal space between the two signals, they were treated as two 
signals.
Complete karyotype and intephase FISH results of the 22 cases are listed in Table
3.1.1.
Five cases had failed to yield suitable material for cytogenetic analysis. In 
three of these cases (numbers 5, 12, and 17), no abnormality was detected 
by interphase FISH for the probes used. In the remaining 2 cases, case 9 was 
shown to have additional copies of chromosome 4 and 20 in a proportion of cells 
(3 signals; 7% in normal control) and also to lack either a chromosome 13 or 
21 in over 60% of cells (3 signals; 17%, 4 signals; 74% in normal control), but it 
was difficult to identify the exact hyperdiploid group. Case 20 was shown to have 
an additional copy of chromosome 18 and chromosome 6 in the majority of cells, 
and can be allocated into the hyperdiploid group which are according to the 
strategy of this experiment (Fig 3.1-A).
Six of the 22 cases studied had a normal karyotype by conventional cytogenetic 
analysis (cases 8, 11, 14, 15, 16, and 18). No abnormalities were detected by the 
probes used.
Three cases were identified by conventional cytogenetics as having structural 
abnormalities (cases 1, 4, and 10) and again no further abnormality was detected 
by the probes used here.
Three further cases (cases 7, 19, and 22) had shown both structural and numerical 
abnormalities on G-banding. In case 7, no abnormality was detected by the 
panel of probes, while in case 19 the presence of an additional chromosome 8 
was confirmed (3 signals; 2 % in normal control). However in case 22 interphase 
FISH using probes for four chromosomes including chromosome 8 did not 
confirm the trisomy 8 detected by cytogenetic analysis. This was thought to be 
caused by mosaicism with the additional abnormal clone and normal cells.
Four hyperdiploid cases had been identified by conventional cytogenetics of 
which three (cases 2, 13,and 21) were in the high hyperdiploidy subgroup
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and one (case 6) was in the low hyperdiploidy subgroup. In case 2 the 
cytogenetic analysis had been incomplete, and FISH allowed identification of 
three chromosomes involved as chromosome X, 6, and 13 or 21. In cases 6, 13, 
and 21, FISH confirmed the cytogenetic results where probes for the 
chromosomes involved were included in the panel.
The final case (case 3) was in the triploid/tetraploid subgroup having been shown 
to have a count of 90 chromosomes and almost complete tetraploidy. FISH for 
the probes used was in almost complete agreement with this result, although it 
was interesting that 66% of nuclei showed 4 signals for chromosome 12, which 
was one of the two chromosomes with trisomy by conventional analysis (2 
signals; 91%, 3 signals; 2% in normal control).
In some cases, the percentage of abnormal signals was not definite but was 
significantly different from the normal control. For example, in case 13, the 
percentage of abnormal signals of chromosome 18 (3 signals) was 44% compared 
with below 5% in normal control. This was thought to be caused by mosaicism 
with normal cells.
All results of interphase FISH for the probes used were consistent with the results 
from conventional karyotyping and in addition FISH provided information in the 
cases which could not be analysed by routine cytogenetics.
130
Table 3.1.1 Summary of the results of interphase FISH & conventional
karyotyping of 22 cases with ALL
No Karyotype Probes Number of signals per nucleus (%)
0 1 2 3 4 5
1 46,XY,i(9)(qlO), 
del(13)(ql2q22), 
der( 19)t( 1; 19)(q23 ;p 13)
X 85 15
18 2 96 2
13/21 3 2 10 18 60 7
10 19 72 9
16 9 79 11
2 50-53,XY X 5 94* 1
18 2 10 78 10
6 1 2 28 67* 2
13/21 2 2 10 53 33*
3 90,XX,YY,del(2)(p?)x2,-4, 
t(8;14)(q24;q32)x2,add(ll)(q23)x2, 
-12,del( 17)(p 11 )x2
X 83* 13 4
18 12 19 67* 2
16 7 9 77* 7
20 6 11 74* 9
12 2 32* 66*
4 46,XX,del(6),del( 12),add( 12) X 2 11 87
6 5 95
8 5 86 9
10 10 82 8
5 46,XX (failed case) X 8 89 3
6 9 91
8 5 94 1
10 12 86 2
6 49-50,XX,del(5),+6,-11,+12,+17,-22 X 84 16
6 4 19 75* 2
8 3 87 4 3 3
10 89 10 1
7 45 ,XX,add( 1 )(q?21 ),add(2)(q 14), 
der(3)t(l ;3)(q21 ;p25),del(6)(q21), 
-7,der(9)add(9)(p 12),add(9)(q34), 
del(22)(qll), 
45,idem,del(ll)(q23)
46,XX
X 5 94 1
18 10 85 5
13/21 3 11 82 4
10 8 90 2
16 1 88 11
8 1 88 9
8 46,XY X 2 96 2
18 4 92 4
13/21 3 11 83 3
10 6 89 5
16 6 86 7 1
8 7 87 5 1
9 Failed case X 5 91 4
18 7 91 2
13/21 7 66* 27
10 10 87 3
16 12 85 3
4 5 58* 37*
6 5 95
8 6 94
20 2 78 20*
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No Karyotype Probes Number o f signals per nucleus
0 1 2 3 4 5
10 46,XX,t(l;13)(plO;qlO) 
46,XX
X 1 94 5
18 1 6 93
13/21 9 18 72 1
10 10 87 3
16 7 88 5
8 8 86 6
11 46,XX X 1 93 6
18 10 90
13/21 3 17 79 1
10 10 90
16 8 88 4
8 11 86 3
12 Failed case X 89 10 1
18 4 90 6
13/21 6 18 75 1
10 4 92 4
16 3 88 9
8 6 92 2
13 53,XY,+X,+6,+10,+14,+l 8,+21 ,+21 
46,XY
X 3 87* 10
18 3 52 44*
13/21 1 9 83*
6 13 87*
8 8 92
14 46,XY X 2 95 3
18 7 92 1
13/21 3 21 76
10 8 92
16 8 90 2
8 11 89
15 46,XX X 5 93 2
18 4 95 1
13/21 3 14 81 2
10 9 90 1
16 8 91 1
8 5 93 2
16 46,XY X 97 3
18 8 92
13/21 4 19 76
10 7 93
16 11 89
8 1 15 83 1
17 Failed case X 97 3
18 11 88 1
13/21 9 27 64
10 6 94
16 14 86
8 9 91
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No Karyotype Probe Number o f signals per nucleus (%)
0 1 2 3 4 5
18 46,XX X 3 96 1
18 5 95
13/21 3 14 81 2
10 11 89
16 8 92
8 2 97 1
6 1 96 3
20 8 86 6
19 46,XX
46,XX,+8,-14,
der( 16)t( 16; 17)(q 10 ;q 10)
X 10 89 1
18 5 94 1
13/21 7 19 74
10 5 91 3 1
16 8 87 5
8 4 65 31*
20 Failed case X 15 85
18 34 66*
13/21 1 17 79
6 31 69*
21 56,XY,+X,+4,+6,+8,+10,+11 ? 
+14,+ 18,+21,+21
X 9 91
18 2 66 32*
13/21 14 74*
6 37 63*
22 45,XX,-5,-22,+mar 
42-47,XX,+8,-14 
dic( 16; 17)(p 11.2 ;p 11.2), 
add(19)(ql3?), +marl, +mar2
X 3 97
18 15 84 1
13/21 3 19 78
8 5 86 9
* abnormal result compared with normal control
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3.2 Establishment of the CGH Technique
In the second part of the project, the aim was to apply CGH to the study of 
hematologic malignancies and to compare the results with those of conventional 
cytogenetic analysis. In order to become familiar with the technique, a number of 
control samples of both fresh and fixed bone marrow cells were processed.
Both direct and indirect labelling of test and control DNA were investigated and 
experience was gained in monitoring the critical factors such as metaphase 
preparations, probe size, and hybridisation conditions.
Initially, CGH experiments were carried out according to the indirect method as 
described by Kallioniemi et al (1992) and Du Manoir et al (1993). The 
results obtained were unsatisfactory because the intensity of control DNA (red) 
was weaker than that of the test DNA (green). After several experiments with 
modifications, it was possible to obtain analyzable CGH results (Fig 3.2-A). The 
direct labelling method by Kallioniemi et al (1994) was then applied to CGH 
experiments with satisfactory results (Fig 3.2-B). The trial group was too small to 
compare both methods exactly. From literature reviews, it appears that CGH with 
directly labelled probe can produce more uniformly hybridized images and fewer 
non-specific signals and is more convenient to use than that with indirectly 
labelled probe (Buckle and Kearney, 1994; Isola et al., 1994).
134
9 I  y <  -  s ,
\  i - c '  /
FIG 3.2-A Global CGH image using indirect labelling method; test DNA was 
normal female DNA labelled with Biotin - 11- dUTP, control DNA was male DNA 
labelled with digoxigenin -11- dUTP, and hybridised on maie metaphase 
chromosomes, a) CGH image following colour equalisation b) colour ratio image of 
the same metaphase.
FIG 3.2-B Global CGH image using direct labelling method; test DNA was 
normal male labelled with FITC-12-dUTP, control DNA was female DNA labelled 
with Texas Red-5- dUTP, and hybridised on male metaphase chromosomes, 
a) CGH image following colour equalisation b) colour ratio image of the same 
metaphase.
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3.3 CGH analysis in cases with Hematologic Malignancies
3.3.1 CGH Analysis on Samples with ALL
The aim of this study was to assess whether CGH would be an approach to 
help identify hyperdiploidy in cases of ALL, especially when conventional 
karyotyping cannot be completed due to inadequate mitoses. Interphase 
FISH using selected probes was also performed as a complementary method to 
detect hyperdiploidy in these patients.
Nineteen bone marrow samples from suspected or confirmed cases of ALL were 
analysed. All samples were selected randomly when sufficient material remained 
after setting up diagnostic cultures. In 16 cases genomic DNA was prepared from 
fresh bone marrow samples and in 3 cases from stored fixed metaphase 
preparations.
Of the 19 cases of ALL studied, 9 cases showed a normal karyotype and a 
normal CGH result. The results of the remaining 10 cases are shown as Table
3.3.1. The summary of interphase FISH results of three hyperdiploid/hypotriploid 
cases is presented in Table 3.3.2.
Three of 19 cases studied (cases 8, 14, and 19) had numerical abnormalities 
with or without marker chromosomes by conventional cytogenetics. CGH 
profiles of two hyperdiploid (case 8 & 14) are shown in Fig.3.3.1-A. Both cases 
were hybridised on metaphases of the same sex with test materials for 
detection of abnormalities on sex chromosomes.
In case 8, the CGH result was in almost complete agreement with conventional 
karyotyping except that gains of DNA material of chromosome X and Y were 
detected. FISH results using whole chromosome Y painting probe revealed 
that one of the marker chromosomes originated from chromosome Y material as 
shown in Fig 3.3.1-B. Insufficient material remained for FISH with an 
chromosome X library. Case 14 also showed hyperdiploidy with complete 
agreement with both results. Four copies of chromosome X and 21 were revealed 
by single chromosome normalisation of chromosome 14 which was an already 
known trisomy. In case 19 there was discordance between CGH and conventional 
karyotyping results. CGH could not detect the presence of trisomy 4 because this 
cell line was present in only 33% of cells by cytogenetic analysis.
Three of 19 cases (cases 13, 18, and 20) studied had shown both numerical and
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structural abnormalities or structural abnormalities only on G-banding. In case 13, 
conventional karyotyping had shown del(6)(q21), der(9)?t(9;21 )(p 13 ;q 11.2), -21, 
compared with CGH results which revealed loss of chromosomal regions 6ql 1- 
q21, 9pl3.2-pter, and normal result for chromosome 21. Considering both 
results, it is likely that chromosome 21 material was rearranged to the deleted 
chromosome 9p and the der(9) was presumably dicentric. There was discordance 
between conventional karyotyping and CGH results about the breakpoint on 
chromosome 6. Case 18 showed high level of gain (amplification) of 
chromosome 6p23-6pter by CGH (Fig 3.3.1-C). The finding of add(6)(p2?) by 
conventional karyotyping was thought to be material from 6p23-6pter. In Case 20 
cytogenetic analysis has shown loss of chromosome 4, gain of chromosome 8, 
and various complex chromosomal aberrations which could not be detected 
by CGH. CGH revealed only gain of chromosome 8 and normal result for 
chromosome 4. FISH using chromosome 4 library was then applied to metaphase 
preparations from bone marrow, and showed that chromosome 4 material was 
present in several rearranged chromosomes such as der(ll), add(17), and ring 
chromosome.
The final four cases (cases 7, 9, 10, and 17) had failed to yield successful G- 
banding results. Two cases (cases 9 and 10) showed normal CGH result. In the 
remaining two cases, case 7 was shown to have loss of material chromosome 
Xpter-q24 but the result could not be confirmed by FISH because adequate 
metaphases were not available. Case 17 was shown be triploid by using CGH 
analysis (2-4 copies of each chromosome except chromosome X). The initial 
analysis (CGH) appeared to show loss of chromosome X, partial loss of 
chromosome 3, 9, and 12 (degree of loss of chromosome; 3> 9> 12), gains of 
chromosome 20 and 21, and partial gains of 16, 17, 19, and 22, and balanced 
state of remaining chromosomes in images by global analysis. But interphase 
FISH had predominantly shown 3 signals for all probes tested except 
chromosome X. Because CGH can only evaluate relative copy numbers, it cannot 
completely evaluate ploidy levels or absolute copy numbers of chromosomal 
regions. There are some documented limitations in detecting hyperdiploidy by 
existing methods of normalization. So in this case the full status of numerical 
abnormalities could be evaluated by global method (pixel by pixel 
fluorescence intensity ratio image) with multiple single chromosome 
normalization (Rosenberg et al., 1997) (Fig 3.3.1-D).
Interphase FISH results (cases 8, 14, and 17) corresponded with CGH results, but
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case 8 showed one discrepancy (chromosome X) with conventional karyotype 
results (Table 3.3.2). It was thought be that chromosome X was in one of the 
marker chromosome.
Table 3.3.1. Results of karyotype and CGH analysis in 10 cases with ALL
Case Sex Karyotyype CGH result
7 F Fail - X(pter-q24)
8 M 55-56,XY,+4,+6,+10,+14,+17,+18,+21, 
+marl,+mar2, +mar3[CP9]
46,XY[4]
+X, +Y, +4, +6, +10, +14, +17, 
+18,+21
9 F Fail Normal
10 F Fail Normal
13 M 45,XY,del(6)(q21),der(9)?t(9;21)(pl3;qll.2),-21 -6(qll-q21), -9(pl3.2-pter)
14 F 55,XX,+X,+?X,+4,+5,+10,+14,+18,+21 ,+21 [CP3] 
46,XY[10]
+X, +X, +4, +5, +10, +14, +18, 
+21,+21
17 F Fail Normal X, +3x2/3, +9x2/3,
+ 12x2/3(3), +16x3/4, +17x3/4, 
+19x3/4, +22x3/4, +20x4, 
+21x4, others x3
18 F 46,XX,add(6)(p2?)[CP9]
46,XX[5]
Amplification of 6(p23-pter)
19 M 47,XY,+4[CP4]
46,XY[8]
Normal
20 F 47,XX,add(3)(p25),-4,+8,inv(9)(pl2ql3)c, 
del( 10)(q24),der( 11 )t(4; 1 l)(q21 ;q23), 
add(17)(11.2),+r[CP8] 
46,XX,inv(9)(pl2ql3)f2]
+8
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Table 3.3.2. Interphase FISH3 results in 3 hyperdiploid / hypotriploid cases with 
ALL
iignalCh.
No
Case No
87%*10% 3%
72%* 4%11% 13%
8% 1%4% 87%
99%
3%
1%
96% 1%
57%*42%* 1%
97% 1%2%
77%* 15%8%
77%*22% 1%
83%* 4%13%
3% 93% 4%
84%*16%
81%* 7%11%
7%*90%*3%
1% 98% 1%
68% * 20%12%
2% 98%
82%*6% 12%14/22
8% * 44%*46%*
83% 1%8% 8%
83%* 3%14%
2% 96% 2%
84%* 2%14%
91%*9%
2%4% 94%
79%* 1%2% 18%
74%*16% 10%
82%*8% 4%6%
8% 91% 1%
3 FISH, Flurorescence In Situ Hybridisation; ALL, Acute Lymphoblastic 
Leukemia
* abnormal result comparing with normal control 
c normal control
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FIG 3.3.1-A CGH ratio profiles of case 8 & 14; Case 8 shows gains of material on 
chromosome 4, 6, 10, 14, 17, 18, 21, X, and Y and case 14 shows gains of material on 
chromosome 4, 5, 10, 14, 18, 21, and X. Both cases show incomplete coverage of 
whole length of chromosome in some chromosomes.
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FIG 3.3.1-B Dual-colour FISH hybridized on 
patient metaphases (case 8) Probes used 
were WCP Y (green)/ chromosome 1 5 (red). 
Choromosome Y material was incorporated 
into one of the marker chromosomes.
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FIG 3.3.1-C CGH ratio profile of case 18, which is shown amplification on the region 
of chromosome 6p23-6pter
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Fig 3.3.1- D: CGH image by global analysis 
and images following single chromosome 
normalisation of the same metaphase (case 
17). Green; over-represented chromosome 
regions (FR>1). White; balanced state of the 
chromosome material (FR=1), RED; under­
represented state of chromosome regions 
(FR<1). (A) CGH image without fluorescence 
equalisation, (B) CGH image with ch.X 
normalisation, (C) CGH image with ch.3 
normalisation, (D) CGH image with ch.1 
normalisation, (E) CGH image with ch.20 
normalisation.
3.3.2 CGH Analysis in cases with AML or AML/MDS
Detection of the Origin of Marker Chromosomes by using CGH and FISH
In Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS), 
there are frequently karyotypes with multiple structurally altered chromosomes, 
many of which are marker chromosomes of unknown origin.
The aim of this study was to assess if CGH could be used as a tool to identify 
the origin of marker chromosomes or other unbalanced structural aberrations 
detected during diagnostic cytogenetic analysis.
Nineteen bone marrow samples from patients with AML or MDS in 
transformation were randomly selected depending on availability of the samples. 
Conventional karyotyping and CGH were performed independently. FISH was 
performed using whole chromosome paints which were carefully chosen on the 
basis of discordance between CGH results and standard cytogenetic analysis.
Conventional karyotyping and CGH results
In 7 of the 19 patients, normal results were observed both by cytogenetics 
and CGH. Cytogenetic analysis of the remaining cases revealed complex 
karyotypes with multiple chromosome aberrations in 8 cases and two cases 
showed a balanced t ( l5:17); two cases failed to yield a result. CGH analysis of 
these two failed cases (case 8 and 17) showed a normal result in case 8 and 
showed multiple gains and losses of specific chromosome regions in case 
17. CGH could not detect any imbalance in the two cases with balanced 
translocations. This is a known limitation of the technique. Complete karyotypes 
and CGH data of these 19 cases are listed in Table 3.3.3. A summary of 9 
abnormal CGH profiles is shown in Fig.3.3.2-A.
From this data, the most frequently observed abnormality on CGH analysis is 
loss of material from 5q (6 out of 19 cases) especially loss of 5q23-31 (5 cases). 
Cases 4 and 7 showed amplification at 8q24 (C-MYC gene region) and llq23 
(MLL gene region) respectively, neither of which could have been deduced from 
routine cytogenetics. Both cases were accompanied by an unbalanced t(5;17). 
Amplification of 8q24 (case 4) was shown by FISH to be present in double 
minutes (Fig 3.3.2-B) and 11 q23 (case 7) was shown to be incorporated in two 
marker chromosomes (Fig 3.3.2-C).
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By comparing CGH with conventional karyotyping results, four cases (cases 4, 7, 
9 and 12) revealed unbalanced rearrangements involving chromosomes 5 and 17 
with different break points, all accompanied, to a varying extent, by deletion of 5 
and 17. In case 4, CGH revealed loss of 5ql4-qter and 17pl2-pter whereas 
conventional karyotyping revealed loss of most of the material from 5q and 17p 
resulting from an unbalanced t(5;17). One of these cases (case 12) was thought to 
have a dicentric rearrangement retaining the centromeres of both chromosomes, 
and two cases (cases 7 and 9) showed an unbalanced translocation 
with interstitial deletion of chromosome 5.
FISH results
The composition of chromosomal aberrations, marker chromosomes and ring 
chromosomes could be identified using FISH with specific probes which were 
chosen because of discordance between CGH and conventional karyotyping as 
shown in Table 3.3.4.
Cases 7, 9, 12, 13, and 14 showed the composition of the marker chromosomes to 
be complex. Some of these markers were shown to be derived from segments of 
several different chromosomes (Fig 3.3.2-D, E, F). In case 13, chromosomal 
material involving the entire Y chromosome including the centromere, originally 
thought to be missing from the karyotype, was detected by FISH and CGH in the 
marker chromosome (Fig 3.3.2-G). In case 12, a derivative chromosome 7 
was identified by FISH and CGH as a dicentric t(7p;21p) resulting in partial 
loss of 7p and 21p (Fig 3.3.2-H).
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Table 3.3.3 Comparison between CGH and cytogenetic analysis in 19 AML and 
AML / MDS patients
Case FAB-
type
Karyotype CGH results
gains losses Amp.
1 M3 46,XY,t(15;17)[13] 
46,XY fll
_b - -
2 M2 46,XY — — -
3 46,XY — — -
4 M4 46-47,XY,-5,
?der(9)del(9)(p 13)inv(9)(p 13q21.1) 
der(17)t(5;17)(pl3;pll.2),+r,8-13dmin 
[CP 10]
5ql4-qter
9pll-pter
17pl2-pter
8q24
5 M4 46,XY - - -
6 M3 46,XY,t( 15; 17)(q22;q21) - - -
7 Ml 44-47,XY,add(4)(ql3), 
der(5)t(5;17)(ql?2;ql?l), 
del(7)(q22),add( 10)(p 13),
?idic( 11 )(q23),add( 15)(p 11),-17, 
add( 18)(p 11 ),add(20)(q 11.2),-21, 
+r x3,+mar[CP10]
5ql5-q31
7q22-q36
lip
17p
Hq,
esp, 11
q23-
qter
8 Ml Fail - - -
9 (RAEB)t 40-43,XY,der(3)t(3; 15)(q21 ;q22),-4,-5,
-9, del(9)(p2), -15, add(17)(pll.2),-18, 
-20,-21 ,-22,+2r,+mar 1 ,+mar2,+mar3 [CP9] 
46,XY[1]
19
21
22
4
5qll.2-q31
9ql2-q32
18
17p
10 Ml 46,XY - -
11 M4 45,XY,t(3;3)(q21;q26),-7 - 7 -
12 Ml 43,XY,del(3)(pl3),del(5)(qll.2), 
del(7)(pl3pl5) or add(7)(pl3), 
der(8; 17)(q 10;q 10),-18,-21 ,-22, 
+der(?)t(3; ?) (p21) [CP7]
42-43,XY, add(l)(q? 11 ),del(3)(p 13), 
der(5)t(5; 17)(ql 1.2;ql 1.2), 
del(7)(p 13p 15) or
add(7)(p 13),add(8)(p 12),-18,-21 ,-22, 
+der(?)t( l;?)(q?21;?)[CP4]
46,XY[2]
5qll.2-qter
7pl2-pter
8pll.2-pter
17pl3
18q
13 M4 40-45,X,-Y,-5,-6,add(7)(q22),-8(x2),
-16,-20,+r,+mar 1 ,+mar2,+mar3,+mar4, 
+mar5[CPll]
46, XY [3]
6p21.1
8p21.2-
q21.2
5q23-qter
6p22-pter
7q21.2-qter
16q
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14 RAEB 45-47,XY,add(l)(q4?),-9,-11,-13, 
add( 15 )(p 11 ),add( 19)(p 13),+mar 1, 
+mar2, +r 1, +r2 [CP 13 ]
46,XY[41
19p
15 46,XY - — —
16 (RAEB)t 47,XY,+mar [CP3] 
46,XY [17]
16p
22
— —
17 Fail lp32-pter
9q31-qter
llq l2 -
13.3
16p
17, 19, 20
5q ll.l-q 22
13q21
Xq
18 46,XY - -
19 46,XY - -
3 CGI4, Comparative Genomic Hybridisation; AML, Acute Myeloid Leukemia; MDS,
Myelodysplastic syndromes; FAB, French-American-British, RAEB, Refractory Anemia 
with Excess Blast. 
b no gain, loss or amplification
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FIG 3.3.2-A Summary of CGH ratio profiles of 9 abnormal cases with AML/MDS; 
losses of DNA copy numbers are represented by vertical Nines on the left side of 
each chromosome with red colour, whereas lines on the right side represent gains 
with green colour.
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Fig 3.3.2-B CGH profile of chromosome 8 in case 4, which is represented 
amplification at 8q24 (A) and Mono-colour FISH hybridised on patient 
metaphase using WCP 8 (green). Result: Amplification of C-MYC  
incorporated in double minutes (B).
A A
w t
v .
Fig 3.3.2-C CGH profile of chromosome 11 in case 7, which is shown 
amplification at 11q23 (A) and Mono-colour FISH hybridised on patient 
metaphase (case 7) using MLL gene specific probe (red). Result: 8 
copies of the MLL gene on two der(11).
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Table 3.3.4 The origin of unidentified regions within the karyotype identified 
by CGH/FISH
Case Unidentified regions of the 
Karyotype
Origin of the 
unidentified regions
Probes used by FISH 
(WCP)b
4 + r 5q Ch 5 WCP
8-13 dmin 8q24 Ch 8 WCP
7 mar l(idic 11) 11 Ch 11 WCP
mar 2(add 20) 4 Ch 4 WCP
add (15) 11 Ch 11(B)/15(D) WCP
add (10) 4 Ch 4 WCP
9 mar 1 20/ 22 Ch 20(D)/22(B) WCP
mar 2(add 17) t(5;17) Ch 5 WCP
mar 3 3 Ch 3 WCP
r 1 9/ 21 Ch 9(B)/21(D) WCP
r 2 15 Ch 15 WCP
12 add (7) dic(7;21) Ch 7(B)/21(D) WCP
der (?) 3 / 1 8 / 2 2 Ch 3(B)/18(D) 
+22(B)/18(D) WCP
13 mar 1 Y / 6 / 8 Ch 8(B)/6(D)+8(D)/Y(B)
mar 2 6 / 8 / 2 0 8(B)/6(D)+6(D)/20(B)
mar 3 8 Ch 8 WCP
mar 4 6 / 2 0 Ch 6(D)/20(B) WCP
mar 5 16 Ch 16 WCP
14 mar 1 11 / 19 Ch 11(B)/19(D) WCP
mar 2 11 / 19 Ch 11(B)/19(D) WCP
r 1 11 / 19 Ch 11(B)/19(D) WCP
r2 11 Ch 11(B)/19(D) WCP
add (15) 11 / 19 Ch 11(B)/19(D) WCP
add (19) 9 Ch 9(B)/19(D) WCP
a CGH Comparative Genomic Hybridisation; FISH, Fluorescence In
Situ Hybridisation; dmin, double minutes
b Ch, chromosome; B, probe labelled with biotin; D, probe labelled with
digoxigenin
WCP, FISH using whole chromosome painting
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Fig 3.3.2-D Dual-colour FISH 
hybridised on patient metaphases 
(case 9).Probes used were WCP 20 
(red) and WCP 22 (green). Results: 
The region of chromosome 20 and 22 
in the make up of the marker 
chromosome (arrowed) is identified. It 
is possible that the marker 
chromosoem is an isoderivative 
chromosome 20. A G-banded image of 
the marker chromosome is also 
included.
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Fig 3.3.2-E (A)(B) Dual-colour FISH hybridised on patient metaphases containing the 
same cytogenic marker chromosome (case 12). (A) Probes used were WCP 3 (green) 
and WCP 18 (red). Result: The marker chromosome is composed of chromosome 
3/18 material. (B) Probes used WCP 22 (green), WCP 18 (red). Results: The marker 
chromosome is composed of chromosome 22/18 material. A composite of both 
images shows the marker chromosome to be composed of regions from chromosome 
3, 18, and 22. A G-banded image of marker chromosome is also included.
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Fig 3.3.2-F (A)(B) Dual-colour FISH hybridized on patient metaphases (case 14). 
(A Probes were used WCP 11 (green) and WCP 19 (red). Results: One marker 
chomosome shown as a G-banded image is composed mainly of chromosome 19
material with intervening sequences of chromosome 11. (B) Probes used were 
V\OP 11 (green) and WCP 19 (red). Results: The additional material on 
chomosome 15 is identified as material from chromosome 11/19. The ring 
chomosome is composed mainly of chromosome 11 material interspersed with
material from chromosome 1 9.
Fic3.3.2-G Dual-colour FISH hybridized 
onDatient metaphases (case 13) using 
WCP 8 (red) and WCP Y (green).
Result: The marker chromosome 
(arowed) also shown as G-banded 
inruge, is composed of Chromosome 8 
ani Y materials.
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Fig 3.3.2-H Dual-colour FISH hybridized 
on patient metaphases (case 12) using 
WCP 7 (green) and WCP 21 (red). 
Results: The unidentified material on 7q 
(arrowed) also shown as a G-banded 
image is identified as chromosome 21 
material. This chromosome was also 
identified as being dicentric.
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3.3.3 CGH analysis on samples with various hematologic malignancies
Fourteen cases of various hematologic malignancies were analysed. 
A comparison of CGH and cytogenetic data is shown in Table 3.3.5. One of the 
documented limitations of CGH is that it cannot detect balanced abnormalities. 
Thus the Philadelphia chromosome was not detected by CGH in cases 
with CML. Case 9 & 11 showed chromosomal aberrations by G-banding analysis 
but CGH did not detect any abnormalities. Probably it was caused by mosaicism 
with normal cells (50%-70%).
In case 10 CGH revealed loss of 13q, compared with normal karyotyping result. 
Table 3.3.5. Comparison between CGH and cytogenetic analysis in 14 various
hematologic malignancies
No Disease3 Karyotype CGH
1 PRV 46,XY Normal
2 PRV 46,XX Normal
3 NHL 46,XY Normal
4 NHL 46,XX Normal
5 NHL 46,XX Normal
6 Persistent leukocytosis 46,XX Normal
7 MPD 46,XX Normal
8 MPD 46,XX Normal
9 CLL 46,XX, add(4)(q3 ?3 ),
add( 13 )(q3 ?2), add( 17)(p 11.2)[3 ]
46,XX[91
Cannot detect 
abnormality
10 CLL 46,XX Loss of13q
11 CLL 47,XY+mar[2]
46,XY[28]
Cannot detect 
abnormality
12 Anemia 46,XX Normal
13 CML 46,XX,t(9;22) Cannot detect 
abnormality
14 CML 46,XY,t(9;22) Cannot detect 
abnormality
a PRV, Polycythemia rubra vera; NHL, Non-Hodgkin’s Lymphoma; MPD,
Myeloproliferative disorders; CLL, Chronic Lymphocytic Leukemia; CML, Chronic 
Myeloid Leukemia.
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3.4 CGH Experiments on fresh frozen solid tumour samples
The main aim of the project was to extend the study to the analysis o f solid 
tumours first using fresh frozen samples and then moving on to use paraffin- 
embedded samples. It was particularly hoped to analyse early and sequential 
melanoma samples with the aim of highlighting chromosome regions involved in 
the onset of disease.
The first samples in this part of the study included 5 cases of well-differentiated 
liposarcoma (WDLS) and 17 cases of melanoma. Application of the CGH 
technique to the study of solid tumours has allowed a
great improvement in identification of the genetic changes in various stages of 
cancer. CGH especially is the most convincing method to detect exact location of 
amplification on the chromosome, where a possible candidate oncogene may be 
located. The present study was planned to assess the usefulness of CGH in 
detecting net gains, losses, and amplifications of DNA copy number in solid 
tumour, which had not been detected by conventional karyotyping.
3.4.1 CGH analysis in cases with Well Differentiated Liposarcoma (WDLS)
Five samples from four individuals with WDLS investigated by the diagnostic 
laboratory were also studied by CGH using the standard method. All the 
samples yielded relatively high concentration, good quality DNA after extraction 
from the frozen samples except case 5 which was extracted from a cultured cell 
line. Chromosome analysis and CGH results are shown in Table 3.4.1.
One sample (case 5) gave a normal result by CGH. Because the DNA of this 
sample was extracted from cultured cell lines, it is possible that this reflects 
loss of the abnormal cell line during culture. All the remaining samples showed 
amplification of the chromosome region between 12ql3 and 12q21 as a common 
chromosomal abnormality. But all three cases (cases 2 and 4; samples from 
same patient) showed slightly different locations and extent of amplifications. 
From the literature review, supernumerary ring and/or giant rod-shaped marker 
chromosomes were well-known frequent cytogenetic abnormalities in WDLS. 
These marker chromosomes are known to derive from material of chromosome 
12, as well as less frequently from material from chromosome 1, 4, 8, 16 
(Suijkerbuijk et al., 1994).
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In case 1, the karyotyping result showed a hypotriploid/hyperdiploid 
clone including two giant derivative chromosomes. As already discussed, CGH 
cannot evaluate absolute copy numbers by standard normalization method. This 
case again showed that the computer software program readjusted internally to 
show 3 copies as the balanced state (Fig.3.4.1-A). But 
hypotriploidy/hyperdiploidy could be detected by applying single chromosome 
normalization. CGH results showed one copy of chromosome X, two copies of 
chromosome 2, 4, 9, ll(except llpl5.3; 4 copies), 14, 15, four copies of 
chromosomes 8, and 18, and three copies of the remaining chromosomes (except 
chromosome 5pl5.3; 2 copies) in addition to amplification of 12ql 3-21. The 
discrepancies between CGH and conventional karyotyping result were two 
copies of chromosome 11 (except lip  15.3; 4 copies), three copies of 
chromosomes 22 and 5 (except 5pl5.3; 2 copies) and amplification of 
chromosome 12ql3-21. After CGH, confirmatory FISH could not proceed 
because of unavailability of sufficient metaphase chromosomes. But it is likely 
that the gained and amplified materials could be present in the two giant 
derivative and marker chromosomes.
Cases 2 and 4 were from the same patient but taken at different times. Case 2 was 
the first sample approximately 4 months earlier than case 4. Conventional 
cytogenetics showed a ring chromosome to be present in 2 (case 2) or 3 copies 
(case 4). It was thought that these ring chromosomes were composed of material 
from chromosome 12. This interpretation was confirmed by FISH, which also 
showed that the chromosome 12 paint did not completely cover the rings. CGH 
analysis of these samples indicated that additional amplification material from 
chromosome 3 (3ql2-13.3) was present (Fig 3.4.1-C). This amplification material 
could be present in the ring chromosomes, but unfortunately no material 
remained to confirm this by FISH.
The karyotype of case 3 when studied by cytogenetics contained 4 copies of a 
ring chromosome shown by FISH to be composed in part of material from 
chromosome 12. In addition to amplification of chromosome 12q21, two 
prominent peaks were detected at the lq21-24 and lq31 (amplification on 
chromosome lq21-24, high level of gain on lq31) by CGH and could be 
present in the ring chromosomes (Fig 3.4.1-B).
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Table 3.4.1 Summary of cytogenetic and CGH results of 4 cases with WDLS
No Karyotype CGH
1 64,X,+1 ,+3,+add(5)(p 14).ish der(5)(wcp 12+), 
+6,+7,+8,+8,+10,+11,+12,+13,+16,+17,+18, 
+18,+19,+20,+21 ,+mar. ish der(?)(wcp 12+)
Amplification of 12ql3-21 
lxX,  2x2/4/9/ll(+ llpl5.3) 
/14/15, 4x 8/18,
3x others(-5pl5.3)
2 48,XX,+2r 
46,XX
Amplification o f 12ql3-21 
Amplification of 3q 12-13.3
3 48-50,XX,+4r[cp 11] 
46,XX
Amplification of 12q21 
Amplification of lq21-24, 
High level of gain of lq 3 1
4 49,XX,+3r 
46,XX
Amplification of 12ql3-21 
Amplification of 3q 12-13.3
5 47,XY,+r.ish r(wcpl2) 
46,XY
normal
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Fig 3.4.1-A CGH ratio profile from case 1 with well differentiated liposarcoma. This 
profile shows normal 2 copies of chromosome are represents as loss, 3 copies as 
balanced state, 4 copies as gain and in addition to amplification of 12q13-21.
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Fig 3.4.1-B CGH ratio profile from case 3. This profile shows amplification on 
chromiosome 12q21, 1 q21 -24. and high level of gain on 1q31.
Fig 3.4.1-C CGH ratio profile from case 4. This profile shows amplification on 
chromosome 12q13-21 and 3q1 2-13.3.
3.4.2 CGH Analysis on Samples with Melanoma
In the first part of the melanoma study seventeen fresh frozen samples were 
studied. Because human cutaneous melanoma is one of the commonest cancers as 
well as the most malignant cancer, identification of genetic changes from early to 
metastatic stage is very critical. In samples of primary melanoma, it was very 
difficult to obtain pure malignant specimens because of contamination with 
normal surrounding tissue.
The aim of this study was to define chromosomes or chromosome regions which 
were frequently involved in karyotypic changes in early stages of the tumour. It 
was hoped that the application of CGH would help evaluate true net gains and 
losses and point to areas where a target gene involved in the progression of 
cancer might be located.
The seventeen samples studied were selected by the Dermatology department. 
The CGH experiments were performed without information about patient’s status, 
histological subtype, or stage of tumour progression. No other cytogenetic 
analysis, including FISH, was possible on these samples.
A summary of the copy number changes in thirteen abnormal cases is shown as 
Fig 3.4.2-A. Losses of genetic material are represented by vertical lines on the 
left side of each chromosome, whereas lines on the right side represent 
gains. Remaining four cases showed normal CGH findings.
The most frequent finding was a loss of DNA segment on chromosome 1 Oq with 
10qll.2->q24 as the smallest under-represented segment (7 out of 17), a loss of 
6q (7 out of 17), and loss of 9p (7 out of 17). Chromosome 10 was not always 
lost as the whole chromosome (loss of chromosome lOp; 5 out of 17). Losses of 
chromosome 6q were almost always accompanied with gains on chromosome 
6p in our cases (6 out of 17, except case 14). In loss of chromosome 6q, the 
losses mostly involved the entire q arm with 6ql6.1-q23.3 as minimal common 
lost area. Among cases with loss of 9p, six of the seven cases 
showed involvement of 9p21. One remaining case showed loss of 9pl3.1-q22.1. 
Another chromosomes showing frequent loss was 13q (5 out of 17). Cases 4, 10, 
and 14 showed loss of material from chromosome Y.
Gains most frequently involved chromosome 6p (7 out of 17), and this gain 
was of almost the entire p arm.
Other chromosomes showing frequent gains were p and/or q arms of 
chromosome 1 (7 out of 17), 8q (6 out of 17), 17q (6 out of 17), p and/or q
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arms of 7 (5 out of 17), and 22 (3 out of 17). Gains of chromosome 1 were 
random over the whole length of the chromosome, but especially involved the 
region lp33-36.1 (3 out of 17). In cases with gains on chromosome 8, 8q24 was 
the most frequently involved region (6 out of 17). Chromosome 7 
showed inconsistent gains; the most commonly involved areas were 7q31.32-qter 
(5 out of 17) and 7q 11.21 (4 out of 17). Gains on chromosome 17 
mostly involved the 17q24-qter region.
In this study, high level of gains on chromosome lq21, Ilql2.3-ql3.1 and 
amplifications on chromosome lp ll.2 -p l2 , 3p24, 17q24-qter, and 22
were identified (threshold; > 1.5) (Fig 3.4.2-B). The degree of amplification of 
some regions appeared relatively low because the sizes of the amplicons were 
small and these samples were diluted with normal cells.
Two samples (case 6 and case 17) were from the same patient but taken at 
different times (time difference was 7 month 14 days). Case 6 showed gains of 
several small areas (llql3.2-13.4, 17q23-qter, +19), loss of 6ql4.2-23.2, loss of 
9pl2-p22 and high level of gain of the region 3p24-25.2 including 
amplification on 3p24. After the gap in time, case 17 showed gains on 
chromosome 5ql2-14, 5q21, 6p, +7 and losses on chromosome 2p, 6q, 9p22- 
q31.1, 13q22-34. These results are quite different from the original - all the 
regions showing gain in sample 6 had disappeared in sample 17. The features 
common to the two samples were loss of 9p21 and of 6q 14.2-23.2.
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FIG 3.4.2-B Amplifications of four different regions on chromosomes 
1 p11,2-p1 2, 3p24, 17q24-qter, 22 in three melanoma cases
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3.5 Optimisation of the CGH Technique in Very Small 
Amounts of DNA from Paraffin Embedded Tissue in Solid 
Tumours
CGH was developed to overcome the problem of cytogenetic analysis of solid 
tumours. Two of the problems of using sections are i) neoplastic tissue to be 
analysed may only be a small fraction of the cells in the specimen and ii) the 
amount of DNA obtained may be insufficient for CGH. The first problem can 
be overcome by separation of the malignant cells by microdissection, the second 
by whole genome amplification of the DNA obtained from microdissected 
malignant cells. CGH with amplified DNA from paraffin embedded tissue 
provides a powerful method to study the pathogenesis of cancer by identifying 
genetic progression from premalignant lesions to metastatic tumours (Speicher et 
al„ 1993; Isola et al., 1994).
The samples used during optimisation were paraffin-embedded ovarian cancer 
tissue. The results of each modification were measured first by smear on the 
1.2% agarose gel and secondly by ability to give good CGH after 
amplification. Even when the smear did not appear satisfactory amplification 
and CGH experiment were still attempted. The summary of the optimisation 
process in this experiment is present in Table 3.5.1.
The first step in the present project was to find the optimal method of 
production of high molecular weight DNA from formalin fixed, paraffin- 
embedded tissues.
3.5.1 Various kinds of DNA extraction methods from paraffin embedded 
tissue
Before starting CGH experiments with paraffin embedded samples, several 
modifications were investigated to find the optimal method for production of 
high molecular weight DNA for proceeding to whole genome amplification 
to obtain successful CGH.
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Table 3.5.1 Summary of the optimization process in this experiment
No of DNA 
Isolation 
method
Souce of 
samples
Size of 
sample
Method of 
amplification
cEnzyme
used
Result 
of CGH
aPEP bDOP
1 Ovarian ca 1x7 pm
2 Ovarian ca 1x7 pm PEP-1 AmpliTaq pol failed
DOP-1 Topo + T7 failed
DOP-2 T7 failed
3 Ovarian ca 1x7 pm
4 Ovarian ca 3x7pm PEP-2 AmpliTaq pol failed
DOP-3 AmpliTaq LD failed
DOP-5 Topo + T7 good
5 Ovarian ca 3 x7 pm DOP-4 AmpliTaq LD inadequate
6 Ovarian ca 1x7pm
7 Ovarian ca 1x7 pm
8 Ovarian ca 1x7 pm
9-1 Ovarian ca 1x7 pm PEP-3 AmpliTaq pol failed
9 -2 Ovarian ca PEP-3 AmpliTaq pol inadequate
PEP-11 AmpliTaq LD good
10-1 Ovarian ca 1x7pm PEP-4 AmpliTaq LD good
PEP-6 AmpliTaq LD failed
10-2 Ovarian ca PEP-5 AmpliTaq pol failed
PEP-7 AmpliTaq pol failed
11 -1 Ovarian ca 1x7 pm PEP-8 AmpliTaq LD inadequate
11-2 Ovarian ca PEP-9 AmpliTaq LD inadequate
11 -3 Ovarian ca PEP-10 AmpliTaq LD failed
12 Ovarian
Cancer
1x7 pm PEP-12 AmpliTaq LD good
DOP-6 Thermoseque
nase
good
13 Ovarian
Cancer
1x7pm PEP-13 AmpliTaq LD good
DOP-6 Thermoseque
nase
good
14 melanoma 1x7 pm PEP-14 AmpliTaq LD *
DOP-7 AmpliTaq LD *
15 melanoma 1x7 pm PEP-15 EHF PCR *
DOP-8 EHF PCR *
a; PEP, primer-extension preamplification b; DOP-PCR, degenerate oligonucleotide-primed
PCR
c; pol; polymerase, Topo; topoisomerase 1, T7; T7 sequenase, EHF; Expand High Fidelity PCR 
* The results were depended on the samples.
1 63
The quality and quantity of extracted DNA depends on the status of the 
samples including the fixative used in the tissue processing, the duration of the 
fixation, the age of the paraffin block and the size of the DNA fragment to be 
amplified. In the work described here, all the tumour samples were provided 
from outside the department and there was no opportunity to vary the fixation etc., 
so that it was not possible to make any comparison of basic conditions.
The basic protocol was method 2 used by Isola et al(1994). In this experiment, 
the parameters investigated were amount of test material, pre-incubation before 
de-waxing or not, changing composition of lysis buffer, changing 
concentration or length of incubation in proteinase K, adding booster proteinase 
K or not, extraction with phenol/chloroform or not. The DNA extraction from 
paraffin-embedded tissue has some limitations as the formalin fixation of the 
tumour tissues results in tissue DNA forming tight complexes with proteins, and 
being fragmented. Nuclear proteins are also extensively cross linked with 
each other (Isola et al., 1994).
For each parameter, Table 3.5.2 shows modifications and Table 3.5.3 shows 
results of experiments of each method.
First of all, comparing the quantity of test material (Table 3.5.2; isolation 
methods 3 and 4), 3 x 7 pm thickness sample (method 4) showed better quality of 
DNA (from over 12000 bp to less than 500 bp) than using 1 x 7  pm sections. 
Methods 5, 6, and 7 included a preincubation step (from 3 hrs to overnight) 
before dewaxing. DNA fragments produced by method 5 showed higher 
molecular weight DNA (1000 to over 12000 bp) with stronger intensity than 
that of method 4. Methods 6 and 7 showed that the samples were dried slightly 
after pre-incubation over 6 hours.
In experiments 9 and 10, three parameters were changed- lysis buffer, amount 
and incubation time in proteinase K, and phenol/chloroform extraction. Lysis 
buffer was changed to lx PCR buffer 11 (lOmM Tris HC1 pH 8.3, 50mM KC1) 
because SDS has an inhibitory effect on PCR. The amount of proteinase K 
was increased (0.3 mg/ml-> 1-2 mg/ml) and incubation time was decreased 
(55°C for 3 days—> 65°C for 90 min) from method 9. In methods 9 and 10, there 
was no significant difference in results between different amount of proteinase K 
(2mg/ml and 1 mg/ml). Finally in experiments 9-2 and 10-1 phenol-chloroform 
extraction step was omitted. In experiments 9-1 and 10-2 (with 
phenol/chloroform extraction), a less strong smear on the agarose gel 
was obtained rather than in 9-2 and 10-1 (without phenol/chloroform extraction).
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Afterwards, the phenol-chloroform extraction procedure was omitted
during isolation of DNA as DNAs in these samples were of relatively small 
amount. It was better to use a single step extraction method than a two step 
method and remnant phenol, used for the removal of protein such as proteinase 
and nuclease, also had an inhibitory effect on PCR. In experiments 9-2 and 10-1, 
the results showed great improvement in the size of extracted DNA (most 
fragments >1000 bp) and the success rate in CGH experiments.
In method 11, different incubation times (90 min, 3 hours, 24 hours) and 
temperature (65°C and 55°C) of proteinase K were applied on the same sample 
and results showed no significant difference among the three different 
modifications.
With completion of method 12, the DNA extraction method was finalised with 
the exception of further alterations in the lysis buffer.
In method 13, lysis buffer with high concentration of Tris HC1 
and EDTA was used. The result did not give a strong smear when the DNA was 
run on agarose gel probably because EDTA with high concentration (> 0.5 mM) 
also has an inhibitory effect on PCR.
Finally, from method 14 DNA extraction procedure moved on to investigate the 
microdissected samples from paraffin-embedded melanoma tissue. Depending on 
the enzyme used to be (Ampli-Taq DNA Polymerase LD or Expand High Fidelity 
DNA Polymerase), different lysis buffers were used in the DNA extraction 
procedure.
In conclusion this series of experiments determined the optimal conditions for 
DNA extraction from paraffin embedded sections.
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Table 3.5.2 Summary of different DNA isolation methods
No. Amount 
of test 
material
Preinc.
Before
dewax.
Lysis buffer Proteinase K Protein
aseK
booster
Phenol/ 
chlor. E 
xt.
Amount Inc.
time
1 lx7|j.m No 500ul nuclei 
lysis buffer 
0.5% SDS
0.4mg/ml 10 hrs
(55°C)
No Yes (x2)
2 lx7|im No lOOmmol/L Nacl 
lOmmol/L Tris 
Hcl
25mmol/LEDTA 
0.5% SDS
0.3mg/ml 3 day 
(55°C)
0.5mg/ml
24hr,48hr
Yes
3 lx7n.ni No Same as No. 2 0.3mg/ml 4 days 
(55 °C)
0.5mg/ml
24hr,48hr
Yes
4 3x7y.m No Same as No. 2 0.3mg/ml 4 days 
(55°C)
0.5mg/ml
24hr,48hr
Yes
5 3x7 i^m 3hrs at 
65°C
Same as No. 2 0.3mg/ml 4 days 
(55°C)
0.5mg/ml
24hr,48hr
Yes
6 lx7nm 6hrs at 
65°C
Same as No. 2 0.3mg/ml 3 days 
(55°C)
0.5mg/ml
24hr,48hr
Yes
7 lx7|j.m Overnight 
at 65°C
Same as No. 2 0.3mg/ml 3 days 
(55°C)
0.5mg/ml
24hr,48hr
Yes
8 lx7n.ni
(M)
No Same as No. 2 1 mg/ml 1 day
(55°Q
No No
9 lx7nin No lxPCR bufferll lmg/ml 90min
(65°C)
No 9-l;Yes
9-2;No
10 1x7 H.m No lxPCR bufferll 2 mg/ml 90min
(65°Q
No 10-l;No
10-2;
Yes
11 lx7jj.ni No lxPCR bufferll 2mg/ml ll-l;90min(65°C)
ll-2;3hrs(65°C)
ll-3;24hrs(55°C)
No
12 lx7H.m No lxPCR bufferll lmg/ml 24hrs
(55°C)
No No
13 lx7jun No 50mM TrisHcl 
ImM EDTA 
0.5% Tween 20
lmg/ml 24hrs
(55°C)
No No
14 1x3 H-m
(M)
No lxPCR bufferll lmg/ml 2davs
(55°C)
No No
15 1x3 nm 
(M)
No EHF buffer 
0.5% Tween 20
4mg/ml 24hrs
(48°C)
No No
M; microdissection
1 6 6
Table 3.5.3 Results of different DNA isolation methods
No of DNA 
isolation method
Size of DNA 
fragments
Result of CGH Method of 
amplification
Order of 
Intensity 
(smear)
1 Failure to get
2 < 500 bp failed
failed
DOP-PCR&
PEP
5
3 < 500 bp 5
4 200 to over 
12000 bp
successful
failed
DOP-PCR & 
PEP
4
5 1000 to over 
12000 bp
inadequate DOP-PCR 2
6 < 500 bp
7 < 1000 bp
8 Failure to get
9 -1 500-12000 bp failed PEP 3
9 -2 1000 to over 
12000 bp
successful PEP 1
10-1
10-2
500- 12000 bp 
500 to over 
12000 bp
successful
failed
PEP
PEP
3
4
11 -1 
11 -2 
11 -3
1000 to over 
12000 bp 
1000 to over 
12000 bp 
1600-12000bp
inadequate
inadequate
failed
PEP
PEP
PEP
2
2
2
12 500-12000 bp successful
successful
DOP-PCR & 
PEP
1
13 500 to over 
12000 bp
successful
successful
DOP-PCR & 
PEP
4
14 * *
failed
DOP-PCR & 
PEP
*
15 * *
failed
DOP-PCR & 
PEP
*
order of relative intensity; very strong- moderate strong- strong- faint- very faint 
(1-2-3-4-5)
* The size of DNA fragments and intensity of smear and results of CGH vary in
the original melanoma samples.
1 6 7
3.5.2 Universal amplification of DNA
Whilst the optimal method of DNA extraction was being determined, the next 
steps to whole genome amplification and CGH experiment were also evaluated. 
These methods were developed to allow genetic analysis to be undertaken on 
very small samples of DNA. Several trials have been described where CGH had 
been attempted after universal amplification using DOP-PCR but the technique 
required to be optimized, as did the alternative PEP.
To optimize the universal amplification method the following factors 
were investigated: cell lysis method (DNA extraction method), amplification 
cycles and enzymes.
Degenerate Oligonucleotide Primed PCR (DOP-PCR)
DOP-PCR is a type of PCR which uses primers which include partially 
degenerate oligonucleotides. The important points of DOP-PCR are the 
degenerate nature of primer and a low initial annealing temperature because these 
conditions induce priming from multiple evenly dispersed sites within a given 
genome.
The aim of this part of the study was to assess whether amplified DOP- 
PCR products could produce successful CGH results without significant bias and 
to evaluate the effect on DOP-PCR product of changing various parameters, 
which were the enzyme used, number of initial low annealing temperature cycles, 
and different kind and size of template DNA.
Table 3.5.4 shows some modifications during optimization of DOP-PCR and the 
results of different DOP-PCR methods are presented in Table 3.5.5. The first 
part of this experiment used samples of paraffin-embedded tissue from ovarian 
cancer (method number 1-6).
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Table 3.5.4 Summary of DOP-PCR modification protocol
No Amount of 
template 
(No. of 
Table 
3.5.2)
topoi
some
rase
1st low annealing temp, 
cycles
1st high annealing temp, 
cycles
Cone.
of
DNAEnz. Cycles Enz. cycles
1 3jj.1
lx7|am
(No.2)
+ T7seque
nase
94°C lmin 
30°C lmin30s 
37° 2min x7
Ampli
Taq
LD.
94°C lmin 
56°C lmin 
72°C 3minx35
320ng
/Hi
2 3|il
1x7 jam 
(No.2)
T7seque
nase
Same as No. 1 Same 
as Nol
Same as No.l 220ng
/Hi
3 3(_il
3x7jj.ni
(No.4)
Ampli 
Taq LD
94°C lmin 
30°C lmin30s 
37°C 2min x7
Same 
as Nol
Same as No.l 460ng
/jLll
4 3p.l
3x7jim 
(No.5)
Ampli 
Taq LD
Same as No.3 Same 
as Nol
Same as No.l 320ng
/jjl
5 3jj1
3x7jj,m
(No.4)
+ T7seque
nase
94°C lmin 
30°C lmin30s 
37°C 2min x7
Same 
as Nol
Same as Nol 50ng/
jil
6 3jj.l
lx7jj,m 
(No.12,13)
Thermo
seque
nase
94°C lmin 
25°C lmin 
74°C 2min x4
Ampli
Taq
LD
94°C lmin 
56°C lmin 
72°C 2minx30
450ng
/Hi
7 5jj,1
lx3jj.m
Ampli
Taq
LD
93°C lmin 
30°C lmin 
72°C 3min x7 
or x8
Ampli
Taq
LD
93°C lmin 
60°C lmin 
72°C 3minx28
8 5jj,1 or 
IO jj.1
lx3jj.m or 
lx7|j.m, 
microdisse 
cted
EHF
DNA
polymer
ase
93°C lmin 
30°C lmin 
72°C 3min x8
EHF
DNA
polym
erase
93°C lmin 
60°C lmin 
72°C 3minx28
1 69
Table 3.5.5 Results of different DOP-PCR methods
No of DOP- 
PCR method
Size after first 
DOP-PCR
Size after 2nd 
DOP-PCR
*Order of 
intensity on 
smear (1st)
CGH results
1 (Fig 3.5.2-A) from over 12000 
to below 500 bp
< 500 bp 2 fail
2 (Fig 3.5.2-A) from 3000 to 
below 500 bp
< 500 bp 3 fail
3 (Fig 3.5.2-C) from 2000 to 
below 1000 bp
mainly 200 to 
500 bp
3 fail
4 (Fig 3.5.2-C) from 12000 to 
below 1000 bp
200 to 1000 bp 2 inadequate
5 (Fig 3.5.2-E) from over 12000 
to below 500 bp
300 to1000 bp 1 good
6 (Fig 3.5.2-G) from 12000 bp 
to below 500 bp
300 to 500 bp 1 good
7 (next chapter)
* the order of relative intensity from strong to very faint (1—» 2—>3)
1 7 0
Although DOP-PCR methods 1 and 2 were performed with the same amount of 
DNA from the same sample, method 1 employed topoisomerase and T7 
sequenase in 7 cycles with lower annealing temperature. Method 2 used T7 
sequenase without topoisomerase 1. One function of topoisomerase 1 is 
to unwind the supercoiled DNA structure. In this study, topoisomerase 1 was not 
expected to produce a marked effect. Because the DNA in an interphase cell has 
a less condensed structure the efficiency of initiation complex formation is better 
than that in metaphase chromosomes due to increased access of primer and 
polymerase to the genomic template DNA. T7 sequenase functions well at lower 
annealing temperature to stabilize the random priming complexes and can 
synthesize long stretches of DNA by displacing other primers that have already 
annealed to the DNA. However, the method using T7 sequenase involved 
repeated pipetting because of the heat-labile nature of this enzyme and hence had 
an increased chance of contamination. Comparing both results, method 1 gave 
longer fragments of DNA and a slightly stronger smear on standard agarose gel 
than those of method 2, but both of them showed distinct bands around 400 bp 
region (Fig 3.5.2-A). Both methods on CGH showed less intensity of green (test 
DNA) in comparison with red (control DNA). Intensity was further reduced over 
regions corresponding to dark G-bands. Over-representation of some telomeric 
regions, and distal part of chromosome lp, 16p, 19, and 22 was observed. Neither 
method could obtain any analysable CGH images (Fig 3.5.2-B). It was thought 
that DNA amplified by these methods was too fragmented and at too low a 
concentration to produce proper CGH results.
Methods 3 and 4 used increased starting material ( 3 x 7  pm) for Whole Genome 
Amplification (WGA) in a similar way to method 2 in DOP-PCR protocol (no 
topoisomerase 1, with AmpliTaq LD instead of T7 sequenase). The only 
difference between method 3 and 4 was the DNA isolation method 
(DNA extraction method 3; without preincubation, method 4; with 
preincubation). In comparison of method 3 with 4, both showed a faint smear but 
method 4 showed a slightly longer, stronger smear than method 3 after first DOP- 
PCR (3.5.2-C). Both products were used for CGH after labelling by nick 
translation. Only method 4 gave CGH images with matched sex chromosomes 
(test DNA; female, reference DNA; male hybridised on female metaphase) which 
showed less prominent incorrectly over-represented regions and banded pattern 
(Fig 3.5.2-D).
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FIG 3.5.2-A
Gel electrophoresis of the first DOP-PCR 
products amplified by method 1 & 2
L; Ladder
1; DOP-PCR method -1 
2; DOP-PCR method -2 
5; negative control
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FIG 3.5.2-B a) CGH image following colour(fluorescence) equalisation 
and b)colour ratio image using product amplified by DOP -PCR method 1
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FIG 3.5.2-B a) CGH image following colour (fluorescence) equalisation 
and b) colour ratio image using product amplified by DOP -PCR method 2
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FIG 3.5.2-C
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Gel electrophoresis of the 
first DOP-PCR products 
amplified by method 3 & 4
1 kb ladder 
DOP-PCR m ethod-4 
DOP-PCR m ethod-3 
negative control
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FI3 3.5.2 - D a) CGFI image following colour (fluorescence) equalisation and 
b)colour ratio image using product amplified by DOP-PCR method 4
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To avoid further fragmentation during nick translation, the labelling method was 
changed from method 5 onwards. DOP-PCR labelling was applied during the 
second or the third rounds of PCR.
Method 5 was performed on the same DNA as was used in DOP-PCR method 3 
and the method used in the first part of the experiment was that employed in 
DOP-PCR method 1, but labelling was carried out during the second PCR rather 
than by nick translation. The DNA size of the product after the first DOP- 
PCR was from very small fragment to over 12000 bp (especially over 3000 bp) 
(Fig 3.5.2-E). After the second PCR with labelling, DNA size was relatively ideal 
for CGH (approximately 300 to 1000 bp). The CGH result showed more 
homogeneous hybridisation than the previous ones and some abnormal regions 
with matched sex chromosomes (test DNA; female, reference DNA; male 
hybridized on male metaphase) (Fig 3.5.2-F).
Method 6 applied another protocol with minor modifications (Kuukasjarvi et al., 
1997) to a DNA sample of lx7p,m thickness of paraffin-embedded ovarian cancer 
tissue using thermosequenase for decreasing the chance of contamination. The 
DNA size of amplified products after the first DOP-PCR was from 300 bp to 
12000 bp with a distinct band at 400-500 bp region (Fig 3.5.2-G). Relatively 
smaller sized DNA (300-500 bp) with a strong intensity on agarose gel was seen 
after the second PCR with labelling. CGH showed analysable good images for 
the first time, but this result still had a problem, in that the CGH image appeared 
still slightly granular with over-represention of some telomeric regions including 
chromosome 19 and 22 (Fig 3.5.2-H).
Using method 6, DOP-PCR was applied to various samples including some 
melanoma samples, serially diluted DNA from normal female blood, abnormal 
bone marrow samples and thick sectioned paraffin embedded ovarian cancer 
tissue. Successful results were not always obtained because there are many 
variables during the stages from isolation of DNA to the end of CGH with many 
critical steps at each stage of the process.
To obtain more consistent CGH results, some modifications were 
tried including increasing the number of the first low annealing temperature 
cycles, extension time, and decreasing the number of high annealing temperature 
cycles to increase efficacy of DOP-PCR and to reduce error during PCR. 
However it was felt that by this time the DOP-PCR was fairly well established 
and that the results were reflecting differences in the sample itself not in the CGH 
procedure.
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FIG 3.5.2- E
Gel electrophoresis of the first DOP- 
PCR product amplified by method 5
L; 1 kb ladder 
2; DOP-PCR mehtod -5 
6; negative control
FIG 3.5.2-F CGFI image following colour equalisation (a) and colour ratio image 
(b) using product amplified by DOP-PCR method 5
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FIG 3.5.2-G
Gel electrophoresis of the first 
DOP-PCR product amplified by 
method 6
L; 1 kb ladder 
1; DOP-PCR method - 6 
6; negative control
FIG 3.5.2-H CGH ratio profile using product amplified by DOP-PCR mehtod 6
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The final work in optimizing the DOP-PCR involved a further comparison of 
enzymes in an attempt to improve the reproducibility and reliability of the results 
because microdissected tissue possessed only a very small cell mass. 
Pfu DNA polymerase, which possesses proofreading activity and thermostability, 
was applied. The fidelity of DNA synthesis by Pfu DNA polymerase is 12-fold 
higher than that of Taq DNA polymerase (Newton and Graham, 
1994). CGH using this enzyme could not produce an analysable image at this 
time because further optimisation was required. Next, Expand High Fidelity 
DNA polymerase was tried on the samples of microdissected tumour cells from 
paraffin embedded melanoma tissue. Expand High Fidelity PCR System (EHF 
PCR System) is a mixture of thermostable Taq DNA polymerase and Pwo 
DNA polymerase. Pwo DNA polymerase has a half-life of 2 hours at 
100°C, it is useful for high temperature primer extension. Due to the inherent 3'- 
5' exonuclease proofreading activity of this enzyme, fidelity of DNA synthesis is 
3-fold higher than that of Taq DNA polymerase. After processing optimization 
the EHF PCR system was used to analyse microdissected melanoma samples in 
parallel with very small amounts of DNA from three different sources as a 
positive control and results are presented in next part of this thesis.
Primer Extension Preamplification (PEP)
Primer Extension Preamplification (PEP) is an in vitro procedure developed to 
amplify a large fraction of the genome from limited amounts of DNA. Primer is 
composed of templates which are totally degenerated and fifteen nucleotides long. 
The template is first denatured at 92°C, and then primers are allowed to anneal at 
a low stringency temperature (37°C). The reliability of whole genome 
amplification by PEP has not yet been established and may prove difficult to 
evaluate in a few microdissected formalin fixed and paraffin-embedded solid 
tumour cells. It is possible that unequal allelic amplification may take place as a 
result of the small amount of template DNA derived from the small number of 
cells (Zhang et al., 1992; Faulkner et al., 1998). It is also possible for incorrectly 
amplified sequences to be produced due to the intrinsic error rate of Taq 
polymerase and for deletion mutations to be produced due to secondary 
structures of the template DNA (Dietmaier et al., 1999).
The aim of this experiment was to assess if whole genome amplification 
(WGA) using PEP could produce analysable CGH images and if so what
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volume of starting template DNA could produce CGH images after WGA using 
PEP. Another aim was to evaluate some of the limitations and difficulties of using 
PEP and to assess the advantages and disadvantages in comparison with DOP- 
PCR.
Originally, protocol of PEP was developed by Zhang et al. (1992), and since then 
several modifications have been introduced into the basic protocols including 
changing the size or concentration of the primer, changing the number of cycles, 
the temperature or the enzyme used.
The PEP method of Faulkner et al. (1998) was used as the basic protocol in this 
experiment. This protocol was characterized by 1 in 10 primer concentration with 
12-mer random oligonucleotides, minor changes of temperature and number of 
cycles (50 cycles to 40 cycles) in thermal cycling in comparison with the original 
PEP protocol by Zhang et al (1992). The modifications during the 
PEP optimisation are shown in Table 3.5.6.
In PEP method 1, the starting DNA was obtained from tumour cells in a 1 x 7 jam 
thickness section of ovarian cancer sample. When the product was run on gel 
after amplification by PEP, it was found that most of the DNA remained within 
the well.
DNA samples ( 3 x 7  pm sections) subjected to 4 days proteinase K treatment 
(DNA isolation method 4) were used in PEP method 2. The DNA smear on 
agarose gel (1.2 %) extended from the well to very small fragment size(< 100 bp) 
and intensity was very faint (Fig 3.5.2-1). CGH failed to produce adequate images. 
DNA from the same sample but extracted by different methods (DNA isolation 
method 9-1,2) were investigated in PEP method 3. The first DNA (9-1) was 
extracted with phenol/chloroform extraction, the other DNA (9-2) was extracted 
without this step. By observation of the subsequent agarose gel with PEP 
amplification products, the DNA with phenol/chloroform extraction still 
remained in the well, while the DNA without phenol/chloroform extraction 
showed a smear from 12000 bp to below 300 bp (Fig 3.5.2-J). Amplified 
product using PEP with DNA obtained by DNA extraction method 9-2 
produced CGH images in agreement with the combination of sex 
chromosomes used and some abnormal findings such as gains on chromosome lq, 
12p and losses on chromosome lp, 11, and 15, but with prominent 
heterochromatin-rich regions on chromosome 1, 9 (Fig 3.5.2-K).
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Table 3.5.6 Summary of PEP modification protocol
No Amount of 
DNA
(No.of Table 
3.5.2 )
Primer MgCL Phenol/
chlor.
Extract.
Enz. Conc.of 
DNA 
after PEP
12mer
(conc.)
15mer
(conc.)
1 10|j.l,lx7fj.m 
(No. 2)
200pmol 5mM + AmpliTaq
polymerase
2 10fil,3x7|im
(No.4)
200pmol 5mM + AmpliTaq
polymerase
450ng/p.l
3 10|j.l,lx7(!m 
(No.9-1,2)
200pmol 5mM — AmpliTaq
polymerase
340ng//p.l
4 10|il,lx7pm
(No.10-1)
200pmol 5mM — AmpliTaq
LD
600ng/p.l
5 10|il,lx7jj.m 
(No. 10-2)
200pmol 5mM — AmpliTaq
polymerase
510ng/p.l
6 10|il,lx7jim
(No.10-1)
200pmol 5mM + AmpliTaq
LD
460ng/(il
7 10|j.l,lx7jj.m 
(No. 10-2)
200pmol 5mM + AmpliTaq
polymerase
44ng/|il
8 10|ul,lx7fim
(No.11-1)
200pmol 5mM — AmpliTaq
LD
710ng/p.l
9 10p.l,lx7jam 
(No. 11-2)
200pmol 5mM — AmpliTaq
LD
750ng/|il
10 10jil,lx7pm 
(No. 11-3)
200pmol 5mM — AmpliTaq
LD
540ng/|j,l
11 10|il,lx7|j.m
11-1
11-2
200pmol 5mM AmpliTaq
LD 400ng/|il
490ng/(il
12 10(j.l,lx7(j.m 
(No. 12)
200pmol 2.5m
M
AmpliTaq
LD
13 10pl,lx7pm 
(No. 13)
200pmol 5mM — AmpliTaq
LD
510ng/p.l
200pmol 5mM 490ng/)ii
14 10p.l,lx3pm 200pmol 5mM - AmpliTaq
LD
15 10p.l,lx7pm 800pmol 5mM — EHF PCR 
system
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FIG 3 .5 .2 -1
Gel electrophoresis of PEP product 
amplified by method 2 
L; 1 kb ladder 
1; PEP method - 2 
2; negative control
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FIG 3.5.2- J
Gel electrophoresis of PEP products 
amplified by method 3 (9-1, 9-2)
1 kb ladder
PEP method - 3 ( DNA sample 9-1) 
PEP method - 3 ( DNA sample 9-2) 
negative control
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FIG 3.5.2-K a) CGH image following 
colour equalisation and b) colour ratio 
image using product amplified by PEP 
method 3 (9-2).
Methods 4, 5, 6 and 7 compared the results of PEP performed with or without 
phenol/chloroform extraction and using different enzymes. The results of gel 
running showed a wide spread from the well to very small fragmented DNA with 
faint intensity. Only method 4, which used AmpliTaq LD instead of AmpliTaq 
polymerase without phenol/chloroform extraction, produced 
rather improved CGH image. CGH showed true abnormal gains (chromosome lq 
and 12p) and losses of DNA copy numbers (chromosome 5, 11, and 15) with 
disproportionately prominent centromeric region of chromosome 1 and 9, and the 
short arms of the acrocentric chromosomes but not accompanied 
with under or over-represented regions on chromosome lp32-pter, 16, 19, and 22. 
The results indicated that phenol/chloroform probably decreases the yield of the 
PEP amplification to generate successful CGH. This was thought to be caused by 
the fact that the tissue sample might be too small to extract by the two-step 
standard method and remaining phenol might be having an inhibitory effect on 
PCR. Thereafter it was possible to make a decision to proceed with further 
experiments without phenol/chloroform extraction, and to use AmpliTaq 
DNA polymerase LD instead of AmpliTaq DNA polymerase.
In PEP methods 8, 9, and 10, template DNAs were produced by a slightly 
different method as described in experiments 11-1, 2, and 3 of previous 
section on DNA isolation methods. Methods 8 and 9 showed a very good size of 
DNA smear after PEP. From the point of view of CGH result, method 9 showed a 
better result but the intensity of green signal was still too weak to make 
analysable images but the finding of prominent centromeric regions on 
chromosome 1, 9, and the short arm of acrocentric chromosomes was not 
specific in comparison with previous results. The intensity of signal in method 8 
was weaker than that of method 9 and was inadequate for analysis.
Method 10 failed to produce a CGH result.
In method 11, more complex strategies were applied to the same DNA sample as 
method 3 (DNA isolation method 9-2);
Sample 1; only PEP 
Sample 2; PEP + DOP-PCR
After nick translation, the sample with PEP only showed a very faint but even 
smear, but the sample with PEP + another cycle of second DOP-PCR showed 
clear specific bands on the agarose gel as in the previous results of some DOP- 
PCR products (Fig 3.5.2-L). Comparing both CGH results, there were some 
discrepancies between these two results. Sample 1 showed the first reliable,
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homogeneous CGH image obtained until now, which could distinguish sex 
chromosomes and abnormal findings as in the previous experiments. No 
disproportionately over- or under-represented regions were seen except slightly 
prominent centromeric regions of chromosome 1 and 9 (Fig 3.5.2-M). Sample 2 
showed matched sex chromosomes and some abnormal findings but also under­
represented G-band regions and over-represented chromosome 19, 22 and some 
telomeric regions (Fig 3.5.2-N). CGH result with sample 2 was similar to 
the CGH findings with pure DOP-PCR product. Even though both CGH 
experiments used the same amount of Cot-1 DNA for suppression, over or under­
represented regions were different between the two methods.
In methods 12 and 13, a better result was obtained from 5mM MgCl2 with 12-mer 
primer, but the difference was not significant in the size of DNA fragments and 
the quality of CGH was also similar. To recognize the difference of amplification 
method between PEP and DOP-PCR, DOP-PCR was applied to the same DNA as 
these PEP experiments. CGH results using PEP amplification products showed 
very homogeneous, uniform images with constant abnormal findings in 
comparison with previous experiments, and were accompanied with 
disproportionately prominent green on heterochromatin-rich area such as 
centromeric regions on chromosome 1, 9, 16, and the short arms of the 
acrocentric chromosomes. CGH results using DOP-PCR amplification products 
showed a less homogeneous, granular pattern with the same abnormal findings 
but were less distinctive than those for PEP and some telomeric regions, and 
chromosomes 19 and 22 were over-represented. Interestingly, the centromeric 
regions on chromosomes 1, 9, and 16 appeared well suppressed even when the 
same amount of Cot-1 was used for blocking middle and highly repetitive 
DNA sequences (Fig 3.5.2-0).
Overall, the difference between CGH results by PEP and that by DOP-PCR was 
recognizable. More homogeneous, better quality images were obtained by PEP 
rather than by DOP-PCR above certain amounts of template DNA. PEP tended to 
amplify heterochromatin-rich regions; DOP-PCR tended to amplify some 
telomeric regions (G-light band areas) and GC-rich areas. The concentration of 
template DNA was critical in the production of reliably amplified product.
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Gel electrophoresis of PEP 
products amplified by method 11
L; 1 kb ladder 
1; negative control 
2; PEP method - 11 (sample 1) 
3,4; PEP m ethod-11 (sample 2)
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Fig 3.5.2-M a) CGH image following colour (fluorescence) equalisation and 
b) colour ratio image using product amplified by PEP method 11-1
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Fig 3.5.2-N a) CGH image following colour (fluorescence) equalisation and 
b) colour ratio image using product amplified by PEP method 11-2
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Fig 3.5.2-0 CGH ratio profiles of two amplification methods using the same DNA. 
(A) CGH ratio profile using product by DOP-PCR amplification (B) CGH ratio profile 
using product by PEP amplification
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After that, PEP was changed to the schedule of thermal cycling reported by 
Dietmaier et al (1999) and the EHF PCR system was introduced to the 
experiment to increase efficiency and fidelity of PEP amplification. Template 
DNAs were obtained from many melanoma samples, serially diluted DNA from 
normal female blood, abnormal bone marrow and thick section of paraffin- 
embedded ovarian cancer tissue. CGH results using these amplified products 
produced hardly any successful results.
The most troublesome problem during PEP amplification was that the negative 
control frequently showed a positive smear on agarose gel. The source of 
contamination was difficult to find because all reagents except primer and 
equipment were the same as for DOP-PCR which had not shown any 
contamination at all. CGH of amplified negative control which had shown a 
positive smear on the gel revealed no gain or loss of DNA copy number, and 
repeated CGH of amplified test DNAs from the same sample showed consistent 
results.
3.5.3 Labelling the amplified probe
The amplified genomic DNA (test DNA or reference DNA) was directly labelled 
with FITC-conjugated dUTP or Texas-Red-conjugated dUTP by PCR or nick 
translation. This method has an advantage in the simplicity of detection and in 
the improvement of quality of hybridisation although the detection signal is 
slightly reduced in comparison with the indirect detection method. Enzymatic 
labelling of DNA from paraffin-embedded tissue by nick translation may result in 
production of fragments which are smaller than the ideal size for CGH. Although 
the fragmented probe length of 200-400 bp is suitable for in situ hybridisation, a 
longer probe length (500-2000 bp) is required for CGH.
In the first part of this experiment, two modifications of nick translation 
were investigated to try to achieve longer size of probe, including adjusting the 
ratio of DNase 1 to DNA polymerase 1 enzymes in the reaction mixture and/or 
the incubation time. The length of DNA fragments after nick translation was 
thought not to be seriously affected by changing these parameters.
Later the labelling method was changed to incorporation during 
PCR amplification. The PCR labelling procedure was carried out during the 
second or the third rounds of PCR. The problem was that it was very difficult to 
estimate the labelling efficiency of both labelling methods especially the
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PCR labelling procedure. Incorporation of fluorochrome-labelled nucleotides can 
be checked by placing a small amount of probe on a glass slide and examining 
for fluorescence using an epifluorescence microscope with appropriate filters or 
by rapid labelling assay. Labelling efficiency was roughly estimated by these 
methods. When PCR-labelled test DNA was hybridized with nick translated non- 
amplified reference DNA, it was very complicated to estimate the required 
amount of DNA from each sample because the two labelling methods showed 
different efficiency in the incorporation of fluorochromes (FITC or Texas-Red 
conjugated dUTP) into the DNAs.
Labelling of DOP-PCR products
Comparing probe labelled by nick translation and by PCR, the size of 
DNA labelled by DOP-PCR was slightly longer than that by nick translation. The 
summary of results depending on the DOP-PCR method is listed in Table 3.5.7. 
Smears in agarose gels of each case are shown in Fig 3.5.3-A.
From the data in Table 3.5.7 it also is clear that obtaining the optimum size of 
probe depends not only on the labelling method but also on the quality and 
quantity of starting DNA. The latter appears to be more critical than any of 
the other parameters investigated.
Table 3.5.7 Summary of the gel running results comparing PCR labelling with 
nick translation
No.(same as Table 
3.5.4)
Labelling during 
third PCR
Nick translation Probe size after gel 
running
1 - + < 500 bp
2 - + < 500 bp
3 — + < 500 bp
4 - + 200- 1000 bp
5 + - 300- 1000 bp
6 + - 300- 500 bp
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FIG 3.5.3-A Gel electrophoresis of the 
DOP-PCR products labelled by nick 
translation and DOP-PCR labelling
L; 1 kb ladder
4; DOP-PCR method - 1 after nick 
translation 
5; DOP-PCR method - 2 after nick 
translation
L; 1 kb ladder
8: DOP-PCR method - 5 after PCR 
labelling
L 1 2 3 4 5
J i t j  *•
L: 1 kb ladder
2; DOP-PCR method - 4 after nick 
translation 
3; DOP-PCR method - 3 after nick 
translation
L; 1 kb ladder
2.3; DOP-PCR method - 6 after PCR 
labelling
1 8 7
Labelling of PEP product
All PEP products were labelled by nick translation. When run on a gel, the nick 
translated DNA was extremely faint, but the smear of DNA fragments on agarose 
gel showed mostly from 1000 bp to 200 bp with some remaining near the well in 
some PEP experiments (Fig 3.5.3-B). Sometimes the size of probe was longer 
than that obtained by DOP-PCR labelling, but in these instances there 
was insufficient product for CGH. The difference of efficiency of amplification 
between the two methods was thought to be affecting the success rate for CGH.
Problems encountered after the labelling procedure
One of the major problems associated with labelling procedures is the question of 
what proportion of probe (test and control DNA) has been labelled by both 
labelling methods. Consequently, unbalanced amounts of DNA between test and 
control DNA induced false positive or false negative results and unmatched sex 
chromosomes. After several failures of CGH, these problems were somewhat 
resolved by using hybridization with simultaneously amplified and labelled 
reference DNA by same method. But differences of length of fragments 
(complexity) between test DNA (usually from paraffin embedded tissue) and 
reference DNA (from fresh normal male and female blood) caused 
difficulties in obtaining good quality of CGH images due to different competition 
effects during hybridisation.
To optimise the amount to be hybridised after labelling procedure, two different 
methods were applied to the amplified product to estimate the percentage of 
DNA labelled with fluorochrome. First, amplified and labelled product was 
purified using High Pure PCR Product Purification Kit (Boehringer Mannheim). 
The DNA concentration before and after purification was estimated by 
measuring optical density (O.D.) at 260 nm in a spectrophotometer. The 
percentage of DNA labelled with fluorochrome was calculated by the fact that 
this purification kit can remove salts, proteins, dimerized primer, 
and unincorporated nucleotides. Examples of the results are shown in Table 3.5.8 
and 3.5.9.
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1 kb ladder
PEP method - 2 after nick 
translation
PEP method - 3 after nick 
translation
1 kb ladder
PEP method - 4 after nick 
translation
PEP method - 5 after nick 
translation
PEP method - 6 after nick 
translation
Table 3.5.8 DNA concentration before and after purification of Nick translation 
products after PEP
Case number DNA conc. before 
purification (/pi)
DNA conc. after 
purification (/pi)
Percentage of DNA with 
fluorochrome incorporated
1 280 ng 130ng 46.4%
2 250ng llOng 44%
3 390ng 170ng 43.6%
4 300ng 120ng 40%
5 380ng 140ng 36.8%
Table 3.5.9 DNA concentration before and after purification of PCR labelling 
products after DOP-PCR
Case number DNA conc. before 
purification (/pi)
DNA conc. after 
purification (/pi)
Percentage of DNA with 
fluorochrome incorporated
1 660 ng 40ng 6%
2 750ng 65ng 8.6%
3 710ng 80ng 11.3%
4 860ng 95ng 11%
5 900ng 65ns 7.2%
By observation of these results, it was roughly estimated that 6 to 11% of DOP- 
PCR product was labelled during DOP-PCR labelling, 36 to 46% of PEP product 
was labelled during nick translation.
The second method was semi-quantitative labelling assay which was designed 
based on the fluorescent properties of the label. In this rapid labelling assay, the 
labelled probe was dotted onto a membrane (hybond-N+ nylon), then membrane 
washed for 20 min at 60°C to remove unincorporated nucleotide and the bound 
probe was visualized by a U.V. transilluminator. When compared with 
diluted original fluorochrome (100%, 75%, 50%, 25%, 12.5%, 6.25%), DOP- 
PCR labelling efficiency was approximately from 6.25% to 12.5% by rough 
estimation. This result was compatible with that of purification kit method.
After rough estimation of the concentration of labelled DNAs, the next step was 
to optimise the amount of test DNA per reference DNA to be hybridised. When 
the hybridisation with same amount of test and reference DNA was applied to 
a CGH experiment, the CGH result always showed less intensity of green than of 
red. Because the amount of optimally sized DNA fragments in test DNA was less 
than that in the control DNA, competitive binding of test DNA during
190
hybridisation might be less effective. In this experiment, when 2-2.5 fold of test 
DNA was hybridised with reference DNA the CGH result revealed mostly 
analysable images.
3.5.4 CGH Experiments with serially diluted DNA samples
The aim of the next part of the work was to evaluate the limiting amount of initial 
test DNA (template DNA) required to produce analysable CGH images from the 
various types of sample and to provide standards of validation to 
results of unknown samples as a positive control.
The basic DNA sources for these experiments were DNA from normal female 
blood (initial conc.: 800ng/fil), DNA from abnormal bone marrow with AML/ 
MDS (initial conc.: 1 jig/pl), DNA from abnormal paraffin-embedded ovarian 
cancer tissue (initial DNA conc.: 1 p.g/p.1).
Samples were diluted carefully inside the containment hood to avoid 
contamination. A serial dilution of each sample was conducted on the basis of an 
amount of template DNA in 50 pi of the first PCR buffer.
Primer-Extension Pre-amplification (PEP) and DOP-PCR as a method of whole 
genome amplification were performed on each sample.
CGH was performed with three control samples along with DNA from test 
samples of unknown karyotype.
Three different strategies were applied to each DNA sample.
1) Amplified test DNA was hybridised with non-amplified, nick-translated 
control DNA.
2) Amplified test DNA was hybridised with amplified control DNA (Starting 
concentration was the same.).
3) Different kinds of enzyme were used during amplification.
Ampli Taq DNA Polymerase
Pfu DNA Polymerase
Expand High Fidelity DNA Polymerase;
enzyme mix containing thermostable Taq DNA and Pwo DNA polymerase
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DNA from Normal Female Blood
Table 3.5.10 Schematized strategy applied on DNA from normal female blood
Basic source of DNA Amplification
method
Amount of
template
DNA
CGH
result
Enzyme used
Hybridisation Method; amplified test DNA with non-amplified
Nick-translated control DNA
Normal female blood PEP 40 ng fail AmpliTaq LD
4 ng fail AmpliTaq LD
2 ng fail AmpliTaq LD
PEP 40 ng inadeq­ EHF PCR system
uate
DOP-PCR 12 ng good Thermosequenase
1.2 ng good Thermosequenase
600 pg good Thermosequenase
300 pg good Thermosequenase
150 pg good Thermosequenase
75 pg good Thermosequenase
50 pg fail Thermosequenase
25 pg fail Thermosequenase
Hybridisation Method; amplified test DNA with amplified
control DNA
PEP 40 ng good EHF PCR system
Normal female blood
(test DNA) DOP-PCR 100 pg good AmpliTaq LD &
Normal male blood 50 pg good EHF PCR system
(control DNA) 10 pg good
1) Amplified test DNA (normal female) hybridised with non-amplified, nick- 
translated DNA
Amplification Method; PEP
Both the amplified test DNA and the non-amplified control DNA were labelled 
by nick translation. Before nick translation, DNA concentration of each amplified 
sample was checked by measuring the optical density with a spectrophotometer 
and the amount of test DNA compared with reference DNA required for
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hybridisation was calculated.
After PEP amplification with 40 ng of template DNA, the DNA smear on 
ethidium bromide-stained agarose gel showed from 500 bp to high molecular 
weight DNA (mainly over 12000 bp) (Fig.3.5.4-A).
After labelling by nick translation, product amplified from 40 ng of normal 
female DNA was still mainly near the well on agarose gel.
In the case with amplification products from 40 ng of normal female template 
DNA using PEP with AmpliTaq LD, CGH showed a very weak intensity of 
green in comparison with the intensity of red. Prominent strong green showed on 
heterochromatin-rich area (centromere on chromosome 1, 9, 16, short arm of 
acrocentric chromosomes) and on some telomeric regions with a lot of non­
specific background signals (Fig. 3.5.4-B).
In the case with amplification from 4 ng of template DNA, the intensity of the 
DNA smear was very faint with over 1000 bp sized DNA fragments (Fig 3.5.4- 
A). Several trials of CGH using PEP product amplified from 40 ng, 4ng, and 2 
ng of normal female template DNA failed to produce successful CGH images.
Up to this point PEP had been performed using the enzyme AmpliTaq LD. 
Because of the repeated failure to achieve CGH results, the EHF PCR system was 
substituted, and amplified product from 500 to over 12000 bp with 
strong intensity was achieved (Fig. 3.5.4-C). After nick translation, the size of 
DNA fragments was from 300 bp to 1000 bp and subsequent CGH 
produced improved images (test DNA; labelled with Texas-Red, control DNA; 
labelled withFITC, hybridised on male metaphase) (Fig. 3.5.4-D).
Two different sizes of primer (12 mer, 15mer) were investigated for PEP, but no 
difference in the amplified product could be detected.
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L 1 2 3 4 5 6 7 8 9
FI G 3.5.4-A
Gel electrophoresis of the PEP 
products using AmpliTaq LD
1 kb ladder
4 ng of normal female DNA 
40 ng of normal female DNA 
negative control
Fig 3.5.4-B (a)CGH image following colour 
equalisation (test DNA; 40 ng of template 
DNA from normal female blood amplified by 
PEP using AmpliTaq LD and labelled FITC, 
control DNA; non-amplified, nick translated 
normal male DNA and labelled with texas- 
red, and hybridised on normal male 
metaphases, (b) colour ratio image of same 
metaphase, (c) hybridisation pattern of 
FITC labelled test DNA of same 
metaphase after split colour cord.
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L 1 2  3 4 5 6  7 8 9 1 0 1 1
FIG 3.5.4-  C
Gel electrophoresis of the PEP product 
using EHF PCR system (EHF) and 
Expand long Template system (EL)
L; 1 kb ladder
2; case 5 (982963) with EHF 
3; 40 ng of normal female DNA with 
EHF
7; 40 ng of normal female DNA with 
EL ~
11; negative control
' /  / I  
• ' " I  / «
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Fig3.5.4-D (A) CGH image following colour equalisation (test DNA; 40 ng of normal 
fenrale template DNA amplified by PEP with EHF PCR system and labelled with 
Te)as-Red, control DNA: non-amplified, nick translated normal male DNA and 
labelled with FITC, hybridised on male metaphases. (B) colour ratio image of the 
sane metaphase.
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Amplification Method; DOP-PCR
Normal female DNA was amplified using DOP-PCR and the template 
DNA which had been diluted from 12 ng to 25 pg in 50 \x\ of PCR reaction 
mixture.
Amplified product from 12 ng of template DNA showed stronger intensity than 
that from paraffin-embedded ovarian cancer tissue (lx  7 pm) and amplified 
product from 1.2 ng showed a very faint smear on agarose gel (Fig 3.5.4-E). 
After PCR labelling, both normal female samples (12 ng, 1.2 ng) showed bigger 
DNA fragment sizes (300-1600 bp) than DNA from paraffin-embedded 
tissue of unknown test sample (below 500 bp).
DNA sizes of amplified product from 300 pg of normal female DNA was from 
500 bp to over 12000 bp (not remaining in well), and the intensity was similar to 
that of amplified product from 1.2 ng of DNA from abnormal bone marrow. 
DNA smears of 150 pg of normal female DNA showed less intensity and similar 
sizes of DNA fragment (Fig.3.5.4-F).
At the level of 75pg, DNA smears after the first DOP-PCR amplification showed 
relatively ideal sizes of DNA (220-1600 bp) with moderate intensity (Fig 3.5.4- 
G ).
Below the concentration of 75 pg further dilutions of template DNA yielded after 
amplification smears which were barely visible on the gel (Fig 3.5.4-G). 
However even if the DNA smear after first DOP-PCR was very weak on running 
the gel, CGH could sometimes be successful after the second amplification with 
labelling.
Thermosequenase was used as an enzyme in the first low annealing temperature 
cycles in this part of the work.
In CGH experiments of this part of the work all diluted samples were labelled by 
DOP-PCR labelling, and hybridised with non-amplified, nick-translated control 
DNA (normal male DNA) on male metaphases. CGH results of each diluted 
sample showed within normal range of fluorescence intensity ratio when 
threshold was decreased from 1.5/0.5 to 1.35/0.65. However these results 
revealed a tendency to under-representation on some chromosomal regions such 
as lp32-pter, 16p, 17 (?), 19, and 22. After reaching the threshold 1.20/0.80, the 
latter findings became more obvious. Actually since these test samples were not 
contaminated with any other cells, it may be reasonable to apply a threshold of 
1.5/0.5.
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FIG 3.5.4 - E
Gel electrophoesis of the first DOP- 
PCR products using thermosequenase
L; 1 kb ladder
1 x 7 um paraffin-embedded 
ovarian cancer tissue 
12 ng of normal female DNA 
1.2 ng of normal female DNA 
negative control
L 1 2 3 4 5 6  7 8 9  10 FIG 3.5.4 - F
Gel electrophoresis of the first 
DOP-PCR products using 
thermosquenase
L; 1 kb ladder
1; 1.2 ng of abnormal BM DNA 
2; 600 pg of abnorma BM DNA 
7; 300 pg of normal female DNA 
8; 1 50 pg of norma! female DNA 
10: negative control
L 1 2 3 4 5 6 7 8  9 10 11
FIG 3 .5 .4- G
Gel electrophoresis of the first DOP- 
PCR products using thermosequenase
L; 1 kb ladder
2; SviO pg of abnormal BM DNA 
3: 1 50 pg of abnormal BM DNA 
4; 300 pg of DNA from PET 
5; 1 50 pg of DNA from PET 
6: 75 pg of normal female DNA 
7; 50 pg of normal female DNA 
8: 25 pg of normal female DNA 
11; negative control
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In this experiment, it was difficult to know what percentage of fluorochrome has 
been incorporated during PCR labelling or nick translation. Then problems 
were induced by unbalanced amounts of labelled DNA between test and 
reference DNA because unbalanced amount of labelled DNAs may be too much 
for normalisation to take place.
From a literature review, even when the test DNA had not been 
amplified, in CGH results with indirectly labelled DNAs, GC-rich regions such 
as distal lp, 16, 19, and 22 often show wide variability in the CGH ratio 
(Kallioniemi et al., 1994). The work presented here also showed a tendency to 
disproportionately under-representation on chromosome lp33-pter, 16p, 17, 19 
especially 19p and 22 until the amount of template DNA was above 75 pg. When 
the amount of template DNA was below 75 pg amplified product could not 
produce reliable CGH images. At very low concentrations of template DNA (50 
pg, 25 pg), chromosomes distal lp 19, 22 and some telomeric regions 
appeared unreasonably over-represented, where they were previously under­
represented when the starting template DNA was above 75 pg. Dark band regions 
with G-banding showed much weaker green than other parts of the 
chromosomes. Chromosome 17 has not been highlighted as a target chromosome 
which showed a variable CGH ratio but in this study it frequently had a variable 
ratio.
2) Amplified test DNA hybridised with amplified control DNA 
Amplification method: PEP
In this experiment, 40 ng of template DNAs (normal male and female) were 
amplified by PEP using EHF PCR system, then labelled by nick translation with 
two different fluorochromes (normal female DNA; labelled with Texas-Red, 
normal male DNA; labelled with FITC) and hybridised on normal male 
metaphases. The size of DNA fragments after amplification was very good with a 
strong intensity. The CGH result showed very uniform, reliable CGH images 
without any disproportionately over-or under-represented regions (Fig 3.5.4-H).
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FIG 3.5.4-H (A) CGH image following colour equalisation (test DNA: 40 ng of 
normal female template DNA amplified by PEP with EHF PCR system and 
labelled with Texas-Red. control DNA: 40 ng of normal male template DNA 
amplified by PEP with EHF PCR system and labelled with FITC. hybridised on 
male metaphases. (B) colour ratio image of the same metaphase.
Amplification method: DOP-PCR
In this experiment, test DNA was obtained from normal female blood, reference 
DNA was from a normal male blood and the starting concentration for 
amplification using DOP-PCR was the same for both.
Because CGH using the previous strategy failed to produce a result when the 
amount of template DNA was below 75 pg, in this experiment template 
amounts of 100 pg, 50 pg and 10 pg were used.
AmpliTaq LD and EHF PCR system were used as enzymes during DOP- 
PCR amplification.
The intensity and size of DNA on agarose gel showed some differences among 
three different starting amounts of template DNA with AmpliTaq LD, on 
the other hand, products with EHF PCR system showed similar size 
and intensity of DNA fragments in addition to stronger and longer 
DNA fragments than those with AmpliTaq LD (Fig 3.5.4-1).
The CGH results with both enzymes showed quite uniform, evenly 
hybridised image and profiles (Fig 3.5.4-J). This experiment showed 
reliable CGH results without unreasonably over or under-represented regions on 
chromosome lp32-pter, 19p, and 22. Sex chromosomes were also matched even 
at the 10 pg level and regardless of the enzyme used.
This experiment was started at the same concentration of both test and control 
DNAs, amplified by DOP-PCR simultaneously, hybridised with the same 
amount of test and control DNA. These conditions made it possible to avoid 
disproportionately over-represented or under-represented findings induced by 
mismatching of the amount between test and control DNA, 
different incorporation rate depending labelling methods, and bias from 
amplification process itself.
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Gel electrophoresis of the first DOP-PCR 
products using EHF PCR system (EHF) and 
AmpliTaq LD (A)
EHF PCR system; Expand High Fidelity PCR 
system
1 kb ladder
100 pg of normal female DNA with A 
50 pg of normal female DNA with A
10 pg of normal female DNA with A
100 pg of normal female DNA with EHF 
50 pg of normal female DNA with EHF
10 pg of normal female DNA with EHF
negative control
20 1
(A)
I
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Fig 3.5.4-J CGH ratio profiles using products of DOP-PCR with 10Opg of template 
DNA from normal female blood, hybridised the same amount of amplified normal male 
DNA. (A) DOP-PCR using AmpliTaq LD, (B) DOP-PCR using EHF PCR system
2 0 2
Fig 3.5.4-J CGH ratio profiles using products of DOP-PCR with 50pg of template DNA 
from normal female blood, hybridised with the same amount of normal male DNA. (A) 
DOP-PCR using AmpliTaq LD, (B) DOP-PCR using EHF PCR system
Fig 3.5.4-J CGH ratio profiles using products of DOP-PCR with 10pg of template 
DNA from normal female blood, hybridised with the same amount of normal male 
DNA. (A) DOP-PCR using AmpliTaq LD, (B) DOP-PCR using EHF PCR system.
3) Application of different kind of enzyme during PCR
Four different enzymes were investigated: thermosequenase, AmpliTaq LD, 
Pfu DNA polymerase, and Expand High Fidelity DNA polymerase on the 
course of this WGA using DOP-PCR and PEP
By PEP amplification, only products using EHF PCR system could 
produce CGH images.
All samples hybridized with non-amplified control DNA were produced by DOP- 
PCR amplification with thermosequenase (DOP-PCR method 6). All showed 
relatively reasonable CGH results with good coverage of the whole 24 
chromosomes with an under-represented tendency on chromosome lp32-pter, 16, 
17, 19, and 22. Then the schedule of thermal cycles in the DOP-PCR protocol 
was changed such as increasing number of lower annealing temperature cycles (4 
cycles—>• 7 cycles) and extension time (2 min—>3 min) and was AmpliTaq 
LD used instead of thermosequenase. Although the concentration of starting 
DNA was different in each case, results using either thermosequenase or Ampli 
Taq LD did not show significant difference.
As the concentration of template DNA was decreased, a more reliable DOP- 
PCR method was required. Pfu DNA polymerase and EHF DNA polymerase 
were introduced to WGA during the DOP-PCR.
Pfu DNA polymerase failed to yield a proper result in these samples 
because of inadequate optimisation. EHF PCR system could be optimised 
by increasing the concentration of primer and MgCl2
Comparing the CGH results between Ampli Taq LD and EHF DNA polymerase, 
the result with EHF DNA polymerase showed a remarkable improvement. The 
size and intensity of DNA fragments appeared larger (500 to 7000 bp), and 
stronger than those by Ampli Taq LD on the ethidium bromide-stained agarose 
gel (Fig 3.5.4-1). CGH profiles produced by product using EHF PCR system 
presented on nearly the 0 line without noise.
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DNA from Known abnormal bone marrow samples
Table 3.5.11 Schematized strategy applied on DNA from abnormal bone marrow
Basic source of DNA Amplification
method
CGH
result
Amount of
template
DNA
Enzyme used
Hybridisation Method; amplified test DNA with non-amplified
Nick-translated control DNA
Abnormal bone PEP fail 40 ng AmpliTaq LD
marrow with AML/ fail 4 ng AmpliTaq LD
MDS fail 2 ng AmpliTaq LD
DOP-PCR good 12 ng Thermosequenase
good 1.2 ng Thermosequenase
good 600 pg Thermosequenase
good 500 pg Thermosequenase
good 300 pg Thermosequenase
fail 100 pg Thermosequenase
fail 50 pg Thermosequenase
Hybridisation Method; amplified test DNA with amplified
Abnormal bone control DNA
marrow (test DNA) PEP Good 40 ng EHF PCR system
Normal male blood
DOP-PCR good 200 pg EHF PCR system
good 100 pg EHF PCR system
good 50 pg EHF PCR system
This original DNA was extracted from abnormal bone marrow with AML/MDS, 
conventional karyotyping result was as follows:
46-47, XY, -5, ?der(9)del(9)(p 13)inv9(p 13q21.1), der( 17)t(5; 17)(p 13;p 11.2), +r, 
8-13 dmin
The CGH result using original non-amplified DNA was loss of DNA copy 
number on the chromosome regions of 5ql4-qter, 9pl3-p22, 17pl2-pter and 
amplification on 8q24.
1) Amplified test DNA hybridized with non-amplified, nick translated DNA 
Amplification Method: PEP
PEP was performed with serially diluted known abnormal bone marrow samples.
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As in the case of the normal female samples, two different sizes of primer (12 
mer, 15mer) were used. The starting amount of template DNA was 40 ng, then 4 
ng, and finally 2 ng.
The size of the amplified DNA fragments obtained from 40 ng of template 
DNA was from 500 bp to over 12000 bp (the latter mainly remained near the 
well). The amplified DNA fragments obtained from 4 ng and 2 ng of template 
DNA also remained near the well and were of very faint intensity on the agarose 
gel (Fig 3.5.4-K).
After labelling by nick translation, the size of DNA of all samples was over 500 
bp with the major portion of DNA near the well.
These products amplified by PEP could not detect real abnormal copy number 
changes when used in CGH. The image usually showed less intensity of green 
(test DNA) than red (reference DNA) and over-represented heterochromatin-rich 
area.
Amplification Method: DOP-PCR
This experiment was designed to assess the reliability of whole genome 
amplification by DOP-PCR.
This sample had previously been analysed by CGH without amplification to 
allow comparison with results from with amplification. The original 
DNA concentration was lpg/pl and the sample was diluted serially from 12 
ng/50 pi to 50 pg/50 pi.
Table 3.5.12 showed abnormal findings from diluted bone marrow samples 
compared with known abnormal results.
The DNA smear from 12 ng of template DNA amplified by DOP-PCR showed 
fragment sizes from over 2000 bp to below 300 bp with strong intensity (Fig
3.5.4-L). The size of DNA amplified from 1.2 ng and 600 pg was also from over 
2000 bp to below 500 bp with a strong intensity (Fig 3.5.4-F). After the first 
DOP-PCR amplification with 300 pg and 150 pg of template DNA, the size of 
DNA on agarose gel was 500 to 1600 bp with relatively strong intensity (Fig
3.5.4-G).
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L 1 2 3 4 5 6  7 8 9 10 11
FIG 3 .5 .4 -K
1000“ -
V.
Gel electrophoresis of the PEP products 
using AmpliTaq LD 
PET; paraffin-embedded tissue 
BM; bone marrow 
L; 1 kb ladder
2; 4 ng of template DNA from abnormal BM 
(200 pmol)
3; 2 ng of template DNA from abnormal BM
gnn— "  _  (200 pmol)
4; 4 ng of template DNA from abnormal BM 
(100 pmol)
7; 4 ng of template DNA from PET 
(200 pmol)
8; 2 ng of template DNA from PET 
(200 pmol)
9; 4 ng of template DNA from PET 
(100 pmol)
11; negative control
L 1 2 3 ^  5 6 7 8 9 10 111213 FIG 3 5 4 - L
fcf W  &  ‘
i III
Gel electrophoresis of the first DOP-PCR 
products using thermosequenase
L; 1 kb ladder
3; 12 ng of template DNA from abnormal BM 
10; 12 ng of template DNA from PET 
13; negative control
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Above 500 pg of template DNA, this experiment showed relatively reliable CGH 
results but with under-represented regions on lp33-pter, 19p, and 22. 
The intensity of amplification of 8q24 became weaker with decreasing amount of 
template DNA. But below the 300 pg level the reliability of CGH was markedly 
decreased. Iq33-qter, 19, 22, some telomeric regions appeared to
be incorrectly over-represented but dark banding sites on G-banding seemed to 
be erroneously under-represented.
Actually under lOOpg, this experiment could not produce any reliable abnormal 
finding. Below this level findings presented in below 300 pg level were more 
exaggerated and even amplification of 8q24 could not reliably identified.
Finally, at the end of this experiment, it was clear that an enzyme with proof­
reading activity and optimization of amount of both test and control DNA for 
hybridisation were urgently required.
Table 3.5.12 Summary of CGH results from the serial dilution of DNA from
abnormal bone marrow sample
Ch.
No
gain loss 12
ng
1.2
ng
600
Pg
500 pg 300
Pg
100
Pg
50
Pg
1 -lp33-
pter
-lp33-
pter
-lp
33-
pter
-lp33-
pter
+lp
32-
pter
+lp
32-
pter
2
3
4
5 5ql4-qter ± ± ± + ± ? ?
6
7
8 8q24(A) + > + > + > + > + - -
9 9pl3-p22 - - - - - + +
10
11
12
13
14
16
17 17pl2-pter + + -17p -17p ■17p - -
18
19 -19p -19p -19p -19p -19p +19 +19
20 +20p +20 +20
21
22 -22 -22? -22? -22 +22 +22
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2) Amplified test DNA hybridized with amplified control DNA
Amplification method: PEP
In this experiment, amplified product using PEP with EHF PCR system from 40 
ng of template DNAs (test and control DNA) only produced relatively 
reasonable CGH result, which showed distinct abnormal findings- loss of 5q, 
9pl3-p22 and amplification 8q24 except 17 pl2-pter (Fig 3.5.4-M).
Amplification method: DOP-PCR
This study performed whole genome amplification with both test and control 
DNA samples using DOP-PCR, labelled during the second PCR in the same 
setting. EHF DNA polymerase was applied to whole DOP-PCR procedure. The 
starting amount of test DNA in the first DOP-PCR was 200 pg, 100 pg or 50 pg. 
The same amount of starting control DNA was used.
The DNA smear after the first DOP-PCR showed very large sized DNA (1000 to 
5000 bp with maximum intensity) and strong smear (Fig 3.5.4-N). There was no 
significant difference when using different amounts of template DNA. By 
calculating DNA concentration of the product after second DOP-PCR, 
DNA concentrations also did not show a big difference between the three 
samples.
The CGH results from this study revealed more reliable, homogeneous finding 
with almost complete agreement with original abnormal findings (3 out of 4 
abnormal findings) and did not show incorrectly over- or under- represented 
regions even on the 50pg level (Fig 3.5.4-0).
The summary of the result of this method comparing with original 
abnormalities is shown in Table 3.5.13.
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Fig 3.5.4-M (a)CGH image following colour equalisation (test DNA; 40 ng of 
template DNA from abnormal bone marrow sample amplified by PEP using EHF 
PCR system and labelled with Texas-Red, control DNA: 40 ng of template DNA 
from normal female blood amplified by PEP using EHF PCR system and labelled 
with FITC, and hybridised on normal male metaphases, (b) colour ratio image of 
the same metaphase (c)CGH image following colour equalisation (test DNA; 40 
ng of template DNA from abnormal bone marrow sample amplified by PEP using 
EHF PCR system and labelled with FITC, control DNA; 40 ng of template DNA 
from normal female blood amplified by PEP using EHF PCR system and labelled 
with TexasRed, and hybridised on normal male metaphases, (d) colour ratio
image of the same metaphase.
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FIG 3.5.4- N
Gel electrophoresis of the first DOP-PCR 
products with EHF PCR system 
PET; paraffin-embedded tissue
L; 1 kb ladder
1; 200 pg of normal female DNA 
3; 50 pg of normal female DNA
5; 200 pg of abnormal BM DNA 
6; 100 pg of abnormal BM DNA 
7; 50 pg of abnormal BM DNA
8; 50 pg of DNA from PET 
9; 1 00 pg of DNA from PET 
10:200 pg of DNA from PET 
12; negative control
Fig. 3.5.4-0 CGH ratio 
profiles using products 
of DOP-PCR with DNA 
from abnormal bone 
marrow, hybridised with 
amplified normal 
female DNA. (A) DOP- 
PCR using 200 pg of 
template DNA, (B) 
DOP-PCR using 100pg 
of template DNA, (C) 
DOP-PCR using 50 pg 
of template DNA
Table 3.5.13 Summary of CGH results from the serial dilution of DNA from 
abnormal bone marrow sample using the EHF PCR system
Ch. No. gain loss 200 pg 100 pg 50 pg
1
2
3
4
5 5ql4-qter -5q21-qter* -5q21-qter* -5ql5-qter*
6
7
8 8q24 (A) + (decreased 
intensity)
+ (decreased 
intensity)
+ (decreased 
intensity)
9 9pl3-pter - - -
10
11
12
13
14
15
16
17 17pl2-pter + + +
18
19
20
21
22
cannot detect original abnormal finding
+; detect the same abnormal finding
*; Quite similar finding was detected but location of abnormal copy number 
changes was different
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DNA from Known abnormal paraffin-embedded tissue samples
In this study, the basic DNA sample was extracted from paraffin- 
embedded ovarian cancer tissue and CGH was performed with non- 
amplified original DNA of this paraffin-embedded tissue.
The CGH result using original non-amplified DNA was losses of DNA copy 
number on chromosome 7p21-pter, 8p, 13ql3-q21, 15ql 1.2-21.2, 16pl2-pter, 
17q, 18q21 and gains on chromosome 3q21-qter, 5pl3-pter, 7q31-qter, 8q22-qter, 
10q24-qter, llql3-qter, and 12p.
Table 3.5.14 Schematized strategy applied on DNA from known abnormal 
paraffin-embedded tissue
Basic source of DNA Amplification
method
CGH
Result
Amount of
template
DNA
Enzyme used
Paraffin-embedded 
ovarian cancer tissue 
(non-amplified)
Hybridisation Method; amp
Nick
ified test DNA with non-amplified 
translated control DNA
PEP
DOP-PCR
fail
fail
fail
good
good
good
good
good
fail
40 ng 
4 ng 
2 ng
12 ng 
1.2 ng 
1 ng
600 pg
500 pg
100 pg
AmpliTaq LD 
AmpliTaq LD 
AmpliTaq LD
Thermosequenase
Thermosequenase
Thermosequenase
Thermosequenase
Thermosequenase
Thermosequenase
Paraffin-embedded 
ovarian cancer tissue 
(test DNA)
Normal male blood 
(control DNA)
Hybridisation Wethod; amplified test DNA with amplified 
control DNA
PEP
DOP-PCR
fail
good
good
good
40 ng
200 pg 
100 pg
50 pg
EHF PCR system
EHF PCR system 
EHF PCR system 
EHF PCR system
1) Amplified test DNA hybridized with non-amplified, nick translated DNA 
Amplification Method: PEP
This study was performed in the same way as the normal female and abnormal
bone marrow samples. The original DNA sample was diluted to 40 ng, 4 ng, and 
2 ng.
The size of amplified DNA fragments obtained from 40 ng of template DNA was 
from 300 bp to over 12000 bp. In the PEP amplification with 4 ng and 2 ng of 
template DNA, two different concentrations of primer (200 pmol and 100 pmol) 
were applied to the samples. The size of amplified DNA from 4 ng and 2 ng of 
template DNA with 200 pmol of primer concentration was spread from the well 
to 500 bp, but mainly remained near the well (Fig 3.5.4-K). After labelling by 
nick translation, these amplified products showed from high molecular weight 
DNA to below 300 bp and had a very faint intensity. In the case of amplification 
with 100 pmol of primer concentration, the size of the DNA fragments obtained 
from 4 ng of template DNA was from 500 bp to 12000 bp without high molecular 
weight DNA (Fig 3.5.4-K). After the labelling procedure this product showed 
below 500 bp sized DNA.
CGH with these amplified products could not reproduce the original 
abnormalities and showed a lot of non-specific background signals.
For reducing non-specific signals, CGH was performed with purified probes, but 
showed low intensity of green signals with slightly decreased non-specific 
background signals.
Amplification Method: DOP-PCR
The original DNA concentration was lpg/fil. It was then serially diluted to 12ng, 
1.2ng, lng, 600pg, 500pg, lOOpg, 50pg of template DNA in 50pi of the first 
DOP-PCR buffer.
Above the level of 500 pg of template DNA, the first DOP-PCR products showed 
200 to 1000 bp sized DNA fragments with a relatively strong smear. Below the 
level of 500 pg, DNA smear from paraffin-embedded tissue showed less intensity 
and smaller sized DNA than that of bone marrow on the same amount of starting 
DNA (Fig 3.5.4-G).
Above the level of 500 pg of template DNA, CGH results were also relatively 
compatible with original abnormal findings but with less intensity (detection rate; 
70-85%) and there were some under- and over-represented regions. 
Disproportionately under-represented regions (-lp34-pter, -17p, -19, and -22) 
were more predominant than over-represented regions (+ 6ql2-ql6). From below 
that concentration, the detection rate of original abnormal findings was markedly
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decreased (4 out of 14 abnormal finding) and under-represented findings 
presented in above 500 pg were started to change reversibly. The summary of 
the CGH results with serially diluted samples comparing with original 
abnormalities is presented in Table 3.5.15.
2) Amplified test DNA hybridized with amplified control DNA
Amplification method: PEP
In this experiment, PEP amplified product using EHF PCR system from 40 ng of 
template DNAs failed to obtain a proper CGH result.
Amplification method: DOP-PCR
DOP-PCR was performed with EHF DNA polymerase to improve the reliability. 
To avoid the problem induced by mismatched concentration of test and reference 
DNAs during hybridization, both samples were amplified by DOP-PCR, and 
labelled during DOP-PCR in the same setting. Although the size and intensity 
were weaker and smaller than other bone marrow or normal control samples, 
relatively good DNA (300-1000 bp) was revealed on an agarose gel running after 
the first DOP-PCR (Fig 3.5.4-N).
CGH on 200 pg and 100 pg of template DNA showed more reliable results in 
comparison with previous results. The CGH result with the amplified 
product obtained from 50 pg of template DNA showed about 64% of original 
abnormal findings with decreased sensitivity and accurate definition of abnormal 
regions (Fig 3.5.4-P).
The summary of CGH results in comparison with original abnormal findings is 
shown in Table 3.5.16.
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Table 3.5.15 Summary of the CGH results from the serial dilution of DNA from
paraffin-embedded ovarian cancer tissue
Ch.No gain loss 12ng 1.2ng lng 600pg 500pg lOOpg
1 -lp34- -lp34- -lp34- -lp34- -lp34-
pter pter pter pter pter
2
3 +3q21-
qter
+ + + +? + -
4
5 +5pl3-
pter
+ +5p* +5p* +5p* +5p* -
6 +6ql2 
-q 16
+6ql2-
ql6
+6ql2-
ql6
+6ql2- 
q 16
+6ql2- 
q 16
7 +7q31- + + + + + -
qter
-7pl 1.2- -7p21- -7p21- ± -7p21- -7p21- +
pter pter* pter* pter* pter*
8 +8q22- + + + + + -
qter
■8p ±? ± + ± + ±
9
10 +10q24
-qter
+ - +? - -
11 + llq l3
,3-qter
+ + + + +? +
12 +12p + + + +? + +
13 -13ql3-
q21
- - - - - +
14
15 -15q l1. 
2-21.2
- -15ql 3- 
ql5*
-15ql3- 
q 15*
-15qll. 
2-q15*
-15ql3- 
q 15*
-
16 -16pl2-
pter
+ + + -16p + -
17 -17q -17* -17* -17* -17* -17* -
18 -18q21 - - + - + -
19 -19 -19p -19p -19p -19? -
20 +20p +20 +20
21
22 -22 -22 -22 -22 -22
cannot detect original abnormal finding
+; detect the same abnormal finding
*; quite similar finding was detected but location of abnormal copy number 
change was different 
± or ?; suspicious abnormal finding
2 1 7
Fig 3.5.4-P CGH ratio 
profiles using products of 
DOP-PCR with DNA from 
thick section of paraffin- 
embedded tissue, 
hybridised with amplified 
normal female DNA. (A) 
DOP-PCR using 200 pg of 
template DNA, (B) DOP- 
PCR using 100 pg of 
template DNA, (C) DOP- 
PCR using 50 pg of 
template DNA
S E E
n =  0  
Y
Table 3.5.16 Summary of the CGH results from the serial dilution of DNA from
paraffin-embedded ovarian cancer tissue using EHF PCR system
Ch. No gain loss 200 pg 100 pg 50 pg
1
2 -2p22-pter -2p22-pter
3 +3q21-qter + + ±
4
5 +5pl3-pter + + +5pl4
6 +6ql3-ql5 +6ql3-ql5
7 +7q31-qter
-7pll.2-pter
+
-7pll.2-pl4
+
-7pll.2-pl4
+
8 +8q22-qter
-8p
+
+
+
+
-
9
10 +10q24-qter +? - -
11 +llq l3 .3-
qter
+ + +
12 +12p + + +12pll.2-
pl2
13 -13ql3-q21 - - -
14
15 -15ql 1.2- 
21.2
-15ql 5-21 -15ql5-21 -
16 -16pl2-pter + .? -
17 -17q -? .? -
18 -18q21 + + -
19 +19p +19p
20
21
22
cannot detect original finding
+: detect the same abnormal finding
*; quite similar finding was detected but location of abnormal copy number change was slightly 
different.
?; suspicious abnormal finding
2 1 9
3.6 CGH experiments on very small amounts of DNA in solid 
tumours
3.6.1 Ovarian cancer
Section 3.5 has described the development of the technique using a very small 
amount of tissue from ovarian tumours. No cytogenetic analysis was possible 
from the tumour sections used, but the CGH results were consistent and showed 
abnormalities in regions known to be associated with ovarian cancer, in particular 
losses of chromosome regions lp, 5, 11 and 15q, and gains of lq and 12p. It 
therefore seems likely that these were true findings reflecting the chromosome 
constitution of the tumour tissue.
3.6.2 Malignant Melanoma
CGH with 1 x 7 pm whole tissue sections
The object of the various experimental trials just described was to obtain an 
analy sable CGH image from the very small amount of DNA that can be extracted 
from paraffin embedded tissue. From this point onwards, the optimised method 
was applied to melanoma samples although some further improvements in the 
method were made during this study.
The numbering of these cases was as below:
Case 1: 972961 (male)
Case 2: 980804 (male)
Case 3: 981350 (male)
Case 4: 981746 (female)
Case 5: 982169 (male)
In the first experiment five paraffin-embedded melanoma samples were studied 
with DNA being extracted from one entire 7pm thick section from each. It is 
possible that the tumour DNA was contaminated with normal DNA from stromal 
cells.
At first, DNA from these samples was amplified by PEP. The DNA smear of
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these samples after PEP showed different patterns for each individual sample. 
The size of DNA fragments in cases 1 and 2 was over 12000 bp, which mainly 
remained in the well (Fig 3.6.2-A). In cases 3, 4, and 5, the intensity of smear 
decreased sequentially from 4, 5, to 3. Although case 5 showed a reasonable 
size of smear as 500 bp-12000 bp without high molecular weight DNA in the 
well (Fig 3.6.2-B) the DNA smear appeared weaker and more fragmented after 
nick translation. Although CGH experiments after PEP were tried several 
times, it was not possible to obtain analysable CGH images except in case 5 
which showed relatively analysable CGH images compared with those of 
the other cases (Fig 3.6.2-C).
The experiment was then repeated substituting the proofreading enzyme 
(Pfu DNA polymerase) for increasing the fidelity during PEP. The result of 
DNA amplification with this enzyme when visualized on ethidium bromide- 
stained agarose gels was similar to that with AmpliTaq LD. These amplified 
products also failed to achieve proper CGH images. In amplification using PEP, 
the main obstacle was to avoid contamination as already mentioned.
When DOP-PCR amplification was applied to DNA from the same five samples, 
cases 1, 2, and 3 showed very faint smears, especially case 3 which showed 
almost nothing on the agarose gel. In cases 1 and 2, the size of amplified 
DNA was from over 12000 bp to below 500 bp. Intensity of DNA smear of these 
amplified samples was weaker than the product from 600 pg of normal female 
DNA or 12ng of DNA from paraffin embedded tissue. Case 4 showed rather less 
but relatively similar intensity to the product from 600 pg of normal female DNA. 
The size of the amplified DNA isolated from case 5 was 2000 to 12000 bp with 
strong intensity (Fig 3.6.2-D).
In this experiment Pfu DNA polymerase was applied to whole genome 
amplification using DNA from these melanoma samples except case 
5. Comparing the results between Pfu DNA polymerase and thermosequenase, 
cases 1 and 2 showed mainly below 500 bp sized DNA smear, case 3 showed still 
nothing on agarose gel, case 4 revealed 400 to 1000 bp with maximum intensity 
(Fig 3.6.2-E).
The first DOP-PCR products of these samples could not produce proper CGH 
results. The cause of failure could not be exactly evaluated because so many steps 
were involved, but the major cause of failure was the amount of template of DNA. 
After several trials, CGH produced analysable images. The summary of the 
results of these 5 cases is presented in Table 3.6.1.
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FIG 3.6.2-A
Gel electrophoresis of the PEP 
products with whole section of 1 x7 urn 
paraffin-embedded melanoma using 
AmpliTaq
L; 1 kb ladder 
1; case 1 
2; case 2
3; normal female control
FIG 3.6.2-B
Gel electrophoresis of the PEP 
products with whole section of 1 x7 
urn paraffin-embedded melanoma 
using AmpliTaq
L; 1 kb ladder 
1; case 3 
2; case 4 
3; case 5
4; 40 ng of DNA from PEP 
5; 40 ng of normal female DNA 
7; negative control QOO
FIG 3.6.2-C CGH image following 
colour equalisation using case 5 PEP 
amplification product
FIG 3.6.2- D
Gel electrophoresis of the first DOP- 
PCR products with whole section 1x7um 
ot paraffin-embedded meianoma tissue 
using thermosequenase 
PET; paraffin-embedded tissue 
BM; bone marrow
L; 1 kb ladder 
1; case 1 
2; case 2
3; 12 ng of abnormal BM DN A 
5; negative control 
7; case 3 
8; case 4 
9; case 5
10; 12 ng of DNA from PET 
11: 600 pg of normal female DNA 
13; negative control
FIG 3.6 .2- E
Gel electrophoresis of the first DOP-PCR 
products with whole section 1x7um of 
paraffin-embedded melanoma tissue 
using Pfu DNA polymerase except case 5
L; 1 kb ladder
2; case 1
3 case 2
4; case 3
5; case 4
6; case 5
9; negative control
Table 3.6.1 Summary of the CGH results of five melanoma cases 
(lx  7jj.ni thickness of whole tissue sections)
Case number gains losses
1 (972961) lq, 2p21-pter, 4p l5.1-pl5.3 
7pl2-pl5.2, 7q31.32-qter, 
9q21.2-q31, 12pl2.2-pl3.2, 
15q22.3-q24, 17q23-q24
6q, 13q21-22.2
2(980804) 6p21.3-pter, 7q32.3-qter 
15q22-q24, 16pl2.2-pter 
17q22-q24
9p, 13q21-q22.2
3(981350) Failed
4(981746) Thermosequenase Pfu 
6p24-pter 6p21.1 -pter
Thermosequenase Pfu 
6ql2-q22 6ql2-q22 
9p21.1 9p21 
13ql4.2-31.1 13ql4.2-31.1
5(982169) lq, 4pter-q21 9pl2-p22, lp31.2-pter
All o f these CGH results except case 5 showed many nonspecific findings such 
as over-represented regions on chromosomes distal lp, 16, 19, 22, or some 
telomeric areas. Case 1 showed consistent results over several trial experiments 
(at least 5). Case 2 revealed matched sex chromosomes and true loss and gain 
such as loss of 9p, gain of 6p21.3-pter together with several suspected regions of 
gains and losses. However these suspected regions are difficult to present as true 
gains and losses because they occur in problematic regions when CGH is 
attempted on very small amount of template DNA. Case 3 failed to produce 
adequate CGH results and this was compatible with DNA smear finding. Case 4 
showed some abnormal findings with the typical pattern which was shown in a 
very low concentration of starting DNA such as over-represented regions on 
chromosome lp32-pter and 20 and under-represented G-dark band positive 
regions, especially chromosomes 4 and 5. Case 5 showed good quality of 
DNA on the gel and the CGH result was also very reliable and did not 
show unreasonably over-represented or under-represented regions.
Comparing the results between Pfu DNA polymerase and thermosequenase, case 
4 only produced successful CGH results using Pfu DNA polymerase. Although 
the CGH findings with both enzymes were quite similar, the result using 
Pfu DNA polymerase revealed more reliable findings with matched sex 
chromosomes. Even though Pfu DNA polymerase was an on going optimization 
process, sensitivity of this enzyme was better than that of thermosequenase.
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CGH with Microdissected Samples
Samples were microdissected from paraffin embedded melanoma tissue 
sections. Cells from the regions of interest were selectively microdissected from 
five paraffin-embedded melanoma tissue sections under the inverted microscope 
by using 25G needle. PEP products of these samples failed to produce 
successful CGH results even after many attempts, indicating that the size of the 
microdissected material was too small to produce a sufficient amount of 
amplified DNA for CGH. The WGA method was then changed to DOP-PCR.
At first, the size of microdissected area was 2 mm2 x 3 pm which was composed 
almost entirely of abnormal cancer cells. Malignant cells were procured as much 
as possible without contamination of normal cells. The microdissected cells were 
treated with proteinase K to release the genomic DNA, which was amplified by 
DOP-PCR and directly labelled with FITC or Texas-Red. This amount of 
microdissected material failed to produce proper results.
After increasing the volume of microdissected material to 18 mm2 x 3 pm or 3 
mm2 x 3 pm reasonable results were obtained. DOP-PCR method was changed 
from method 6 to method 7 due to repeated failure. The summary of the gel 
running results of amplification product (DOP-PCR) and the volume of the 
microdissected materials are shown as Table 3.6.2. The summary of CGH 
results of these 5 cases is presented in Table 3.6.3. All these experiments were 
repeated several times.
Table 3.6.2 Summary of the volume of the microdossected materials and 
DNA size after DOP-PCR amplification of microdissected samples from 5 
melanoma cases
Case number volume of the microdissected material DOP-PCR product (1st)
1(971354) 18 mm2 x 3pm Below 394 bp
2(971496) 3 mm2 x 3pm Below 500 bp
3 (980804) 3 mm2 x 3pm 300 to 1000 bp
4(982186) 18 mm2 x 3pm 300 to 1600 bp
5(982963) 18 mm2 x 3pm 300 to 1600 bp (300-500 bp 
with maximum intensity)
225
Table 3.6.3 Summary of the CGH results of microdissected samples from 5 
melanoma cases (using AmpliTaq LD, hybridised with non-amplified control 
DNA)
Case number Gains Losses
1 (971354) — 17pl2-qter
2 (971496) 6p 10q22-q25.2
3 (980804) 6p22.2-pter, 15q22.3-q23 
17q24
5ql4-q32, 9p, 1 Op, 11 pter- 
q 13
4(982186) — 9p21-23
5(982963) 5p, 6p, 22qll.2 6q, 9p21, lOp, llql4-qter, 
14q23-qter, 17p
*- no gain of DNA copy number
These CGH results showed abnormalities compatible with chromosomal 
aberrations which have commonly been observed in CGH of fresh melanoma 
samples. Gains most frequently involved chromosome 6p (3 out of 5 cases) and 
additional chromosomes with gains were chromosome 5p, 15q22.3-23, 17q24, 
and 22 (?). Losses most frequently involved chromosome 9p (3 out of 5 cases) 
and other chromosomes with losses were lOp, 17pl3, and 6q.
Next, the method was modified by changing to an enzyme with proof-reading 
activity. Two systems were investigated- the Expand High Fidelity PCR system 
(Boehringer Mannheim) and the Expand Long Template PCR System 
(Boehringer Mannheim). The Expand High Fidelity PCR system is composed of 
a unique enzyme mix containing thermostable Taq DNA and Pwo 
DNA polymerase. The Expand Long Template PCR system, which is also 
composed of the same enzyme mixture as Expand High Fidelity PCR system, is 
designed to give a high yield of PCR products from genomic DNA. It amplifies 
fragments up to 27 kb from human genomic DNA.
At first, the PEP method was applied to case 5, with the Expand High Fidelity 
PCR system and the Expand Long Template PCR system, in comparison with 
normal female control (concentration; 4ng/50pl). The results of 
DNA amplification were visualized on ethidium bromide stained agarose gel (Fig 
3.6.2-F). The size of amplified DNA with the EHF PCR system was over 12000 
bp which mainly remained in the well, and showed less intensity than the product 
from normal female sample (concentration; 4ng/50jil). The size of the amplified 
DNA with the ELT PCR system was from 1000 bp to the well, but was uniformly 
spread. When CGH was attempted using the DNA amplified by PEP no reliable
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results were obtained and this remained the same even after several attempts and 
modifications of thermal cycle and enzyme.
Then, the EHF PCR system and AmpliTaq LD were applied to DNA from the 5 
cases during DOP-PCR amplification to compare the efficacy and fidelity. These 
amplified products were hybridised with amplified normal female control 
(amount of template DNA; 1 ng/50ul) using same enzyme.
At first, a 9mm2 x 3 pm thickness section was microdissected from paraffin- 
embedded tissue. This amount of microdissected material from each of the five 
melanoma cases was amplified by DOP-PCR using AmpliTaq LD and the EHF 
PCR system separately. The results showed that products of the EHF PCR system 
generally gave a stronger smear with a larger size of DNA fragments than 
those of AmpliTaq LD (Fig 3.6.2-G). Cases 1 and 2 showed very fragmented 
DNA (below 200 bp), The size of amplified DNA from cases 3 and 4 was 200 to 
500 bp. Case 5 showed 300 to 1000 bp (around 500 bp with 
maximum intensity). Case 5 especially showed up a prominent difference 
between the results of the two enzymes (EHF; 300 to below 1000 bp, AmpliTaq; 
below 500 bp).
All cases except case 5 failed to produce acceptable CGH images, suggesting that 
they could not amplify sufficient DNA to produce an optimal CGH result. In case 
5, the CGH result with the amplified product using AmpliTaq showed 
homogeneous, uniform images but was of lesser intensity than that of the EHF 
DNA polymerase. This method could only detect a gain of chromosome 5p and a 
loss of 14q23-qter when threshold was decreased to 1.12/0.88 but the results 
with EHF DNA polymerase were the most homogeneous and uniform yet 
produced (Fig 3.6.2-H).
After this the thickness of sections was increased to 7 pm to increase the yield of 
DNA amplified from microdissection of the same area (9 mm2) except for case 2 
(3 mm2). It was thought that these amounts of tumour cells were amplified 
sufficiently for each CGH experiment. After DOP-PCR amplification, gel- 
running showed a slightly stronger smear and larger size of DNA fragments 
except in case 1 and 2 than those from previous experiment (Fig 3.6.2-1). All of 
these four cases except case 2 produced analysable CGH images. In case 2, the 
same volume as other samples could not be obtained because of the very small 
tumour mass on paraffin section and failed to produce a reasonable CGH result.
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FIG 3 .6 .2 - F
Gel electrophoresis of the PEP products 
with microdissected melanoma sample 
using EHF PCR system (EHF) and 
Espand long Template system (EL)
L; 1 kb ladder
2; case 5 (982963) with EHF 
3; 40 ng of normal female DNA with 
EHF
6; case 5 with EL 
7; 40 ng of normal female DNA with 
EL ~
11; negative control
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FIG 3.6.2- G
Gel electrophoresis of the first DOP-PCR 
products with microdissected melanoma 
samples using EHF PCR system (EHF) 
and AmpliTaq LD (A)
L: 1 kb ladder 
1; case 1 with EHF 
2; case 1 with A 
3; case 2 with EHF 
4; case 2 with A 
5: case 3 with EHF 
6; case 3 with A 
7; case 4 with EHF 
8; case 4 with A 
9; case 5 with EHF 
10: case 5 with A 
12: negative control 
13: negative control
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FIG 3.6.2-H CGH ratio profile using DOP-PCR product from case 5 (982963; 
3mm x 3mm x 3 urn)
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• *
FIG 3 6 .2 -  I
Gel electrophoresis of the first DOP- 
PCR products with microdissected 
melanoma samples using EHF PCR 
system (3mm x 3mmx 7 urn)
L; 1 kb ladder 
1; case 1 
2; case 2 
4: case 3 
5; case 4
7: case 5 ( 3mm x 3mm x 3 urn)
9; normal female DNA (1 ng/50ul) 
12; negative control
A summary of CGH results produced using these amplified products is 
presented in Table 3.6.4. All of these results were confirmed by repeating the 
experiments about five times and accompanied by various concentrations of 
normal and two positive controls to validate the results.
Table 3.6.4 Summary of the CGH results of microdissected samples of 5 
melanoma cases ( using EHF PCR system, hybridized with amplified control 
DNA)
Case
number
Volume of
microdissected
material
gains losses
1 (971354) 
(male)
9 mm2 x 7jim 17pl2-q22
2(971496)
(female)
3 mm2 x 7jim Failed
3 (980804) 
(male)
9 mm2 x 7|im 6p21.3-p23, 15q22.3- 
q24, 17pl2-qter
5q21.2-qter, 9p, lOp, llpter 
-q22, 6q22-qter
4(982186)
(male)
9 mm2 x 7 jim 9p21-pter
5(982963)
(female)
9 mm2 x 3 jim 5p, 6p, 22 6q, 9p21-pter, lOp, llq l4 - 
qter, 14q21.2-qter, 16q, 
17pl3, Xq
3.7 Validation of CGH results
The reliability of CGH results with amplified product, particularly from single 
cells or a few microdissected formalin-fixed and paraffin-embedded solid tumor 
cells, has not yet been evaluated. During whole genome amplification there are 
potential risks of false over- or under amplification of regions of DNA due to 
the intrinsic error rate of Taq polymerase. Such errors could produce some bias in 
subsequent CGH results.
Many methods have been applied to validate CGH results such as conventional 
karyotyping, FISH, and molecular methods. The fundamental way to obtain 
reliable CGH results is careful control of the quality of hybridization, and use of 
both normal DNA and DNA from known abnormal samples as controls. In this 
study, three control DNA samples from normal female, known abnormal bone
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marrow sample, and known paraffin embedded tissue were applied as a control 
for the fidelity of the CGH results. All these control samples were 
amplified using PEP and DOP-PCR, labelled by PCR or nick translation, 
and CGH was performed along with the test samples of unknown composition. 
The results of all these control samples are mentioned in chapter 3.5.
3.7.1 Inverse (Reverse) CGH
Tumour samples were labelled with Texas-Red and hybridized with FITC- 
labelled normal reference DNA to control for the possible differential 
hybridization efficiency of differently labelled DNA probes.
Larramandy et al (1998) reported that chromosomal regions lp33-pter, 16p, 17p, 
19, and 22 exhibited hybridization artifacts in 15-23% of the tumour samples 
labelled with FITC, but not in samples labelled with Texas-red. However, in this 
study samples labelled with Texas-red showed similar pattern of over- and under­
represented regions to samples labelled with FITC. Additionally, under­
represented G-dark band areas were more exaggerated in reverse CGH.
Review of this inverse CGH showed many false positive and negative copy 
number changes when applying a modal value of 1.20/0.80. There were 
difficulties in differentiating whether these were true or false results. To increase 
the specificity, the threshold was widened to 1.40/0.60, and true copy number 
changes were decided by comparing with the original CGH images.
Case 5 had probably the highest concentration of DNA or the best condition 
(size of DNA). The original and reverse CGH results of this case were 
compatible with each other. They showed only a few over-represented 
chromosome regions namely the distal part of lp, 19p, and 22.
Case 1 failed to produce a reverse CGH image.
Case 2, 3, 4 showed their original abnormalities with some discrepancies in 
addition to similar pattern of false positive and negative results, especially with 
more green (loss) on the dark G-band area and more red (gain) on chromosome 
lp32-pter, 16p, 17, 19, 22. These findings suggested that the concentration of 
template DNA of case 2, 3, 4 was quite low or that optimal size of 
DNA fragments for CGH could not be produced sufficiently after amplification. 
The results of reverse CGH and discrepancies between original CGH and 
reverse CGH are summarized in Table 3.7.1.
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Table 3.7.1 Summary of the results of reverse CGH in five melanoma cases
Case No. gains losses Discrepancies between 
two CGH results 
(original: reverse)
1 failed
2 6p21.1-pter 9pl3.2-pter -9(p 13.2-pter) (reverse) 
-10(q23.2-q25.2) (original)
3 6p21.1-pter, 15q22, 
17q23-qter
9p, 10pll.3-pl3 -5(q21,2-qter),-11 (pter-q22), 
-16(q22-qter) (original)
4 9pl3.2-pter compatible
5 5p, 6p, 19p, 22 6q, 9p21-pter, lOp, 
llql4-qter, 14ql2 
q24, 17pl3, Xq
+19p (reverse), 
-16q (original)
3.7.2 Tissue In Situ Hybridization
The aim of this part of the study was to confirm the abnormal CGH findings in 
the five tumours studied. FISH was performed on 4 pm sections consecutive with 
those used for microdissection. Probes used were specific locus probe on P53 
region (17pl3.1) with chromosome X centromeric probe as a control.
The main problem of this method is that in any given 4-um-thick section, 
portions of nuclei rather than intact nuclei are examined and exact counting is 
very difficult because of overlapping signals.
Case 1 (971354; male) consistently showed 1 signal for the control chromosome 
X centromeric probe. The result of p53 locus specific probe showed 2 signals in 
the majority of nuclei but the presence of one signal and occasionally absence of 
signal was also detected. Cases 2, 3 and 4 showed similar results (Fig 3.7.2-A). In 
case 2, only p53 locus specific probe was used. In this experiment, there are 
many difficulties to obtain proper results such as problems in counting the signals 
and availability of probes for specific locus interested.
3.7.3 PCR with specific primers
PCR using several different specific primers was also performed on the amplified 
products in an attempt to confirm these results.
PCR amplification using primer containing pseudoautosomal sequences was 
performed for sex determination of the samples and normal controls amplified
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from 100 pg of template DNA was subjected to the same PCR amplification. 
This primer consists of a 30-mer derived from psudoautosomal sequences (C) in 
combination with 30-mer from Y-specific and X-specific regions (C:Y:X at a 
ratio of 50: 75: 5). Although specific bands were detected at 771 bp and 917 bp in 
male control and one band at 111 bp in female control, no specific bands were 
detected in the melanoma cases (Fig 3.7.3-A). Finally PCR using primer of p l6  
gene on 9p21 (exon 2) was performed for proving the loss ofp l6  gene. Although 
the strong single band was detected at 337 bp in normal control, no specific 
bands were detected in melanoma cases except case 3 (980804) which showed a 
faint single band at 337 bp, these findings were insufficient to reach a definite 
conclusion.
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FIG 3.7.2-A Dual colour FISH using p53 locus specific probe (red)/ 
chomosome X centromeric probe (green) using paraffin-embedded tissue in 
three melanoma cases a) case 1 (971354), b) case 3 (980804), c) case 4 
(982186) , Mono colour FISH using p53 locus specific probe (red) using 
paraffin-embedded tissue in one melanoma case d) case 2 (971496)
L 1 2 3 4 5 6 7 FIG 3.7.3-A
Gel electrophoresis of the PCR products 
using primer with specific sequences of 
pseudoautosomal regions of sex 
chromosomes in five melanoma samples 
and two amplified normal controls 
L; 1 kb ladder 
1; case 1 
2; case 2 
3; case 3 
4: case 4 
5; case 5
6; normal male (100 pg)
7; normal female (100 pg)
CHAPTER 4. DISCUSSION
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4. Discussion
4.1 Interphase FISH and CGH in Acute Lymphoblastic Anemia
Fluorescent hybridisation using chromosome repetitive sequence probes is 
especially useful for the detection of numerical chromosomal abnormalities in 
prenatal diagnosis and is also of benefit in hematological malignancies 
especially leukemia because in many cases of leukemia it may be difficult to 
obtain any mitoses or good quality metaphase spreads.
The recognition of numerical and structural chromosomal aberrations has 
become an important part in the diagnosis of patients with acute lymphoblastic 
leukemia (ALL) because specific chromosomal aberrations in ALL affect 
therapeutic decisions and prognosis. The recent marked improvement in cure 
rates for children with ALL has induced a great interest about genetic 
abnormalities, including chromosomal number and nonrandom recurring 
chromosomal translocations as independent predictors of treatment outcome in 
childhood ALL. Nevertheless, cytogenetic analysis of ALL is difficult because 
standard chromosome-processing techniques frequently produce poor 
metaphases. In only 55-90% of cases with ALL can clonal chromosomal 
abnormalities be fully evaluated (Raimondi, 1993; Karhu et al., 1997b; Paszek- 
Vigier et al., 1997).
Although numerical changes in ALL occur in similar frequencies as in AML, 
they are difficult to detect systematically because of the variety of 
chromosomes involved in hyperdiploid ALL. The absolute number of 
chromosomes rather than the trisomy or monosomy of specific chromosomes 
correlates with prognosis. Therefore screening with only one or two 
chromosome specific probes is unlikely to result in clinically relevant 
information (Bentz et al., 1994b).
Hyperdiploid cases are divided into three ploidy subgroups according to their 
modal number; low hyperdiploidy (47-50 chromosomes), high hyperdiploidy
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(51-68 chromosomes), and triploidy/tetraploidy (> 68 chromosomes). The good 
prognosis associated with high hyperdiploidy in children and adults is well 
established. The prognostic importance of low hyperdiploidy is less definite, 
and triploid/tetraploid cases appear to have a relatively poor prognosis. 
Chromosomal gain in hyperdiploidy has been shown to be nonrandom. Low 
hyperdiploid cases tend to gain chromosome X, 8, 10, and 21, whereas high 
hyperdiploid cases show nonrandom gain of chromosomes X, 4, 6, 10, 14, 17, 
18, and 21 (Moorman et al., 1996).
Within these ploidy groups, the prognosis can be affected by specific 
chromosomal rearrangements, mainly the t(9;22) and the rearrangements of the 
MLL gene which confer a very poor prognosis whatever the ploidy group is, 
and the recently described t(12;21), which seems to have a very good prognosis 
(Shurtleff et al., 1995). Furthermore, not only the chromosomal number but also 
the nature of gained chromosomes are of prognostic value. Harris et al (1992) 
showed that the gain of chromosomes 4 and 10 was associated with a good 
prognosis, even in the low hyperdiploid subgroup.
Two approaches to the detection of hyperdiploidy were investigated in the 
present study.
In the first approach, samples from 22 patients were studied by interphase FISH 
according to the strategy of Moorman (1996). In this FISH employing 
chromosome-specific probes for alpha satellite, applied singly or together in the 
seven sets, could be used first to identify each hyperdiploid case and then to 
predict its ploidy subgroup.
In 22 cases studied here, interphase FISH detected 2 abnormal cases out of 5 
cases which had failed by conventional karyotyping, and also resolved one 
hyperdiploidy case which had been analysed incompletely by conventional 
karyotyping.
In six cases where a normal karyotype had been found no abnormality was 
detected by FISH, thus adding confirmation to the cytogenetic result.
Of the four hyperdiploid cases which had been identified by karyotyping, three 
were confirmed by FISH, no further abnormalities being identified. In the 
fourth case, complete karyotypic analysis had not been possible but FISH
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identified three of the chromosomes involved.
Although the number of cases studied here is small, it can be concluded that 
FISH, following Moorman’s strategy, can contribute to the classification of 
cases of ALL according to ploidy, especially where karyotyping failed or is 
incomplete. Without selection of centromeric probes for the specific 
chromosomes known to be most frequently involved, this would be a slow and 
tedious process, although use of the centromeric multiprobe device developed 
after this stage of the work had been completed might simplify the analysis.
One of the major problems during interphase FISH for obtaining a reliable 
result was accurate counting of signals and avoiding the problem produced by 
overlapping of interphase domains. Additionally, it was very difficult to 
interpret mosaicism, so in every experiment the inclusion of a normal control 
was critical in deciding if the result was normal or abnormal.
Numerical abnormalities are sometimes accompanied by structural 
abnormalities and as the combination with structural aberrations such as t(9;22) 
or t(4; 11) would affect the prognosis, a more comprehensive and 
straightforward way for detection of structural and numerical aberrations is 
needed. There is however no perfect method as even CGH has the limitation of 
failing to detect balanced translocations.
Interphase FISH can be used as a complementary method to detect 
prognostically important numerical abnormalities, especially hyperdiploidy, in 
ALL as a routine screening of cytogenetically failed cases. The strategy 
presented in this study provides a convenient method for selection of probes for 
this purpose.
Interphase FISH has another benefit in the evaluation of minimal residual 
disease in patients with ALL and a high hyperdiploid clone (>50 chromosomes) 
at diagnosis.
Some high hyperdiploid clones unusually shows an apparent ability to remain 
dormant for many years. Relapse in this subgroup, which occurs in 
approximately 25% of children and 35% of adults, tends to be after the 
completion of treatment and may occur even many years later (Kasprzyk and 
Seeker-Walker, 1997). FISH of specific alpha satellite centromeric probes to
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interphase nuclei provides the opportunity to detect small numbers of remnant 
cells that may be trisomic for these specific chromosomes. This presents the 
possibility of detecting how quickly the leukemic clone is eliminated in these 
patients after chemotherapy and therefore whether the rapidity of loss of the 
leukemic clone affects significantly in their long-term survival. Regular 
monitoring of the clone by FISH may enable early detection of a re-emerging 
clone. At relapse, interphase FISH may be able to estimate the size of the 
leukemic clone more accurately (Heerema et al., 1993; Bentz et al., 1994b; 
Kasprzyk and Seeker-Walker, 1997).
The second approach was to investigate the application of CGH to the detection 
of hyperdiploidy. CGH represents a new, additional technique to evaluate 
chromosomal aberrations in pediatric ALLs, especially in cases where 
metaphases from the malignant cell clone are difficult to obtain and show 
apparently normal cytogenetic findings or complex karyotypes. The other major 
advantage of CGH is the ability to identify the origin of marker chromosomes 
and to resolve complex karyotypes (Karhu et al., 1997b).
Results were obtained for all the 19 cases studied by CGH. Chromosome gains 
were much more frequent than losses and there was some disagreement with 
conventional cytogenetic results. Cytogenetics revealed an abnormal clone in 6 
cases out of 19 cases (excluding failed cases) whereas CGH detected further 2 
abnormal cases. By observation of some discrepancies of results between the 
two methods, missing chromosomes in conventional karyotyping were thought 
to be rearranged into marker chromosome or derivative chromosome. On the 
other hand, some chromosomes which were lost or gained in conventional 
cytogenetics could not be detected by CGH possibly because of mosaicism with 
normal cells. Complete agreement of results between conventional karyotyping 
and CGH was found in 9 cases of the 19 cases studied using CGH.
Case 8 was of interest in that an additional Y chromosome was detected by 
CGH but this was not seen on conventional karyotyping. FISH then showed 
that the extra Y material was present in a marker chromosome. Additional Y 
material is very rare finding in ALL and its significance is unknown.
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Case 13 showed an another feature of interest in the loss of DNA copy number 
of 6qll-q21 (interstitial deletion) and 9pl3.2-pter identified by CGH compared 
with del(6)(q21), der(9)?t(9;21)(pl3;qll.2) by conventional karyotyping. In 
ALL, deletion of 6q usually involves a proximal breakpoint between 6ql3-q21 
with distal breakpoints at q21 and q23, with common loss of band q21 (Barletta 
et al., 1987; Hayashi et al., 1990). Deletion of 6q is found as the sole 
abnormality in approximately 3% of cases but occurs more frequently with 
other abnormalities giving an overall incidence of 8% to 13% of childhood 
cases and 6% of adults (Seeker-Walker, 1994). In this case breakpoints detected 
by CGH were different from those by conventional karyotyping. CGH can 
provide more accurate breakpoints than traditional cytogenetic method. 
Abnormalities of 9p have been reported in approximately 13% of ALL cases. 
Abnormalities of sequences from 9p21-p22 involve loss of sequences by 
deletion or unbalanced translocations. Two important established changes 
which result in 9p loss are i(9)(ql0ql0) and dic(9;12) (Seeker-Walker, 1994). In 
this case (case 13), 9p was deleted together with translocation of the remaining 
chromosome to chromosome 21. Cytogenetically, this derivative chromosome 
was in query but it can be supposed that the derivative chromosome was 
probably dic(9;21) according to the CGH result.
In case 18, a very prominent peak at the 6p23-pter region was identified by 
CGH, suggesting a high-level amplification of DNA sequences originating from 
this chromosomal region. In ALL amplification is not a frequent finding and 
this region is not a frequently amplified region. Additional material of 
add(6)(p2?) by conventional cytogenetics was probably derived from material 
of 6p23-pter. But it was difficult to estimate how many copies were amplified in 
that region.
In case 20, conventional G-banding result showed very complicated results 
whereas CGH showed only one abnormality ie. gain of chromosome 8. By 
using FISH, chromosome 4 material was shown to be rearranged into 
add(3)(p25), der(ll), add(17), and ring chromosome. This result proved that 
CGH can reveal exact true gain or loss, making it possible to resolve the origin 
of marker chromosomes or complex derivative chromosomes.
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Among four cases, which were failed by conventional G-banding, one triploid 
case and one case with loss of Xpter-q24 were identified by CGH. One case of 
triploidy showed a limitation of CGH which cannot evaluate absolute copy 
numbers of chromosome regions. However if information from interphase FISH 
was combined full interpretation was possible.
Two cases of hyperdiploidy showed gains of chromosomes X, 4, 10, 14, 18, 21 
commonly. Gains of these chromosomes were compatible with other 
hyperdiploidy. Although both cases have good prognostic factors in 
hyperdipoidy especially including chromosome 4 and 10, the prognosis in case 
8 was difficult to predict due to the presence of marker chromosomes.
CGH has a great advantage of detecting unbalanced structural abnormalities in 
addition to hyperdiploidy in a single hybridization whereas FISH may require 
several experiments to detect hyperdiploidy and unbalanced structural 
abnormalities cannot be detected using interphase FISH. On the other hand 
FISH, when carefully controlled, can detect mosaicism more accurately, 
especially in lower percentages of tumour cells because mosaicism (< 50%) 
would be missed by CGH.
In the case with hypotriploidy/hyperdiplody, interphase FISH provided an 
important clue about the numerical abnormality because CGH can recognize 
only the difference of relative copy numbers, especially when karyotyping had 
failed to obtain proper results.
Finally, although this sample size was not large enough to confirm applicability 
and advantages of the two methods, both have different advantages and are 
complementary methods for each other. In this study, no attempt was made to 
identify specific balanced translocations such as t(9;22) or t(12;21) which are 
known to influence prognosis within hyperdiploid groups. While these could 
not be detected by CGH, it might be possible to use breakpoint specific probes 
such as BCR/ABL or TEL/AML in interphase FISH to improve the diagnosis. 
Although FISH can be considered as a method to detect numerical 
abnormalities, specific balanced translocations, and to monitor residual disease, 
CGH can be a very comprehensive diagnostic tool for detecting hyperdiploidy, 
unbalanced abnormalities, and amplification in ALL. Furthermore, prognosis
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was estimated more accurately by detecting the exact breakpoint and rearranged 
chromosomal material as an origin of marker chromosome or derivative 
chromosome using CGH.
4.2 CGH analysis in cases with AML/MDS
Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)-related 
AMLs are a very heterogeneous group of hematological diseases which show a 
diverse spectrum of chromosomal aberrations, molecular abnormalities and 
immunophenotypes.
In patients with acute myeloid leukemia, about 20%-40% of patients never 
achieve remission following standard induction chemotherapy. Only 30-40% of 
patients who achieve remission will eventually become long term survivors in 
spite of treatment with intensive chemotherapy, bone marrow transplantation or 
both (de Nully Brown et al., 1997a; El-Rifai et al., 1997). Therefore it is 
beneficial to allocate patients to different risk groups to prevent disease relapse, 
and to increase long term survival rates. There are many parameters which may 
influence the prognosis including age, FAB type, clinical variables especially 
presentation white cell count and the expression of certain immunophenotypic 
surface markers, but appropriate analysis of chromosomal abnormalities is one 
of the most valuable prognostic indicators in AML. Chromosomal 
abnormalities have been reported in between 50 and 95% of patients with 
primary AML in different studies (Bentz et al., 1995a; de Nully Brown et al., 
1997; Musilova et al., 1998). AML patients with specific balanced re­
arrangements such as t ( l5; 17), t(8;21) or inv(16) have a relatively good 
prognosis. AML patients with complex karyotypes, often including several 
marker chromosomes, especially those with monosomy 5 or del(5q), 
monosomy 7 or abnormalities of 3q have been regarded as a poor prognostic 
group (Swansbury et al., 1994; de Nully Brown et al., 1997; Hirons et al., 1997; 
Grimwade et al., 1998; Musilova et al., 1998; Burnett et al., 1999).
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The results of CGH on the 19 cases studied showed that net gains and losses of 
chromosome material could be detected more simply and accurately by CGH 
than by conventional karyotyping in patients with a complex karyotype. This 
study has shown that chromosomes thought to be missing by conventional 
karyotyping can be internally rearranged within the karyotype by incorporation 
into marker chromosomes or derivative chromosomes which have been 
partially identified.
Loss of chromosome 5q material is the most frequent finding in these CGH 
results (6 out of 19 cases). Three of these 6 cases presented with de novo AML. 
Five cases had loss of 5q as part of a complex karyotype. The remaining case 
had failed by cytogenetic analysis. Loss of 5q material has been reported to be 
particularly frequent in therapy-related or secondary AML/MDS and is less 
common in de novo AML (< 10%) (Horrigan et al., 1996). Although the size of 
deletion of 5q varies among the patients studied, a region that includes band 
5q31 was always deleted except for case 17. Loss of 5q31 within the 
hematopoietic stem cell compartment could lead to initiation and clonal 
evolution of MDS/AML because it could be crucial to the preservation of 
genomic integrity following DNA damage (Beretta et al., 1996a; Horrigan et al., 
1996; Wang et al., 1997; Karp, 1998).
In 4 cases of unbalanced t(5; 17) leading to loss of material from chromosomes 
5 and 17, CGH defined the break points relative to the centromere of each 
chromosome more accurately than cytogenetics had done. Three of the cases 
had been reported as having a der(5)t(5;17) or der(17)t(5;17). One of these 
three cases appeared to be dicentric by CGH.
When amplification of a specific locus has been identified by CGH, FISH with 
an appropriate probe can detect its distribution within the karyotype. Although 
the incidence of DMs in AML is only 1-5%, this finding is more frequently 
observed in de novo AML and MDS of the elderly, therapy-related or secondary 
AML/MDS and in a subset of a newly defined FAB M2/M4 leukemia 
characterized by trisomy 4, associated with clonal abnormalities of 
chromosome 5 and 7 (Slovak et al., 1994; Grimwade et al., 1998). In this study 
one case (case 4) is a secondary AML M4, associated with t(5; 17), monosomy
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5q , deleted 9p and 17p and the presence of double minutes (amplification of 
MYC). In case 7 seven copies of the MLL gene locus were confirmed by FISH. 
The amplification of an oncogene in secondary leukemia often happens in 
advanced stages of the disease and is regarded as a poor prognostic sign 
(Schwab et al., 1990; Mohamed et al., 1993; Slovak et al., 1994; Zhang et al.,
1995).
In case 12, where conventional karyotyping reported a del(7)(pl3pl5) or 
add(7)(pl3) and loss of chromosome 21, CGH identified loss of chromosome 
7pl2-pter without loss of chromosome 21. This was confirmed as a dic(7p;21p) 
by FISH. It is known that monosomy 7q is a critical marker of secondary 
leukemia, but the prognostic and clinical implication of monosomy 7p, 
dic(7p;21p) cannot be evaluated at the moment. This case also showed most 
cells to have similar related abnormalities in particular showing further re­
arrangement of chromosome 5, 8 and 17. In this case, despite evidence of clonal 
evolution, CGH followed by FISH was able to detect underlying true gains and 
losses.
In this study, results with targeted FISH following CGH analysis confirm that 
the origin of marker chromosomes may be complex with two or more 
chromosomes involved in their make up. For example in case 12, one of the 
marker chromosomes was composed of material from chromosome 3, 18, and 
22. Analysis of different metaphases may help to identify the evolution of the 
marker chromosomes from a simple stem line during the course of disease 
progression.
In case 13, CGH followed by FISH showed one marker chromosome to be 
composed of material from chromosome 6, 8 and Y. Conventional karyotyping 
by contrast had indicated only loss of the Y chromosome. In the literature 
review, several cases of loss of chromosome Y in association with a complex 
karyotype in AML patients have been reported (United Kingdom Cancer 
Cytogenetic Group, 1992). Further careful CGH studies in these cases is 
required because it may reveal instances where the Y chromosome is involved 
in the make up of the marker chromosomes which has hitherto not been 
reported.
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Although the clinical importance and the events leading to the production of 
marker chromosomes is not yet fully understood, these experiments show that 
they are connected with complex unbalanced karyotypes and are usually 
associated with a poor prognosis.
The present study confirms the importance of CGH in the detection of some 
critical prognostic indicators in patients with AML or MDS transformation. It is 
especially useful in cases with extremely complex chromosomal aberrations 
and in cases which had failed by conventional karyotyping. Identification of the 
chromosome regions involved may also help to clarify their role in the 
pathogenesis of the disease.
4.3 CGH analysis in case with Well Differentiated Liposarcoma
Liposarcoma is one of the most common soft tissue sarcoma types in adults. 
Well-differentiated liposarcoma is one of the major categories of liposarcoma, 
and is characterized by supernumerary ring and giant rod-like marker 
chromosomes as a cytogenetic finding. Knuutila et al (1998) identified 12ql4- 
q21 (7/30), Iq21-q24 (5/22), lp33-pter(l/14), 19(1/14), Xp21(l/14) as 
amplification sites in liposarcoma but the frequencies of amplification were not 
subdivided by liposacoma subtype.
In this study, 5 cases of WDLPS showed ring chromosomes or rod-like giant 
marker chromosomes on G-banding. In four out of the 5 cases, amplification on 
chromosome between 12ql3 and 12q21 of variable extent was observed. By 
comparison with conventional karyotyping, it was thought that this amplified 
material was incorporated into the ring chromosomes or giant marker 
chromosomes with or without other amplified material.
This region (12ql3-21) is a quite specific amplification site in different kinds of 
sarcoma such as liposarcoma and osteosarcoma. This amplicon is very complex 
with the presence of several different genes such as MDM2, SAS, 
CHOP/GADD153. MDM2 and SAS are constantly amplified in WDLS and
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CHOP/GADDI 53 is rearranged in myxoid liposarcoma (Szymanska et al.,
1996). Although the common amplification site involved is in 12ql3-15, 
sometimes amplification in 12ql4-15 and 12q21.3-22 are detected as two 
separate bands or as a broad amplified segment ranging from 12ql4 to q22 
(Suijkerbuijk et al., 1994; Wolf et al., 1997)
In cases with gain of material on chromosome 1, Szymanska et al (1996) found 
that common regions of gain were located at lp22-31, lq21-24, and lq32 (with 
similar results from Suijkerbuijk et al., 1994).
In this study, case 3 showed two peaks of gain at lq21-24 and lq31 represented 
as an amplification band (lq21-24) and a high level of gain ( lq 3 1) 
simultaneously which was a relatively rare finding compared with amplification 
on each region separately.
In case 1, conventional G-banding showed hypotriploidy with a derivative 
chromosome and a marker chromosome. Initial CGH (before multiple 
normalisation of single chromosome) showed gain of chromosomes 8, 18, and 
llpl4.3-pter, loss of chromosomes 2, 4, 9, 11, 14, 15, X, and 5pl5.3-pter and 
amplification of 12pl3-21. By considering both results, the origin of 
add(5)(pl4).ish der(5)(wcpl2+) and mar.ish der(?)(wcpl2+) could be proposed. 
This case also revealed the documented limitation of CGH analysis about 
absolute copy numbers.
The most interesting finding of this study was amplification of chromosome 
3ql2-13.3, which is thought to be a new amplification in liposarcoma. This 
amplification was detected in 2 serial samples of the same patient with 4 
months time difference. In the cytogenetic view, one ring chromosome was 
added to previous findings but the CGH result was not changed. This finding 
suggested that two amplicons were constantly activated for progression of the 
tumour.
These results indicate that CGH is very helpful for evaluation of marker 
chromosome and ring chromosomes by the detection of amplicons and can 
therefore provide a clue about candidate oncogenes or tumour suppressor genes.
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4.4 CGH analysis in cases with malignant melanoma
Although previous cytogenetic, molecular genetic, and linkage studies have 
discovered some genetic changes involved in the pathogenesis of melanoma, 
knowledge about genetic changes in sporadic cases is still limited (Bastian et al, 
1998). It is very important to know about genetic changes from primary lesion 
to metastatic lesion because it may allow evaluation of the risk of metastasis in 
a primary melanoma and to differentiate potential precursors in benign lesions. 
In this study, DNAs of 17 cases were extracted from fresh frozen tissue, which 
had some possibility of contamination with normal stromal cells. This could 
induce false aberrations to be detected by CGH.
Commonly involved chromosomes such as 10, 6, 9, 8, 7, 17 were relatively in 
agreement with the results of previous cytogenetic studies of melanoma (Ozisik 
et al.; 1994, Thompson et al.; 1995, Bastian et al.; 1998). Ozisik et al (1994), in 
a cytogenetic study of 21 malignant melanoma samples showed very 
complicated banding results with many marker chromosomes and/or derivative 
chromosomes. In comparison with previous cytogenetic or CGH analysis, the 
results in their study showed some discrepancies, which were caused by internal 
rearrangement of some chromosomal material into marker chromosome or 
derivative chromosomes.
Although chromosome 1 is highlighted to contain tumour suppressor genes, 
represented by deletions (breakpoints between p32 and p36) or translocations 
(breakpoints in p22 and p36), this study showed randomly scattered gains over 
the entire length of the chromosome without any loss of chromosomal material. 
The fact that lp ll.2 -p l2  region and lq21 showed simultaneously high degree 
of gains of copy numbers (amplification on lp ll.2 -p l2 ) even with the 
suppression of the centromeric regions with unlabelled Cot-1 DNA was thought 
to be significant, even though this region is near the centromere.
Chromosome 3 was known to be a less frequently involved site in cutaneous 
melanoma rather than uveal melanoma. In case 6, a high level of gain on 3p24- 
p25.2 including amplification on 3q24 was noted. In another sample from this
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tumour taken after 7 months and 14 days, this high level of gain could not be 
identified and was replaced by other new abnormalities such as gain of 7, loss 
of material of 2p, expanded lost region of 9, and loss of 13q22-qter. This 
finding suggests that the involvement of chromosome 3 probably appears 
earlier than involvement of chromosome 7, 2, and 13 although just one case is 
not sufficient to reach any conclusion. In other cytogenetic studies, involvement 
of chromosome 3 with breakpoints in pil-p25 is usually found in primary 
cutaneous melanoma.
Chromosome 6 was one of the most frequent involved chromosomes in this 
study. Short arm of chromosome 6 involvement was identified in 7 out of 17 
cases, the most frequent overlapping region was 6p23-pter. Gain of 6p was 
almost always accompanied with loss of 6q. Degree of involvement was 
relatively similar in both arms of chromosome 6. The copy number change in 
chromosome 6 was accompanied with loss of chromosome 9p in nearly all 
cases. The frequent gain of the p arm indicates that a possible oncogene 
involved in melanoma progression resides on the distal part of the p arm of 
chromosome 6. The q arm of chromosome 6 has been shown to harbour a 
suppressor gene related to the pathogenesis of melanoma (Bastian et al., 1998). 
Chromosome 7 was also frequently involved, always as gain of DNA copy 
number from the whole length of chromosome 7 to near the telomeric regions. 
One case showed amplification in 7q31.2-qter, which has been reported before 
(Wiltshire et al., 1995). One of the interesting findings was that chromosome 7 
involvement was frequently associated with loss of 13q (minimal overlapping 
region of 13q22). It has not yet been determined whether this relationship was 
meaningful or just a random finding. As mentioned before, one case which had 
been studied again after more than 6 months showed gain of 7 as a new 
chromosomal change, indicating that it is a later change in tumour progression 
(Wiltshire et al., 1995; Bastian et al., 1998). Bastian et al (1998) reported that 
chromosome 7 was probably involved in later stage of tumour because they 
found statistical significance of chromosome 7 involvement in thicker tumour. 
Although gain of chromosome 8q is one of the most common chromosomal 
aberrations in uveal melanoma, in our study, 6 out of 17 cases showed gain of
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8q and 2 out of 17 showed loss of 8p. Loss of 8p was always accompanied with 
gain of 8q. Bastian et al have suggested that a tumour suppressor gene relevant 
in melanoma may be sited in the 8p21-pter region, and one case of this study 
also showed involvement of same site. Gains on chromosome 8 always 
involved the long arm, with a minimal overlapping region of 8q24-qter, where 
the MYC oncogene is located.
Involvement of chromosome 9p was one of the most frequent finding in this 
study, which highlights it as a location of a candidate gene of the early stage of 
melanoma and this was especially marked in cases with familial melanoma. In 
this study, the common deleted area of chromosome 9 encompassed 9pl3-p22 
including 9p21 which contains the p l6  gene. Involvement of chromosome 9 in 
this study was not the sole abnormality, which was frequently accompanied 
with many other aberrations including loss of 10 and involvement of 
chromosome 6. From the literature review, some papers documented that loss of 
9p was associated with loss of material in chromosome 10, and suggested that 
both findings were early changes in malignant melanoma (Indsto et al., 1997; 
Bastian et al., 1998). However, it is impossible to estimate the time sequence of 
chromosome involvement in this study because of the lack of clinical 
information about the samples. Even if loss of 9p is an earlier finding in 
malignant melanoma, this study showed loss of 9p was probably sustained in 
later stages too.
In chromosome 10 involvement, the most frequently lost area was the q arm. In 
cases with p arm involvement, the distal part of 1 Op 14 was frequently involved. 
According to Indsto et al (1997), all deletions of 10 showed codeletion of 9p in 
their study. This was not a constant finding in the present study. Chromosome 
10 is also suspected to harbour a tumour suppressor gene for progression of 
malignant melanoma because loss of lOq is also important in pathogenesis of 
gliomas.
Chromosome 11 was shown to have random involvement. One case with a high 
degree of gain of Ilql2.3-ql3.1 was identified. This region is an amplification 
site in breast cancer and contains several candidate genes such as CYCLIN 
Dl/PRA D l, BCL1 (Hesketh, 1995; Knuutila et al., 1998).
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In this study, chromosome 17 was frequently involved, especially the distal part 
of 17q with one amplification at 17q24-qter or several high level of gains at 
17q22-qter. Amplification on 17q24-qter has been identified in different organ 
systems such as testicular cancer, MPNST (malignant peripheral nerve sheath 
tumour), and in lung cancer and amplification on 17q25 in melanoma (Bastian 
et al., 1998; Knuutila et al., 1998). It is suggested that the distal part of 
chromosome 17 (17q24-qter) possesses many important genes involved in the 
pathogenesis of melanoma or other tumours and this region may be another 
possible region to search for new candidate oncogenes.
Loss of chromosome Y was noted in 3 cases of this study. It is interesting that 
this finding is a phenomenon caused either by normal aging process or by 
tumour progression.
Finally DNA copy number changes were observed in chromosome 16, 19, 20, 
22. Although these regions show widely variable fluorescence ratio in CGH, 
gain of chromosome 22 was interesting because one case showed very strong 
amplification of this chromosome. In previous melanoma studies, chromosome 
16 and 22 have also been suggested as chromosomal changes in the early stages 
(rapid growth phase) (Thompson et al., 1995).
Although the overall copy number changes identified in this study were in 
agreement with other previous studies, several interesting findings were 
observed and highlight four amplified regions, namely chromosome lp ll.2 -p l2 , 
3p24, 17q24-qter and all o f chromosome 22, that might harbour unknown genes 
involved in melanoma pathogenesis.
Involvement of 10 q and 17q where putative tumour suppressor genes (lOq) and 
putative oncogenes (17q21-22) are contained is very interesting because both 
regions are also involved in glioma and embryologically melanocytes are of 
neural crest origin. These findings suggest that pathogenesis of melanoma may 
be closely related with other neural crest-derived tumours. In this study 3 cases 
showed simultaneous involvement of both regions (high level of gain of 17q 
with minimal overlapping area on 17q22-qter and loss of lOq with minimal 
overlapping area on 10q22.2-24).
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4.5 Various kinds of DNA extraction methods from paraffin- 
embedded tissue
Various kinds of DNA extraction methods were applied in this study by 
changing several parameters. Actually, the success rate for obtaining high 
quality and quantity of DNA depends both on status of the sample and on 
parameters applied during the extraction process. As DNA in paraffin- 
embedded tissue was already fragmented and extensively cross-linked with 
nuclear protein, there are several important steps in the process of DNA 
extraction.
First the de-paraffinization step was performed in two different ways, 
depending on whether or not preincubation was included before the dewaxing 
step. Extending the preincubation step beyond three hours may have no 
beneficial effect on samples according to this study because prolonged 
incubation produced drying of the samples. Although DNA extraction after 
three hours incubation did produce high molecular weight DNA, there was no 
significant difference of CGH results between the DNA extracted with and 
without preincubation.
Secondly, it appears that proteinase K digestion may prove to be the most 
important step during DNA extraction from paraffin-embedded tissue with 
respect to degrading the nuclear protein involved in chromosome packaging. 
Modifications in the initial concentration, the length of incubation time and the 
addition of further proteinase K during incubation were introduced depending 
on the size of the sample. Six different incubation times (4 days, 3 days, 2 days, 
24 hours, 3 hours, 90 min) were investigated. With a large sample, 3-4 days 
incubation with an initial concentration of proteinase K of 0.3 mg/ml and 
addition of further enzyme after 24 hrs and again after 48 hrs was found to give 
good results. In the case of a small sample, best results were found with an 
incubation period of 24 hrs or less and an initial concentration of 1-2 mg/ml. 
The results also indicate that when a short incubation is to be used (3hrs or 90 
min), it may be beneficial to increase the temperature from 55°C to 65°C.
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Third, some components of the buffer solution such as SDS and EDTA can 
affect the efficacy of PCR. Although SDS is an ionic detergent well known for 
its protein denaturing effect, it was found that even at a concentration of 
0.005% SDS decreased the yield of PCR product dramatically. In the presence 
of >0.5 mM EDTA, the yield of PCR product was reduced. In this experiment, 
although other factors also affected the yield of PCR product, experiments 
including these components failed to produce adequate PCR product. Finally it 
was found that when a phenol/chloroform step was included, DNA extracted by 
this method consistently failed to produce sufficient DNA after amplification 
and successful CGH, while the same method but omitting this step, gave a high 
rate of successful CGH. Phenol, used for the denaturation of proteins such as 
protease and nuclease, and for the removal of solutes, is known to decrease the 
yield of PCR product when present at a final concentration over 0.2%. The 
cause of failure in this study was thus thought to be that the phenol was not 
completely removed. Another cause of exclusion of phenol/chloroform 
extraction is that the size of the sample was too small to perform the two step 
extraction method. Although crude DNA without phenol/chloroform extraction 
also could obtain successful PCR results, presumably if some amount of protein 
still remained in the crude DNA, then this remnant protein also might disturb 
PCR amplification. In future studies, it would be better to try a final extraction 
with chloroform or chloroform/isoamyl alcohol to remove residual phenol if 
sample is large enough.
Speicher et al (1993) suggested that an additional incubation step with sodium 
thiocyanate, a strong protein-denaturating agent which dissociates DNA- 
nucleoprotein complexes, introduced after the dewaxing would significantly 
help to increase the DNA yield and efficiency of subsequent DOP-PCR. 
However, some papers reported that they had similar successful results without 
pretreatment with sodium thiocyanate (Isola et al., 1994; James and Vally, 
1996).
Although many different DNA isolation methods were investigated in this part 
of the thesis, it appeared that the most critical factor in obtaining an adequate 
amount of DNA was the size of the initial sample to be extracted.
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4.6 Labelling the amplified probe
Although it is important to match the average length of DNA fragments in both 
test and reference samples, this may be difficult if the DNA from the formalin- 
fixed samples is somewhat degraded to begin with (James, 1999).
During the labelling procedure of the amplified products, two serious problems 
were noted in this study. First, the labelling efficiency either by nick translation 
or by PCR labelling was very difficult to estimate. This problem was more 
serious when amplified products were hybridized with non-amplified, nick 
translated reference DNA because the percentage of fluorochrome incorporated 
into the DNA during both labelling procedures was unknown in addition to the 
difference in quality between the test and reference DNA.
Following from this, the second problem was the difficulty in deciding how 
much reference DNA should be hybridised with a given amount of test DNA 
since an unbalanced amount of optimally sized DNA fragments between the 
two DNAs might produce a biased CGH result. For production of a successful 
CGH result, not only the same amount but also the same quality of both DNAs 
was required. Although minor differences can be overcome by the 
normalisation process during image processing, beyond a certain degree of 
tolerance, biased results and cross-talk phenomena may be produced.
To solve these problems, the percentage of fluorochrome incorporated into the 
probes was roughly calculated by using purification methods and semi- 
quantitative labelling assays as described in the Results section. The optimal 
amount of test DNA/control DNA also needed to be considered carefully due to 
different probe penetrating abilities. After calculation of labelled DNA 
concentrations, the ratio of test/control DNA was increased sequentially from 
1:1, 1.5:1, 2:1, 2.5:1, to 3:1. When 2-2.5 fold of test DNA was hybridised with 
control DNA, an acceptable CGH result was obtained.
Thereafter, the problems caused by differences between efficiency of both 
labelling methods were solved by using hybridisation with simultaneously 
amplified control DNAs, By using this method, CGH image became more
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homogeneous, uniform and reliable but still needed adjustment of the ratio of 
test/control DNA.
In many papers describing CGH after WGA of DNA obtained from paraffin- 
embedded sections, no mention is made of the relative amounts of test and 
reference DNA employed or whether differences in probe penetration were 
encountered. However, in the present study, it proved impossible to achieve 
good CGH images by using equal amounts of test and reference DNA because 
probe made from paraffin-embedded tissue did not have as same amount of 
suitable sized DNA fragments as normal control DNA and also the amount of 
fluorochrome incorporated into the DNA could not be calculated accurately.
In the future, this problem can be solved by using microdissected normal cells 
from the same section as a control DNA. For achieving this, more precise 
method for obtaining pure normal cell and tumour cell mass such as laser 
microdissection and close interdepartmental relationship with pathology are 
absolutely required.
4.7 Universal amplification of DNA
4.7.1 Degenerate Oligonucleotide Primed PCR (DOP-PCR)
Whole genomic amplification is a valuable technique to produce an increase of 
DNA from limiting amount of template DNA in a sequence dependent fashion. 
Various kinds of whole genome amplification have been developed including 
PEP, Alu-PCR, linker adaptor PCR, tagged-PCR, and DOP-PCR.
IRS-PCR has notable advantages for species-specific amplification. In human 
DNA, the major family of short interspersed repetitive sequence group (SINES) 
is the Alu family, which is believed to number 900,000 elements in the haploid 
genome, giving an average distance between copies of 3-4 kb. Although these 
repeats are found ubiquitously in human DNA, Alu sequences appear to be 
enriched in certain chromosomal regions and deficient in others. Alu elements
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are preferentially found in the G-light bands of human chromosomes 
(Korenberg and Rykowski, 1988), therefore hybridization using chromosome 
paints amplified by Alu-PCR showed as a banding pattern (Telenius et al.,
1992).
Linker adaptor PCR consists of several steps including digestion with a 
frequent cutter, ligation to an oligonucleotide, and amplification of the ligated 
product with primers specific to the oligonucleotides. Because there should be 
very little sequence selection bias with linker-adaptor PCR, except on the basis 
of distance between restriction sites, the technique overcomes the problems of 
regional bias and species dependence seen in IRS-PCR (Cheung and Nelson, 
1996).
Tagged-PCR uses primers with a random sequence at the 3' end to allow 
binding to a wide variety of target sequences and with a constant 5' tail. The 
first round of amplification is similar to primer extension preamplification to 
allow many priming sites. After several rounds of non-specific interactions, 
unbound primers are removed, and PCR amplification proceeds with a primer 
specific to the 5' constant region to allow exponential amplification (Cheung 
and Kelson, 1996).
DOP-PCR was developed as a simple PCR technique involving multiple locus 
priming, which allows a more general amplification than IRS-PCR, to allow an 
unselected amplification of any source DNA, and results in a more uniform 
CGH signal than interspersed repeat-based methods of whole genome 
amplification.
The efficiency of amplification of DNA by DOP-PCR depends on two 
fundamental requirements; initial low annealing temperature cycles which 
allow the primer to initiate PCR from short target sequences, and primer 
degeneracy. The six degenerate positions create a pool of 46 primers of different 
sequences, against the single sequence of a nondegenerate primer.
While the DNA of frozen tissue sections can be extracted as high molecular 
weight DNA for DOP-PCR with direct, standard cell lysis protocols, it is very 
difficult to obtain an adequate amount of good quality of DNA from paraffin-
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embedded tissue due to interactions of formalin between DNA and proteins 
during the formalin fixation. When molecular or cytogenetic studies using DNA 
from paraffin-embedded tissue are being performed, artifacts due to the 
formalin interactions or the DOP-PCR itself should be considered (Speicher et 
al., 1993).
In this study DOP-PCR was first carried out by Guan’s method (Guan et al.,
1993) with topoisomerase 1 and T7 sequenase, which was used for 
microdissected chromosomal materials. Although the use of topoisomerase 
followed by sequenase in the low stringency cycle steps gave better results than 
any modification with the Taq DNA polymerase in previous reported studies, 
there was no significant benefit related to topoisomerase 1 pretreatment in this 
experiment. That could possibly be explained by the less condensed nature of 
DNA in interphase nuclei which more easily allows access of enzymes to the 
template DNA.
Then, to improve the size of amplified DNA and to decrease the chance of 
contamination, the thermostable form of sequenase, thermosequenase was used 
in this study (Kuukajarvi et al, 1997). This method was thought to be more 
sensitive than the topoisomerase + T7 sequenase combination on the basis of 
the final CGH result using this method (method 6) which gave images which 
were almost analysable although the template DNA had been obtained from 
only one section of 7 pm thickness. Another important benefit of using 
thermosequenase is that there is no need for repeat pipetting because 
thermosequenase is extremely thermostable. The use of standard sequenase was 
complicated because new enzyme has to be added after the denaturation step of 
each amplification cycle due to its thermolabile nature. Repeated pipetting gave 
an increased chance of contamination (Kuukajarvi et al, 1997).
After moving to experiments with very small amounts of DNA, proper 
amplification using method 6 sometimes could not be accomplished. To 
increase the efficacy of DOP-PCR with very small amounts of DNA, thermal 
cycling conditions were readjusted by increasing the number of low annealing 
temperature cycles. AmpliTaq LD was used as an enzyme to avoid the chance 
of contamination because the first PCR solution for DOP-PCR using Amplitaq
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LD remained during whole DOP-PCR amplification process. The problems in 
this method were the characteristics of AmpliTaq LD such as less 
thermostability and a high error frequency because of lack of 3'-5' exonuclease 
activity. Theoretically, when this amplified product is to be used for CGH, the 
result is probably not seriously affected because polymerase-induced mutations 
are randomly distributed over the amplified fragment and CGH can identify 
DNA copy number changes over 3-5 Mb (Cha and Thilly, 1995).
Finally an enzyme which combines proofreading activity with thermostability 
was needed to increase the reliability of CGH. Pfu DNA polymerase and 
Expand High Fidelity PCR System (Boehringer Mannheim) were investigated 
for this purpose. Although Pfu DNA polymerase has more fidelity than EHF 
PCR System, EF1F PCR System, which is a mixture of thermostable Taq DNA 
polymerase and Pwo DNA polymerase, was finally used as enzyme because it 
was more easily optimised.
Compared with AmpliTaq LD, the results using EHF PCR System with the 
same sample and thermal cycle conditions showed stronger and longer DNA 
smear in agarose gel, and increased sensitivity and specificity in CGH results. 
This suggests that a proofreading enzyme is desirable for amplifying very small 
amounts of DNA or poor quality DNA to increase the reproducibility and 
reliability.
Methods 1 and 5 used the same DOP-PCR method; the only difference was in 
the amount of template DNA (method 1; 1x7 nm, method 6; 3x7 p,m). Method 
1 failed to amplify properly, method 6 showed relatively ideal size of DNA and 
more homogeneously hybridized CGH images, which revealed definite gain of 
chromosome 12p, some suspected abnormal findings and matched sex 
chromosomes. This finding suggested that the amount of template DNA 
profoundly affected the success of DOP-PCR amplification.
In this part of the study, normal reference DNA was not amplified, and was 
hybridized after labelling by nick translation. Therefore, the erroneously over- 
and under- represented regions in the amplified test product could be 
recognized when compared with non-amplified normal control, but CGH
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profiles were very noisy and granular.
CGH results from methods 1 and 2, using DNA amplified by DOP-PCR, 
showed quite similar patterns. Although green signal (test DNA) showed less 
intensity than red signal (normal control DNA), chromosome regions lp32-pter, 
19, 16p, and 22 were over-represented and G-dark band compact areas were 
relatively under-represented under proper suppression. Probably, there are some 
reasons why those regions are preferentially amplified. These over-represented 
regions are all relatively pale areas by G-banding. It has been shown that Alu 
repeats are preferentially located in such regions which are known to be GC 
rich. Conversely, G-dark band areas are rich in AT and contain relatively fewer 
Alu repeats (Holmquist et al., 1982; Korenburg and Rykowski, 1988). These 
results suggest that when the template DNA was at an extremely low 
concentration, Alu or GC-rich sequences might be preferentially amplified. 
False over-representation was also observed at the telomeric regions of some 
chromosomes including 7, 8, 9, and 10 in contrast to the finding in standard 
CGH analysis that telomeric regions exhibit decreased fluorescence intensity. 
This finding also suggests that pale band regions in the end of the chromosome 
were amplified preferentially. Also this regional variability has to be considered 
with non-uniform denaturation, hybridisation properties of the different regions 
of the metaphase, and the quality of the two labelled DNAs such as labelling 
efficiency and size distribution of the fragments.
Even though the combination of DOP-PCR and CGH has many limitations, this 
method will allow the analysis of genomic imbalances in tumours with only a 
few cells or even eventually a intact single cell microdissected from paraffin- 
embedded tissue as starting material in association with the other techniques 
such as laser microdissection to select a pure population of cancer cells. It also 
makes possible a comparison of genetic changes with histological and 
immunochemical features and evaluations of the multiclonality of a tumour and 
evaluation of progression of genetic changes from early stage to metastatic 
tumour.
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4.7.2 Primer-extension preamplification (PEP)
PEP is an another method of WGA, which involves multiple rounds of 
extension with Taq DNA polymerase and a random mixture of 15 base 
oligonucleotides as primers. It produces multiple copies of the DNA sequences 
originally present in the sample. It is estimated that PEP cover at least 78% of 
the genomic sequences in a single human haploid cell and can amplify any 
sequence in the genome to a minimum 30 copies (Zhang et al., 1992).
In this study, experiments were performed to assess the capability of PEP 
amplified DNA to produce CGH images. The variables investigated were 
amount of template DNA temperature and number of thermal cycles, cell lysis 
method, and enzyme used.
First, it appeared that the most critical factor in PEP was the amount of template 
DNA. In these experiments, one 7 pm thickness sections of paraffin-embedded 
ovarian cancer tissue were used as a source of test material. Successful CGH 
images were obtained several times from these samples, but not consistently. 
However when melanoma samples of the same thickness were used as test 
material without microdissection, only one case produced an adequate 
amplified product to produce proper CGH images. It was thought that this was 
probably caused by the difference of cell mass in a certain volume between the 
two different kinds of tumour.
In the first part of the PEP study Faulkner’s protocol (Faulkner et al., 1998) was 
used which involved modified cycles (50cycles to 40 cycles) with more 
segmented temperature cycles and 1/10 amount of primer. They suggested that 
reducing the oligonucleotide concentration to one tenth of its original decreased 
both the level and number of additional nonspecific bands in subsequent PCR 
amplifications without causing any marked loss in product level, and decreasing 
the number of thermal cycles from 50 to 40 also obtained a similar result. 
However Dietmaier et al (1999) have reported that the saturated amplification 
plateau was not reached before about 50 cycles with only two target copies and 
that reduction to 40 cycles resulted in false negative results. In the present study, 
even a primer concentration of 100 pmol showed no difference in yield
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compared with higher concentrations and showed some decrease in the amount 
of high molecular weight DNA remaining in the well. A significant 
improvement was found when the number of thermal cycles was increased to 
50 cycles and this was continued for the remaining experiments.
Cell lysis proved to be another critical step influencing the preamplification 
efficiency. In paraffin-embedded tissue, proteinase K is capable of degrading 
nuclear proteins involved in chromosomal packaging (histones) and thereby 
allows more efficient extraction of DNA. By reviewing results according to 
different cell lysis protocols in this study, it appears that proteinase K treatment 
might be especially important in fixed tissue where DNA packaging proteins 
are covalently cross-linked with each other or with DNA/RNA. Especially in 
small samples a high dose of proteinase K (1-2 mg/ml) and a short incubation 
(< 24 hrs) produced good results.
From the observation of the quality of the CGH results from PEP amplified 
DNA produced by methods 1 to 7, it appeared that success depended not upon 
the PEP method itself but on the amount of starting DNA, the enzyme used, and 
the method of cell lysis.
In method 11, one aliquot of PEP product was further amplified by DOP-PCR 
and the CGH results using this DNA were compared with those produced by 
the original PEP product. The single PEP product showed very homogeneous 
images with true losses and gains of DNA copy number including losses of lp, 
5, 11, 15 and gains of lq and 12p with prominent heterochromatin-rich area 
(centromeric regions on chromosome 1 and 9). By contrast, CGH results with 
PEP followed by DOP-PCR showed under-represented G-dark band regions 
and over-represented chromosome 19 and some telomeric regions. This 
discrepancy is thought to be caused by different characteristics of the primers. 
Also PEP followed by DOP-PCR has a risk of decreasing the reliability because 
too many replication cycles are performed. Products amplified by PEP + DOP- 
PCR showed a discrete band in the gel. This was thought to be caused by non­
specific amplification of some portion of the DNA sequences by DOP-PCR 
amplification.
An interesting question, discussed in several papers, is whether PEP or DOP-
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PCR amplifies the template DNA more precisely. Generally, PEP is the more 
accurate amplification method but cannot amplify the original copies to the 
same extent. Zhang et al (1992) described the advantage of the PEP protocol 
having little chance of mutation due to random amplification without any 
preference for specific sequences and similar chance of primer-extension 
product being involved in primer extension at a subsequent cycle.
By observation of the CGH result using product amplified by each method, 
there are some discrepancies in some regions such as lp32-pter and G-light 
band areas on chromosome 5 and 11 in method 11. The above regions were 
under-represented by PEP in comparison with balanced state by DOP-PCR. 
This was thought to be caused by that regions of true loss were concealed by 
the over-represented nature of DOP-PCR on those areas. It is suggested that 
DOP-PCR preferentially amplifies G-C rich regions to a greater extent than 
PEP and PEP preferentially amplifies heterochromatin rich areas than DOP- 
PCR. In this study, molecular tests to prove this also had a problem because this 
amplified product was from DNA obtained from a whole section of tissue 
containing normal surrounding cells. Microsatellite instability and in particular 
detection of LOH require a homogeneous population of tumour cells to avoid a 
false negative LOH result due to any contamination by surrounding normal 
cells.
In this study, HMW product near the well appeared in almost all PEP 
experiments with the exception of methods 3, 9, and 11 which went on to 
produce relatively successful CGH results. It is certain that the success of CGH 
with PEP amplified product is closely related to HMW product in the well. The 
nature of this byproduct is truly unknown. In this study, it did not come out 
from the well in gel running with bigger ladders and the calculation of the ratio 
of spectrophotometric absorbance (A260/A280), which was around 1.8, can 
rule out contamination with cross-linking protein. By observation of the fact 
that failed cases showed a very faint smear, but with prominent HMW product, 
true effective fragments for the CGH experiment were at a very low 
concentration because efficient amplification and labelling were disrupted by 
this HMW product which might consumed enzymes during PEP amplification
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or during nick translation. This is confirmed by the fact that although efficiency 
of nick translation of PEP product was much better than that of PCR labelling 
with DOP-PCR product, the success rate of the CGH experiments with DOP- 
PCR product was far better than those with PEP product.
In fact, although CGH was attempted many times with PEP product it was very 
difficult to obtain a successful result. So, to improve the efficacy and fidelity of 
PEP, the enzyme was changed from AmpliTaq LD to EHF PCR System and the 
later number of cycles was increased to 50. CGH results with PEP product 
using EHF PCR system showed improved quality of CGH in DNA from normal 
blood and abnormal bone marrow samples but not DNA from paraffin- 
embedded tissue.
Although the PEP method has proved to be applicable to various molecular 
studies, successful CGH using PEP product is very hard to achieve because of 
low degree of amplification ability.
Another problem of PEP amplification was frequent positive smear in negative 
control samples. This happened even when the same reagents, enzymes, 
pipettes and tubes were used as in DOP-PCR amplifications which showed no 
contamination. In this study, amplified negative controls with positive smear 
were used for CGH on several occasions and the results showed a balanced 
CGH image without any gain or loss. By comparing other PCR methods 
including DOP-PCR, PEP is seems to be more vulnerable to contamination by 
tiny amounts of DNA. This is thought be caused by the totally degenerate 
nature of primer.
4.8 CGH with serially diluted samples
After the publication of CGH results obtained from paraffin-embedded tissue 
by Speicher et al (1993), many CGH studies have been performed using 
product amplified from various sources of DNA ranging from microdissected 
paraffin-embedded samples to single cells from blastomere (Kallioniemi et al.,
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1992; Speicher et al., 1993; Wells et al., 1999). Even if the amplified products 
contain preferential amplification and replication error to some extent which 
have been revealed by molecular genetic study (Keohavong and Thilly, 1989; 
Cariello et al., 1991; Cheung and Nelson, 1996; Sanchez-Ces-Pedes et al., 
1998), CGH in association with WGA can become a valuable method to detect 
genomic changes in prenatal field and in cancer genetics if the fidelity and 
efficacy of the WGA method and reliability of CGH analysis could be 
increased.
The aim of this part of the study was to determine the smallest amount of 
template DNA which could be amplified to produce successful images.
In DNA from normal female blood, PEP technique could obtain a result only at 
40 ng level of template DNA (approximately 4000-6000 cells). The best CGH 
results using amplified by PEP were achieved when PEP was carried out using 
EHF-PCR system and the same amount of normal control DNA was amplified 
by the same method. At the level below 40 ng of template concentration, CGH 
showed a disproportionately high level of hybridization to centromeric regions 
and very weak intensity of green signal elsewhere on the chromosomes. This 
finding was different from the results with DOP-product, which rarely showed 
over-representation in centromeric regions. This suggests three possibilities: 
first, regions of highly repetitive sequences were preferentially more amplified 
than other sites of chromosome at low concentration of template DNA: second, 
during hybridisation, probes fragmented into small pieces were reannealed first 
to highly repetitious sequences according to Cot curve: third, incomplete 
suppression of interspersed sequences by unlabelled Cot 1 DNA was an another 
possible explanation. The first assumption is more feasible than the others 
according the observation of several results. Wells et al reported that they failed 
to get any accurate results from DNA amplified using the PEP technique at the 
single cell level (Wells et al., 1999). Dietmaier et al. (1999) also reported that at 
least 10 unfixed cells from fluorescence- activated cell sorting, 10 cells of fresh 
frozen tissue and at least 30 cells from paraffin-embedded tissue were needed 
for reliable microsatellite analysis of PEP- amplified DNA. By considering 
Dietmaier’s result which was performed with products with additional 50 cycles
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of PCR amplification, CGH with PEP- amplified DNA might require over 
several thousand cells.
In DOP-PCR amplification in serial dilution of normal template DNA, CGH 
showed reliable results which appeared within normal range of fluorescence 
ratio profiles with the tendency of under-represented chromosome lq32-pter, 16, 
19, and 22 above 75 pg level of template DNA concentration. By contrast at or 
below the 50 pg levels, these regions appeared disproportionately over­
represented. Also G-dark band regions showed much weaker green signals than 
other parts of the chromosomes. These findings suggest that regions rich in GC 
with CpG islands are preferentially amplified at very low concentrations of 
template DNA even though hybridisation preference also cannot be ignored. In 
this study, specific band around 400 bp on agarose gel was frequently found. 
This was thought to be caused by non-specific amplification of some portion of 
the DNA sequence.
Cheung and Nelson (1996) suggested that the DOP-PCR product cannot 
represent the whole sequence of the starting genomic DNA and usually 
amplifies one third as well. They suggested three possible explanations about 
DOP-PCR amplification: I) production of nonspecific DNA created by non­
specific priming; ii) over-representation of highly repetitive DNAs by the PCR 
process: iii) production of overlapping sets of DNA fragments. The results of 
this experiment can be seen as proof for their first and second explanations.
Then, to increase the reproducibility and reliability of CGH results, the 
proofreading enzyme (EHF PCR system) was used instead of thermosequenase 
or AmpliTaq LD and CGH was carried out by hybridising with reference DNA 
amplified and labelled by the same method. These CGH results showed quite 
uniform, evenly hybridized images and profiles with adequate sexing, and did 
not show disproportionately over-represented or under-represented regions even 
at the level of 10 pg (about single diploid cell) of template DNA. It is suggested 
that any irregularity or preferential amplification of samples during DOP-PCR 
and labelling procedure did not affect the CGH profiles produced using this 
method.
The system was then investigated using DNA from abnormal bone marrow
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from a patient with AML /MDS. The same dilution method and WGA with PEP 
or DOP-PCR were applied. The aim of this experiment was to find how 
accurately the CGH results obtained using products amplified by PEP or DOP- 
PCR compared with the known CGH results of the starting samples.
By applying PEP, the results were nearly the same as that of a normal female 
blood sample. Only a concentration of 40 ng of template DNA, hybridised with 
normal reference DNA amplified by the same method, showed reliable CGH 
images.
In experiments with DOP-PCR, above 300 pg level, CGH results exhibited 
almost all the abnormalities known to be present but the intensity of signals 
became weaker as the concentration decreased. Also distorted findings, which 
were shown at the concentrations below 75 pg in normal sample, appeared from 
the concentration below 300pg of template DNA. But it became possible to 
obtain better results (3 out of 4 abnormal findings) even at 50 pg (about 8 cells) 
of template DNA by using proofreading enzyme and hybridising with normal 
reference DNA amplified simultaneously.
The third trial used DNA from thick sectioned paraffin-embedded tissue as 
template DNA. The original CGH result using DNA without amplification was 
not biased, so this experiment could evaluate the degree of coverage of 
abnormal findings by CGH using amplified product from paraffin-embedded 
tissue.
By PEP amplification, no successful result was obtained. This means that DNA 
from paraffin-embedded tissue was more fragmented than that from other 
samples and so the amount of optimally sized DNA fragment for CGH after 
amplification was lower than that of same concentration of other samples.
In this experiment using DOP-PCR, 6-7 out of 7 abnormalities in gain and 5 out 
of 7 abnormalities in loss were identified above 500 pg level. Losses of DNA 
copy number were less accurate than gains. The 500 pg level was a turning 
point below which unreasonably over-represented regions on lp32-pter, 19, 20, 
and 22 were observed. After experiments using proofreading enzyme and 
hybridizing with normal reference DNA amplified simultaneously, gains were 
reasonably well detected at concentrations above 100 pg (100% at 200 pg,
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85.7% at 100 pg) but losses were less distinctive (71.4% in 200 pg, 57% in 100 
pg). Below 50 pg, the result was not meaningful but did not show up 
disproportionately over- or under-represented regions.
In CGH, usually copy number increase is visible if the gained region is 2 Mb or 
larger. Resolution for deletion of 5-10 Mb might reasonably be accepted in 
practical experiments because of several factors, such as varying condensation 
of the target metaphase chromosomes, intratumour heterogeneity and 
contamination with non-tumour cells (Piper et al., 1995). Therefore, in 
experiments with paraffin-embedded tissue, resolution may be further 
decreased.
In conclusion, CGH using products of WGA can provide reasonable results 
above a certain level of concentration, which is dependent on the quality of the 
original samples. Reliable CGH can be obtained above 10 pg (about a single 
diploid cell) of DNA from normal female blood, above 50 pg (about 8 cells) of 
DNA from abnormal fresh sample and above 100 pg (about 15 complete cells) 
of DNA from paraffin-embedded tissue when amplification is performed with 
EHF PCR system as an enzyme and the normal control DNA is amplified and 
labelled by the same method as test DNA.
4.9 CGH experiments on very small amounts of DNA in solid 
tumours
Genetic study in solid tumours has developed quickly through the introduction 
of various whole genome amplification methods which enabled studies using 
very small amounts of DNA and also the use of archival samples such as 
paraffin-embedded tissue. Even though the DNA is already fragmented or still 
intermingled with nucleoprotein, the development of cell lysis methods, proper 
adjustment of DOP-PCR thermal cycles and development of new enzymes have 
made it possible to produce adequate amounts of DNA for CGH from very 
small amounts of microdissected materials from paraffin-embedded tissue.
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Although there are an increasing number of papers describing CGH using 
WGA with microdissected samples, the minimal requirement of DNA to 
achieve reproducible CGH with minimal artifact, and method for improving the 
fidelity of CGH results from paraffin-embedded tissue samples have not yet 
been systematically evaluated and optimised.
There are many critical points during the progression of this experiment. 
Sample status, cell lysis methods, thermal cycle condition, and enzymes used 
have already been discussed in chapter 4.4. From the point of view of 
diagnostic and prognostic significance of test results, the most important factors 
are the reliability of WGA and the minimum amount of template DNA required 
to avoid serious artifact (false positive or negative results).
To increase the reliability, it is important that as little non-tumour tissue as 
possible is present. Combining whole genome amplification methods with 
novel laser based microdissection techniques has made it possible to decrease 
contamination with non-tumour cells including normal epithelial cells, stromal 
cells, endothelial cells, and inflammatory cells (Emmert-Buck et al., 1996; 
Bohm et al., 1997).
In the first part of these experiments where DNA was extracted from one whole 
section of 7 pm thickness of paraffin-embedded melanoma samples, it was 
possible that the tumour DNA was contaminated with non-tumour DNA, and 
consequently the CGH results with amplified product from these samples 
reflected the average content of all cell types present in the samples. Although 
CGH can detect abnormalities from samples with below 50% contamination of 
non-tumour cells, there are some limitations in accepting this level in paraffin- 
embedded tissue samples because of intratumour heterogeneity in addition to 
contamination with normal cells.
In this study, one sample was the subject of three different kinds of experiments 
(using whole section and microdissected materials with two different enzymes). 
By comparing the three findings, the result from whole sections of 7 pm 
thickness showed a less accurate detection of abnormal findings especially loss 
of DNA copy number (3 out of 3 in gains, 1 out of 5 in losses); on the other
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hand, non-specific findings were much increased. These non-specific findings 
were similar to findings observed when the concentration of template DNA was 
extremely low. This suggests that experiments with whole sections may not be 
able to detect all DNA copy number changes by CGH because true abnormal 
findings are diluted with surrounding normal tissue and this dilution will make 
it more difficult to produce adequate amount of tumour DNA amplification for 
CGH.
Microdissections were then performed on subsequent unstained slides under the 
inverted microscope using 25G sterile needles according to regions of tumour 
cells identified from Haematoxylin-Eosin (H-E) stained slide. H-E staining may 
not be desirable for microdissection because of the adverse reaction on DNA 
(Burton et al., 1998).
Another critical point in this experiment is that microdissected tissue sections 
can encounter a serious problem because the cell and nucleus volume is 
diminished by cutting. As a result, chromosomes or parts of chromosomes can 
get lost, leading to false loss of DNA copy number (Speicher et al., 1995; 
Duddy et al,.1998; Dietmaier et al, 1999). This is supported by the fact that 
control FISH experiments with centromeric probes on normal tissue sections 
showed loss of chromosomes in 15-20% of all nuclei (Speicher et al., 1995). To 
overcome this problem, larger areas should be microdissected from thinner cut 
samples.
In this study, microdissected areas were approximately 2mm2 x 3 pm, 9mm2 x 
3 pm, 18mm2 x 3 pm, 9mm2 x 7 pm. A microdissected volume of 2mm2 x 3 pm 
could not yield an adequate amount of amplified DNA to produce proper CGH 
images. Then microdissected material was increased to 18 mm2 x 3pm and 
successful results were obtained in all cases. At a volume of 9 mm2 x 3 pm 
section, all cases except one showed DNA below 500 bp in size (mainly below 
300 bp) and failed to produce CGH images. However one case, which showed 
300 to 1000 bp sized fragments, obtained reasonable CGH images at the same 
size of microdissected area by WGA with AmpliTaq LD and EHF PCR system. 
The three failed cases were repeated using increased volume of the tumour cell
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mass (9 mm2 x 7 pm) and reasonable results were obtained. The one remaining 
case procured only 3 mm2 x 7 pm because of the very small size of the original 
tumour mass and an adequate result could not be obtained. These results 
suggest that amount of DNA to be extracted may depend on the difference of 
cell mass inside the tumour and the quality of paraffin-embedded tissue in the 
same size of microdissected volume. The critical factors for successful CGH are 
also not only the sample size but also size of DNA fragments after 
amplification.
This study also evaluated the efficacy and reliability of three kinds of enzyme, 
namely AmpliTaq LD, Pfu DNA polymerase, and EHF PCR (Expand High 
Fidelity PCR) system. Although the result with Pfu DNA polymerase was more 
reliable than that with AmpliTaq LD, overall findings were very similar 
especially losses which showed a completely identical result. If Pfu DNA 
polymerase had been more optimized, it would probably have given a better 
result. Comparing AmpliTaq LD to EHF PCR system, the results with EHF 
PCR system were superior from the point of view of reliability and 
reproducibility (more amplified and bigger DNA fragments) than those with 
AmpliTaq LD. Above a certain level of template DNA, there was no significant 
difference of results between AmpliTaq LD and EHF PCR system but in very 
low concentrations of template DNA, experiments with EHF PCR system 
showed more sensitive and reliable results. Experiment with AmpliTaq LD 
showed improved results when both test and reference DNA were amplified 
simultaneously by reducing the noise difference but revealed low hybridization 
intensity. Although proofreading enzyme also affects the efficiency and fidelity 
of whole genome amplification, the degree of fragmentation of DNA in 
paraffin-embedded tissue and the amount of true tumour cell mass in 
microdissected sample are more critical factors than the enzyme in CGH with 
universal whole genome amplification.
Finally, this experiment was to assess whether PEP can amplify sufficient 
amount of product for successful CGH in melanoma samples.
By PEP application, all cases except one showed large amount of high
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molecular weight DNA near or in the well and all of these cases failed to 
amplify an adequate amount and proper quality of DNA for CGH. One case, 
which did not show up high molecular weight DNA, obtained successful CGH 
images. Once again, high molecular weight DNA near or in the well has a 
negative effect on amplification process, labelling process, and CGH. The most 
annoying problem during PEP amplification was positive smear in a negative 
control sample.
The conclusion was that PEP is not a suitable amplification method for 
producing reliable CGH images in this amount of tumour cell mass even though 
many papers have said that PEP offers more complete coverage at lower 
genomic DNA copy for microsatellite instability assay or loss of heterozygosity 
(Dietmier et al, 1999). The cause of failure might be too low concentration of 
amplified product for CGH and decreased efficiency due to consumption of 
primer and enzyme by non-specific HMW product.
DOP-PCR amplification obtained reliable CGH results according to the amount 
of suitable size of DNA, and enzyme used. During this experiment, the 
investigation of how much the sequence of template DNA can be covered by 
DOP-PCR was continued because this directly affects the reliability of CGH 
results. Based on the number and sizes of DOP-PCR products, theoretically 
there should be about one million DOP-PCR fragments generated from the 
entire human genome because DOP-PCR primer probably can anneal every 4 
kb. If the average 500 bp sized product is produced in the haploid human 
genome (about 3x 109 bp), it is possible to anticipate that an arbitrary stretch of 
DNA had only a one in six chance of being included in the DOP-PCR product 
(Cheung and Nelson, 1996). By considering the capability of detection of CGH 
(average 3-5 Mb), this does not affect the CGH result itself. The limitation of 
spatial resolution of CGH is already documented in that deletions detected by 
LOH or FISH were not diagnosed by CGH in several studies (Cher et al., 1994; 
Joos et al., 1995; Benz et al., 1998).
After several trials of CGH experiments with DOP-PCR amplification product, 
relatively consistent results were obtained, although there were some 
discrepancies according to sample size and enzyme used. These results showed
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gains on 6p, 15q and losses on 9p, lOp, 6q, 17p which are known to be areas 
frequently involved in melanoma. But areas frequently involved in fresh frozen 
samples studied here, such as gains on 7, did not appear in this part of the study 
and also in contrast with loss of lOq which was a more prevalent finding in 
fresh frozen samples, lOp involvement was more prominent in the work with 
paraffin sections. By Bastian et al. (1998), a gain of chromosome 7 was found 
more frequently in thicker lesions. This finding suggest that these samples were 
in relatively early stage of melanoma. Because no information about patient 
status was available during these studies, it is not known whether these 
discrepancies are due to the stage of the tumour or are an experimental artifact. 
The small number of samples studied also make it difficult to draw any 
conclusion.
In conclusion, even if CGH results with DOP-PCR products showed some 
unwanted over- or under-represented regions, DOP-PCR was found to be a 
better method of amplification for producing CGH images than PEP in CGH 
experiment with very small amount of DNA and the minimal requirement of 
tissue size is over 3mm x 3mm x 3nm in melanoma case. A proofreading 
enzyme such as EHF PCR system is considered to be the enzyme of choice. 
CGH with WGA can become a useful method to detect true genomic copy 
number changes and to evaluate genomic progression from premalignant lesion 
to metastatic tumour by developing the techniques of WGA.
4.10 Validation of CGH results
The main problem in the amplification of CGH with product amplified using 
WGA is the reliability of the result. During the amplification process, many 
artifacts developed due to high order structure of DNA and varying degree of 
amplification error of enzyme. Generally, estimate of the error rate (error/bp per 
duplication) of Taq polymerase is 2 x 10'4/ bp per duplication. A T to G C 
transitions with Taq polymerase frequently occur (Dunning et al., 1988:
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Cariello et al., 1991).
In order to prove the fidelity of DOP-PCR products, it was important to 
examine how uniformly DOP-PCR amplifies the sequences of template DNA. 
Inclusion of a normal DNA sample in every DOP-PCR reaction batch is very 
important to verify the CGH result. Only if the green to red fluorescence ratio 
of all chromosomes remains in the normal range in the control sample, 
unknown test samples can be reliably analysed (Kuukasjarvi et al., 1997). 
Another validation option is a molecular method such as microsatellite 
instability (MSI) and loss of heterozygosity (LOH). MSI analysis, and in 
particular detection of LOH, require a homogeneous population of tumour cells 
to avoid erroneous underestimation of the LOH frequency due to any 
contamination by adjacent normal cells (Dietmaier et al., 1999). In this study, 
MSI or LOH did not perform because the DNA to be amplified was thought to 
be contaminated with normal surrounding cells in most of the experiments with 
melanoma sections and it was not possible to obtain blood or normal tissue 
sample from the patient as a control. Therefore these amplified products were 
subjected to PCR with specific primers (a 30 mer derived from 
pseudoautosomal sequences in combination with 30 mer from X-specific and 
Y-specific regions, exon 2 of p i  6 on chromosome 9p21). In the PCR results for 
sex determination, all melanoma samples failed to show any band in 
comparison with compatible bands of male and female controls. This finding 
indirectly suggests that all melanoma samples were already fragmented below 
771 bp. In the PCR results with primer of exon 2 (pi 6), normal control showed 
a single band at 337 bp. Among five melanoma samples, only case 3 showed a 
single faint band at 337 bp. From these results, it is not sufficient to reach a 
definite conclusion. This experiment needs more time for optimisation and 
quality control.
FISH to metaphase chromosomes using probes for areas of interest and tissue in 
situ hybridization is a possible method of validation. FISH to metaphase 
chromosomes could be rarely performed because of less availability of 
metaphase chromosomes in solid tumours. Tissue in situ hybridisation also had 
some difficulties arising from loss of chromosome material by cutting, three­
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dimensional structure of interphase nuclei, and in discrimination between 
normal and malignant cells under the DAPI staining. The results showed 
inconsistent findings because of overlapping and biased false negative signals. 
As a validation method, tissue in situ hybridisation on paraffin-embedded 
section showed a possibility in spite of several drawbacks such as difficulties in 
obtaining appropriate probes and in counting signals. For improvement of this 
technique it is recommended to use confocal microscopy for counting and 
increase the availability of probes for specific locus interested.
Inverse CGH was the simplest method for validation of results. Larramendy et 
al (1997) found that when Texas Red was used to label test DNA, over­
representation was observed at 4ql3-q21, 1 lq 2 1-23, 13q21-qter, and Xq21-q22, 
whereas 19p was under-represented. These findings were not observed in this 
study. By considering the difference between two kinds of CGH profile 
according to the ordinary and inverse labelling, CGH with DOP-PCR products 
using template DNAs from melanoma samples showed relatively compatible 
results. In cases 1 and 2, CGH results could not be sure because quality of 
original DNA was extremely poor.
In conclusion, CGH can be an important complementary method to 
conventional karyotyping in hematologic malignancies.
In CGH with serially diluted DNA, the results showed the smallest amount of 
template DNA for reliable CGH- 10 pg (about single diploid cell) from normal 
female DNA, 50 pg (about 8 cells) of DNA from abnormal fresh bone marrow, 
and 100 pg (about 15 cells) of DNA from abnormal paraffin-embedded tissue. 
From these results, if the purpose of study is for the detection of numerical 
abnormalities, reliable CGH results from a single cell can be achieved when 
amplification is performed with EHF PCR system as an enzyme and the same 
amount of normal control DNA is treated by the same method as the test DNA. 
In the case of tumour and in particular melanoma, where cytogenetic studies are 
difficult, this study has shown how methods can be improved to yield good 
quality and reproducible CGH images. It is likely that CGH studies will now be 
able to detect important changes in the early stages of tumour formation, to
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follow these during development from formalin fixed sections and to identify 
new amplicons where might be another possible region to search for new 
candidate oncogenes.
Further improvements might come from use of laser based microdissection 
technique, use of control material from normal tissue on the same slide and 
development of enzymes with high fidelity. The use of touch preparations in the 
early stages would also be of great benefit. It was hoped to include this 
approach in the present study but no suitable cases presented in time.
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